National Medical Assistant Certification Association

NMACA, LLC

Rapid Review

Edition 2026

© 2026 National Medical Assistant Certification Association, LLC | medicalassistantcourses.org | All Rights Reserved

Biochemistry & Medical Genetics

Table of Contents

• Biochemistry

• Enzyme Basics

• Metabolism Carbohydrate Metabolism Lipid Metabolism Amino Acid Metabolism

Nucleotide Metabolism

• Molecular Biology

• Vitamins & Cofactors

• Medical Genetics

• Genetic Terminology & Concepts

• Patterns of Inheritance

• Chromosomal Disorders

• Single-Gene Disorders

• Mitochondrial Inheritance

• Genetic Testing & Counseling

Biochemistry

Enzyme Basics

• Enzyme Function: Biological catalysts that lower activation energy, increase reaction

rate without being consumed.

• Enzyme Kinetics:

• Vmax: Maximum velocity at enzyme saturation.

• Km (Michaelis constant): Substrate concentration at ½ Vmax; affinity inversely

proportional to Km.

• Enzyme Inhibition: | Type | Effect on Km | Effect on Vmax | Mechanism | Example

Drugs | |——————–|——————–|——————-|———————————-|–

• ——————————| | Competitive | ↑ (apparent) | No change | Inhibitor competes

with substrate| Methotrexate, Sulfonamides | | Noncompetitive | No change | ↓ | Inhibitor

binds allosteric site | Cyanide, Digoxin | | Uncompetitive | ↓ | ↓ | Inhibitor binds ES

complex | Rare, e.g., some chemotherapy |

• Enzyme Regulation:

• Allosteric regulation: reversible binding at sites other than active site.

• Covalent modification: phosphorylation (kinases), dephosphorylation (phosphatases).

• Zymogen activation: irreversible cleavage (e.g., trypsinogen → trypsin).

• Coenzymes & Cofactors: Non-protein molecules required for enzyme activity (e.g.,

NAD+, FAD, biotin, metal ions).

Metabolism

Carbohydrate Metabolism

Pathway Location Key Enzymes Regulation Clinical Correlates

Glycolysis Cytoplasm Hexokinase, PFK-1, PFK-1 Pyruvate kinase

Pyruvate kinase (rate-limiting, ↑ by deficiency →

AMP, F-2,6-BP; ↓ hemolytic anemia

by ATP, citrate)

Gluconeogenesis Liver, kidney Pyruvate ↑ by glucagon, Deficiency in gluco

carboxylase, cortisol se-6-phosphatase →

PEPCK Von Gierke disease

Glycogenesis Cytoplasm Glycogen synthase Activated by insulin Glycogen storage

diseases (GSDs)

Pathway Location Key Enzymes Regulation Clinical Correlates

Glycogenolysis Cytoplasm Glycogen Activated by McArdle disease

phosphorylase glucagon, (muscle

epinephrine phosphorylase

deficiency)

Pentose Phosphate Cytoplasm Glucose-6-phosphat NADP+ availability G6PD deficiency →

Pathway (PPP) e dehydrogenase hemolytic anemia

Key Points:

• Glycolysis: Glucose → 2 Pyruvate + 2 ATP + 2 NADH

• Irreversible steps: Hexokinase/glucokinase, PFK-1, Pyruvate kinase

• Anaerobic end product: Lactate (via lactate dehydrogenase)

• Gluconeogenesis: Formation of glucose from non-carbohydrate precursors (lactate,

glycerol, amino acids).

• Glycogen Storage Diseases (GSD):

• Type I (Von Gierke): Glucose-6-phosphatase deficiency → severe fasting

hypoglycemia, lactic acidosis.

• Type V (McArdle): Muscle glycogen phosphorylase deficiency → exercise intolerance,

cramps.

Lipid Metabolism

Process Location Key Enzymes Regulation Clinical Correlates

Fatty Acid Cytoplasm (liver, Acetyl-CoA ↑ by insulin, citrate; Deficiency in

Synthesis lactating mammary carboxylase ↓ by glucagon, acetyl-CoA

gland) (rate-limiting), palmitoyl-CoA carboxylase rare

Fatty acid synthase

β-Oxidation Mitochondrial Carnitine ↑ by glucagon, Carnitine deficiency

matrix acyltransferase I epinephrine → muscle

(rate-limiting) weakness,

hypoketotic

hypoglycemia

Ketogenesis Mitochondria HMG-CoA ↑ by fatty acid Diabetic

(liver) synthase oxidation ketoacidosis

Cholesterol Cytoplasm HMG-CoA ↑ by insulin, ↓ by Statins inhibit

Synthesis reductase glucagon, statins HMG-CoA

(rate-limiting) reductase

Key Points:

• Fatty Acid Synthesis: Acetyl-CoA → Malonyl-CoA (via acetyl-CoA carboxylase) →

Palmitate (16C).

• β-Oxidation: Fatty acids broken down into acetyl-CoA units for energy.

• Ketone Bodies: Acetoacetate, β-hydroxybutyrate produced during fasting or diabetes.

• Lipid Transport:

• Chylomicrons: dietary TG transport (apoB-48).

• VLDL: endogenous TG transport (apoB-100).

• LDL: cholesterol delivery to tissues.

• HDL: reverse cholesterol transport.

Amino Acid Metabolism

Amino Acid Key Metabolic Pathway Deficiency Disease & Presentation

Phenylalanine Converted to tyrosine by PKU: intellectual disability, musty

phenylalanine hydroxylase odor, hypopigmentation

Tyrosine Precursor for catecholamines, Albinism (tyrosinase deficiency)

melanin

Homocysteine Remethylation to methionine (B12, Homocystinuria: lens dislocation,

folate) or transsulfuration to thrombosis, intellectual disability

cysteine (B6)

Branched-chain AAs (Leu, Ile, Val) Catabolized by branched-chain Maple syrup urine disease: poor

α-ketoacid dehydrogenase feeding, sweet-smelling urine

Key Points:

• Urea Cycle: Converts ammonia to urea in liver mitochondria and cytosol.

• Rate-limiting enzyme: Carbamoyl phosphate synthetase I (CPS I).

• Deficiency → hyperammonemia → cerebral edema, asterixis.

• Amino Acid Disorders:

• PKU: phenylalanine hydroxylase deficiency → ↑ phenylalanine, ↓ tyrosine.

• Maple syrup urine disease: defective branched-chain α-ketoacid dehydrogenase →

accumulation of branched-chain AAs.

Nucleotide Metabolism

Pathway Key Enzymes Clinical Correlates

Purine Synthesis PRPP amidotransferase Lesch-Nyhan syndrome (HGPRT

(rate-limiting) deficiency)

Purine Salvage HGPRT (hypoxanthine-guanine Lesch-Nyhan: self-mutilation, gout

phosphoribosyltransferase)

Pyrimidine Synthesis Carbamoyl phosphate synthetase II Orotic aciduria (defect in UMP

synthase)

Pathway Key Enzymes Clinical Correlates

Pyrimidine Salvage Thymidine kinase Rare disorders

Key Points:

• De novo Purine Synthesis: Starts with ribose-5-phosphate → IMP → AMP/GMP.

• Lesch-Nyhan Syndrome: HGPRT deficiency → ↑ uric acid, neurological symptoms.

• Orotic Aciduria: Defect in pyrimidine synthesis → megaloblastic anemia, orotic

aciduria, no hyperammonemia.

• Drugs Targeting Nucleotide Metabolism:

• Methotrexate: inhibits dihydrofolate reductase → ↓ dTMP synthesis.

• 5-Fluorouracil: inhibits thymidylate synthase.

• Azathioprine/6-MP: purine analogs inhibiting de novo synthesis.

Molecular Biology

Process Key Enzymes/Proteins Clinical Correlates

DNA Replication DNA polymerase III (prokaryotes), Xeroderma pigmentosum

DNA polymerase α, δ, ε (nucleotide excision repair defect)

(eukaryotes)

Transcription RNA polymerase II (mRNA), I α-amanitin toxin inhibits RNA Pol

(rRNA), III (tRNA) II

Translation Initiation factors, ribosomes, tRNA Aminoglycosides inhibit 30S

subunit

DNA Repair Nucleotide excision repair, base Lynch syndrome (MMR defect),

excision repair, mismatch repair XP (NER defect)

Key Points:

• Central Dogma: DNA → RNA → Protein.

• Transcription Factors: Bind promoter regions (TATA box).

• Post-Transcriptional Modifications: 5′ capping, 3′ polyadenylation, splicing.

• Genetic Code: Degenerate, unambiguous, universal.

• Mutations:

• Missense: amino acid change.

• Nonsense: premature stop codon.

• Frameshift: insertion/deletion altering reading frame.

• Recombinant DNA Technology:

• Restriction enzymes cut palindromic sequences.

• Southern blot: DNA detection.

• Northern blot: RNA detection.

• Western blot: protein detection.

Vitamins & Cofactors

Vitamin Type Function(s) Deficiency

Syndrome/Notes

Vitamin B1 (Thiamine) Water-soluble Cofactor for pyruvate Wernicke-Korsakoff,

dehydrogenase, α-KG Beriberi

dehydrogenase,

transketolase

Vitamin B2 (Riboflavin) Water-soluble FAD, FMN cofactors in Cheilitis, corneal

redox reactions vascularization

Vitamin B3 (Niacin) Water-soluble NAD+, NADP+ synthesis Pellagra (diarrhea,

dermatitis, dementia)

Vitamin B5 (Pantothenic Water-soluble Component of CoA Rare deficiency

acid)

Vitamin B6 (Pyridoxine) Water-soluble Cofactor for Convulsions,

transamination, sideroblastic anemia

decarboxylation

Vitamin B7 (Biotin) Water-soluble Cofactor for carboxylase Dermatitis, alopecia,

enzymes enteritis

Vitamin B9 (Folate) Water-soluble THF coenzyme for Megaloblastic anemia,

1-carbon transfers neural tube defects

Vitamin B12 (Cobalamin) Water-soluble Cofactor for methionine Pernicious anemia,

synthase, subacute combined

methylmalonyl-CoA degeneration

mutase

Vitamin C (Ascorbic Water-soluble Antioxidant, Scurvy (bleeding gums,

acid) hydroxylation of poor wound healing)

proline/lysine

Vitamin D Fat-soluble Calcium absorption, bone Rickets, osteomalacia

mineralization

Vitamin E Fat-soluble Antioxidant Hemolytic anemia in

newborns

Vitamin K Fat-soluble γ-carboxylation of Bleeding diathesis

clotting factors

Medical Genetics

Genetic Terminology & Concepts

• Allele: Variant form of a gene.

• Locus: Specific location of a gene on a chromosome.

• Genotype: Genetic makeup of an organism.

• Phenotype: Observable traits.

• Penetrance: Probability that a genotype will express the phenotype.

• Expressivity: Degree of phenotype expression.

• Heterozygote: Two different alleles at a locus.

• Homozygote: Two identical alleles.

• Compound heterozygote: Two different mutant alleles at a locus.

• Loss of heterozygosity: Both alleles of a gene are inactivated (tumor suppressor genes).

• Mosaicism: Presence of two or more genetically distinct cell lines in one individual.

• Imprinting: Parent-of-origin specific gene expression.

• Anticipation: Increasing severity or earlier onset in successive generations.

Patterns of Inheritance

Pattern Description Examples Key Features

Autosomal Dominant One mutant allele Huntington disease, Vertical transmission,

sufficient Marfan syndrome variable expressivity

Autosomal Recessive Two mutant alleles Cystic fibrosis, PKU Horizontal transmission,

required often enzyme deficiencies

X-linked Recessive Mutation on X Duchenne muscular Males affected, female

chromosome, males dystrophy, G6PD carriers usually

affected deficiency asymptomatic

X-linked Dominant Mutation on X Fragile X syndrome Rare, males often more

chromosome, both sexes severely affected

affected

Mitochondrial Maternal inheritance Mitochondrial All offspring of affected

myopathies mother affected

Imprinting Disorders Expression depends on Prader-Willi (paternal Different phenotypes

parent of origin deletion), Angelman depending on parental

(maternal deletion) origin

Chromosomal Disorders

Disorder Chromosome Clinical Features Key Diagnostic Findings

Abnormality

Down Syndrome Trisomy 21 or Intellectual disability, flat ↑ nuchal translucency, ↓

(Trisomy 21) Robertsonian facies, single palmar AFP, ↑ β-hCG

translocation crease, congenital heart

defects (AV septal)

Edwards Syndrome Trisomy 18 Clenched fists, ↓ AFP, β-hCG, estriol

(Trisomy 18) rocker-bottom feet,

micrognathia, death by 1

year

Patau Syndrome Trisomy 13 Cleft lip/palate, Severe intellectual

(Trisomy 13) holoprosencephaly, disability, death by 1 year

polydactyly

Turner Syndrome 45,X Short stature, webbed Streak ovaries, ↑ FSH/LH

neck, coarctation of aorta,

gonadal dysgenesis

Klinefelter Syndrome 47,XXY Tall, gynecomastia, ↓ testosterone, ↑ FSH/LH

testicular atrophy,

infertility

Cri-du-chat Syndrome 5p deletion High-pitched crying, Cat-like cry

microcephaly, intellectual

disability

Single-Gene Disorders

Autosomal Dominant Disorders

Disorder Gene/Protein Clinical Features Notes

Huntington Disease CAG repeat expansion in Chorea, dementia, Anticipation,

HTT gene caudate atrophy trinucleotide repeat

Marfan Syndrome Fibrillin-1 mutation Tall stature, lens FBN1 gene, AD

dislocation, aortic connective tissue disorder

aneurysm

Neurofibromatosis Type NF1 gene mutation Café-au-lait spots, Chromosome 17, variable

1 neurofibromas, Lisch expressivity

nodules

Familial LDL receptor mutation Elevated LDL, tendon Homozygotes severe

Hypercholesterolemia xanthomas, early CAD disease

Autosomal Recessive Disorders

Disorder Enzyme/Protein Clinical Features Notes

Cystic Fibrosis CFTR mutation Recurrent pulmonary ∆F508 mutation common

infections, pancreatic

insufficiency, meconium

ileus

Phenylketonuria (PKU) Phenylalanine Intellectual disability, Treat with low

hydroxylase deficiency musty odor phenylalanine diet

Tay-Sachs Disease Hexosaminidase A Cherry-red spot, Ashkenazi Jewish

deficiency neurodegeneration population

Sickle Cell Disease Glutamic acid → valine Vaso-occlusive crises, HbS mutation

mutation hemolytic anemia

X-linked Disorders

Disorder Gene/Protein Clinical Features Notes

Duchenne Muscular Dystrophin gene deletion Progressive muscle Frameshift mutation,

Dystrophy weakness, calf onset <5 years

pseudohypertrophy

Becker Muscular Dystrophin mutation (less Later onset muscle In-frame deletion

Dystrophy severe) weakness

Hemophilia A Factor VIII deficiency Hemarthrosis, prolonged X-linked recessive

PTT

G6PD Deficiency G6PD enzyme deficiency Hemolytic anemia after Heinz bodies, bite cells

oxidative stress

Mitochondrial Inheritance

• Characteristics:

• Maternal inheritance only.

• Variable expression due to heteroplasmy.

• Common Disorders:

• MELAS: Mitochondrial Encephalomyopathy, Lactic Acidosis, Stroke-like episodes.

• Leber Hereditary Optic Neuropathy: Sudden vision loss in young adults.

• Mechanism: Mutations in mitochondrial DNA affecting oxidative phosphorylation.

Genetic Testing & Counseling

Test Purpose Sample Type Notes

Karyotyping Detect chromosomal Peripheral blood Detects aneuploidy, large

abnormalities lymphocytes deletions

FISH (Fluorescence in Detect microdeletions, Interphase or metaphase Faster than karyotype,

situ hybridization) duplications cells targeted

PCR (Polymerase Chain Amplify DNA segments Any DNA-containing Used for mutation

Reaction) sample detection

Southern Blot Detect large DNA DNA Used for trinucleotide

rearrangements repeat disorders

Northern Blot RNA detection RNA Measures gene expression

Western Blot Protein detection Protein Used in HIV diagnosis,

muscular dystrophy

Summary Tables

Enzyme Deficiency Disorders in Metabolism

Disorder Deficient Inheritance Key Clinical Biochemical

Enzyme/Protein Features Findings

Phenylketonuria Phenylalanine AR Intellectual ↑ Phenylalanine, ↓

(PKU) hydroxylase disability, musty Tyrosine

odor

Maple Syrup Urine Branched-chain AR Poor feeding, ↑ Leucine,

Disease α-ketoacid sweet-smelling isoleucine, valine

dehydrogenase urine

Homocystinuria Cystathionine AR Lens dislocation, ↑ Homocysteine

β-synthase thrombosis

Tay-Sachs Disease Hexosaminidase A AR Cherry-red spot, ↑ GM2 ganglioside

neurodegeneration

G6PD Deficiency Glucose-6-phosphat X-linked recessive Hemolytic anemia Heinz bodies, bite

e dehydrogenase after oxidative cells

stress

Common Genetic Disorders: Inheritance & Key Features

Disorder Inheritance Gene/Protein Key Features Notes

Huntington Disease AD HTT (CAG repeat) Chorea, dementia Anticipation

Cystic Fibrosis AR CFTR Pulmonary Sweat test positive

infections,

pancreatic

insufficiency

Duchenne Muscular X-linked recessive Dystrophin Progressive muscle Elevated CK

Dystrophy weakness

Down Syndrome Trisomy 21 Chromosomal Intellectual ↑ β-hCG, ↓ AFP

disability, flat facies

Fragile X Syndrome X-linked dominant FMR1 (CGG Intellectual Most common

repeat) disability, large ears inherited

intellectual

disability

Vitamin Deficiency Syndromes

Vitamin Deficiency Key Enzymatic Role Notes

Syndrome/Presentation

B1 (Thiamine) Wernicke-Korsakoff, Pyruvate dehydrogenase, Alcoholics at risk

Beriberi α-KG dehydrogenase

B3 (Niacin) Pellagra (diarrhea, NAD+/NADP+ synthesis Hartnup disease can cause

dermatitis, dementia) secondary deficiency

B6 (Pyridoxine) Convulsions, Transamination reactions INH therapy can cause

sideroblastic anemia deficiency

B9 (Folate) Megaloblastic anemia, 1-carbon transfers in Supplement in pregnancy

neural tube defects DNA synthesis

B12 (Cobalamin) Pernicious anemia, Methionine synthase, Requires intrinsic factor

subacute combined methylmalonyl-CoA

degeneration mutase

High-Yield Mnemonics

• Enzyme Cofactors (Vitamin-derived):

“The Lovely Coenzymes For Nerds”

Thiamine (B1), Lipoic acid, CoA (B5), FAD (B2), NAD+ (B3)

• Essential Amino Acids:

“PVT TIM HALL”

Phenylalanine, Valine, Tryptophan, Threonine, Isoleucine, Methionine, Histidine,

Arginine, Leucine, Lysine

Arginine is semi-essential.

• Urea Cycle Enzymes:

“Ordinarily, Careless Crappers Are Also Frivolous About Urination”

Ornithine transcarbamylase, Carbamoyl phosphate synthetase I, Citrulline,

Argininosuccinate synthetase, Argininosuccinate lyase, Urease

• DNA Repair Mechanisms:

• Nucleotide excision repair: “Cut out Pyrimidine dimers” (defective in Xeroderma

pigmentosum)

• Base excision repair: fixes small base modifications (e.g., deamination)

• Mismatch repair: fixes replication errors (defective in Lynch syndrome)

• X-linked Recessive Disorders:

“Oblivious Females Will Give Her Boys X-linked Disorders”

Ocular albinism, Fabry disease, Wiskott-Aldrich syndrome, G6PD deficiency, Hunter

syndrome, Bruton’s agammaglobulinemia, Hemophilia A & B, Lesch-Nyhan syndrome,

Duchenne muscular dystrophy

Summary

This section consolidates critical biochemistry and medical genetics concepts essential for

USMLE Step 1 success. Mastery of enzyme kinetics, metabolic pathways, genetic inheritance

patterns, and molecular biology mechanisms is vital. Recognize classic disease presentations,

biochemical defects, and genetic mutations to integrate clinical and basic science knowledge

effectively. Use tables and mnemonics to reinforce retention and rapid recall during exam

preparation.

Immunology & Microbiology

Overview

Immunology studies the immune system’s components and functions, including innate and

adaptive immunity, hypersensitivity reactions, immunodeficiencies, and autoimmunity.

Microbiology focuses on the classification, structure, pathogenesis, and treatment of

microorganisms: bacteria, viruses, fungi, and parasites.

Table of Contents

1. Innate Immunity

2. Adaptive Immunity

3. Hypersensitivity Reactions

4. Immunodeficiency Disorders

5. Autoimmune Diseases

6. Vaccines

7. Bacteriology

8. Virology

9. Mycology

10. Parasitology

11. Antimicrobial Agents

1. Innate Immunity

Components

• Physical barriers: Skin, mucous membranes

• Cellular: Neutrophils, macrophages, dendritic cells, NK cells

• Proteins: Complement system, acute phase reactants (CRP, fibrinogen)

• Receptors: Pattern recognition receptors (PRRs) like Toll-like receptors (TLRs)

recognize pathogen-associated molecular patterns (PAMPs)

Key Features

Feature Innate Immunity Adaptive Immunity

Response time Immediate (minutes to hours) Delayed (days)

Specificity Broad, recognizes PAMPs Highly specific to antigen

Memory None Yes

Major cells Neutrophils, macrophages, NK B cells, T cells

cells

Receptors Germline encoded PRRs Somatically recombined receptors

Toll-Like Receptors (TLRs)

TLR # Ligand Cell Type Response

TLR4 LPS (Gram-negative Macrophages, DCs NF-κB activation,

bacteria) cytokines

TLR3 dsRNA (viruses) Dendritic cells IFN production

TLR9 CpG DNA (bacterial Plasmacytoid DCs IFN-α production

DNA)

Complement System

• Pathways: Classical (antibody-dependent), Alternative (pathogen surface), Lectin

(mannose-binding lectin)

• Functions: Opsonization (C3b), chemotaxis (C5a), MAC formation (C5b-9) causing

cell lysis

• Deficiencies: C3 deficiency → recurrent pyogenic infections; C5-C9 deficiency →

Neisseria infections

2. Adaptive Immunity

Cells

• B cells: Produce antibodies; mature in bone marrow

• T cells: Mature in thymus; subsets include CD4+ helper T cells and CD8+ cytotoxic T

cells

T Cell Subsets and Functions

Subset Surface Markers Cytokines Produced Function Transcription

Factor

Th1 CD4+ IFN-γ, IL-2 Activate T-bet

macrophages,

cell-mediated

immunity

Th2 CD4+ IL-4, IL-5, IL-13 Stimulate GATA3

eosinophils, B cell

class switching to

IgE

Th17 CD4+ IL-17, IL-22 Recruit neutrophils, RORγt

inflammation

Treg CD4+CD25+ TGF-β, IL-10 Suppress immune FoxP3

response

Antigen Presentation

• MHC Class I: Presents endogenous peptides to CD8+ T cells; expressed on all

nucleated cells

• MHC Class II: Presents exogenous peptides to CD4+ T cells; expressed on APCs

(macrophages, dendritic cells, B cells)

Antibody Structure & Function

• Structure: 2 heavy chains + 2 light chains; Fab region binds antigen; Fc region

mediates effector functions

• Classes: IgG, IgA, IgM, IgE, IgD

• Functions:

Antibody Function Location Notes

IgG Opsonization, Blood, extracellular fluid Most abundant;

complement activation, secondary immune

crosses placenta response

IgA Mucosal immunity Secretions (saliva, tears, Dimeric form; protects

breast milk) mucosa

IgM First antibody produced, Blood Pentamer; primary

complement activation immune response

IgE Allergic reactions, Bound to mast cells, Triggers histamine

parasite defense basophils release

IgD B cell receptor B cell surface Function unclear

3. Hypersensitivity Reactions

Type Mechanism Onset Examples Key Features /

Buzzwords

I IgE-mediated mast Minutes Anaphylaxis, Wheal and flare,

cell degranulation asthma, allergic urticaria,

rhinitis eosinophils

II Antibody-mediated Hours to days Autoimmune Complement

cytotoxicity hemolytic anemia, activation,

(IgG/IgM) Goodpasture opsonization

syndrome

III Immune complex Hours to days SLE, serum Vasculitis, low

deposition sickness, post-strep complement levels

GN

IV T cell-mediated 48-72 hours Contact dermatitis, Granuloma

(delayed type) TB skin test, graft formation,

rejection macrophage

activation

4. Immunodeficiency Disorders

Primary Immunodeficiencies

Disorder Defect Clinical Features Lab Findings

SCID (Severe Combined Defective IL-2R γ chain Recurrent viral, bacterial, Low T and B cells; absent

Immunodeficiency) or adenosine deaminase fungal infections thymic shadow

deficiency

X-linked BTK gene mutation → no Recurrent bacterial Absent B cells, low all Ig

Agammaglobulinemia B cell maturation infections after 6 months classes

(Bruton)

Common Variable B cell differentiation Recurrent bacterial Low IgG, IgA, sometimes

Immunodeficiency defect infections, autoimmune IgM

(CVID) disease

DiGeorge Syndrome 22q11 deletion → thymic Recurrent viral/fungal Low T cells, absent

aplasia infections, hypocalcemia thymic shadow

Chronic Granulomatous NADPH oxidase defect Recurrent Abnormal Nitroblue

Disease → impaired respiratory catalase-positive tetrazolium test

burst infections (S. aureus)

Secondary Immunodeficiencies

• HIV infection → CD4+ T cell depletion

• Malnutrition, chemotherapy, immunosuppressive drugs

5. Autoimmune Diseases

Disease Autoantibody Target Antigen / Clinical Features HLA Association

Organ

SLE Anti-dsDNA, Nuclear antigens Malar rash, HLA-DR2, DR3

Anti-Smith nephritis, arthritis

Rheumatoid Rheumatoid factor Fc portion of IgG Symmetric joint HLA-DR4

Arthritis (IgM against IgG inflammation

Fc)

Graves Disease TSH receptor TSH receptor Hyperthyroidism, HLA-DR3

stimulating exophthalmos

antibody

Hashimoto Anti-thyroid Thyroid gland Hypothyroidism, HLA-DR5

Thyroiditis peroxidase, goiter

anti-thyroglobulin

Pernicious Anemia Anti-intrinsic Gastric parietal Megaloblastic

factor, anti-parietal cells anemia, glossitis

cells

Goodpasture Anti-GBM antibody Basement Hematuria,

Syndrome membrane (kidney, hemoptysis

lung)

6. Vaccines

Vaccine Type Description Examples Notes

Live attenuated Weakened pathogen, MMR, Varicella, Sabin Contraindicated in

strong immunity polio immunocompromised

Inactivated (killed) Dead pathogen Salk polio, influenza Safer, weaker immunity,

(injected) booster needed

Subunit / Recombinant Specific antigenic HBV, HPV, acellular Lower risk of adverse

proteins pertussis effects

Toxoid Inactivated bacterial toxin Tetanus, diphtheria Requires boosters

Conjugate Polysaccharide + protein Hib, pneumococcal Enhances response in

carrier infants

7. Bacteriology

Bacterial Classification

Characteristic Gram-Positive Gram-Negative

Cell wall Thick peptidoglycan Thin peptidoglycan + outer

membrane

Stain Purple Pink (safranin counterstain)

Teichoic acids Present Absent

Endotoxin (LPS) Absent Present

Examples Staphylococcus, Streptococcus E. coli, Pseudomonas, Neisseria

Important Gram-Positive Cocci

Organism Catalase Coagulase Hemolysis (Blood Diseases / Notes

Agar)

Staphylococcus + + Beta-hemolytic Skin infections,

aureus abscesses, TSS,

MRSA

Staphylococcus + – Gamma-hemolytic Prosthetic device

epidermidis infections

Streptococcus – – Beta-hemolytic Pharyngitis,

pyogenes (Group rheumatic fever,

A) glomerulonephritis

Streptococcus – – Beta-hemolytic Neonatal sepsis,

agalactiae (Group meningitis

B)

Streptococcus – – Alpha-hemolytic Pneumonia,

pneumoniae meningitis, otitis

media

Viridans – – Alpha-hemolytic Dental caries,

streptococci subacute

endocarditis

Important Gram-Negative Rods

Organism Lactose Fermentation Oxidase Diseases / Notes

E. coli + – UTI, neonatal meningitis,

sepsis

Organism Lactose Fermentation Oxidase Diseases / Notes

Klebsiella pneumoniae + – Pneumonia (currant jelly

sputum)

Pseudomonas aeruginosa – + Pneumonia in CF, burn

infections

Salmonella – – Gastroenteritis, typhoid

fever

Shigella – – Dysentery

Acid-Fast Bacteria

• Mycobacterium tuberculosis: Causes TB; acid-fast bacilli; granuloma formation with

caseating necrosis

• Nocardia: Weakly acid-fast; causes pulmonary infections in immunocompromised

• Mycobacterium leprae: Causes leprosy; infects skin and peripheral nerves

8. Virology

Virus Structure

Component Description

Capsid Protein coat, helical or icosahedral symmetry

Envelope Lipid bilayer derived from host cell membrane

Genome DNA or RNA, single or double stranded

DNA vs RNA Viruses

Feature DNA Viruses RNA Viruses

Genome Mostly dsDNA (except parvovirus) Mostly ssRNA (except reovirus)

Replication site Nucleus Cytoplasm

Examples HSV, CMV, Adenovirus, HPV Influenza, HIV, HCV, Rhinovirus

Important DNA Viruses

Virus Family Disease(s) Key Features / Notes

Herpes Simplex Virus Herpesviridae Gingivostomatitis, genital Latency in neurons

(HSV-1, HSV-2) herpes, encephalitis

Varicella-Zoster Virus Herpesviridae Chickenpox, shingles Latency in dorsal root

(VZV) ganglia

Epstein-Barr Virus (EBV) Herpesviridae Infectious mononucleosis, Infects B cells;

Burkitt lymphoma heterophile antibody

positive

Cytomegalovirus (CMV) Herpesviridae Congenital infection, Owl’s eye inclusions

mononucleosis-like

syndrome

Human Papillomavirus Papillomaviridae Cervical cancer, warts E6/E7 proteins inactivate

(HPV) p53/Rb

Hepatitis B Virus (HBV) Hepadnaviridae Hepatitis B, DNA virus with reverse

hepatocellular carcinoma transcriptase

Important RNA Viruses

Virus Family Genome Type Disease(s) Notes

Influenza virus Orthomyxoviridae (-) ssRNA Flu, pneumonia Antigenic shift and

segmented drift

HIV Retroviridae (+) ssRNA (2 AIDS Reverse

copies) transcriptase, CD4+

tropism

Hepatitis C Virus Flaviviridae (+) ssRNA Chronic hepatitis, No vaccine

(HCV) hepatocellular available

carcinoma

Rhinovirus Picornaviridae (+) ssRNA Common cold Acid labile;

replicates in nose

Rabies virus Rhabdoviridae (-) ssRNA Encephalitis Bullet-shaped;

Negri bodies

9. Mycology

Classification

Fungi Type Characteristics Examples Disease(s)

Yeasts Unicellular, reproduce by Candida, Cryptococcus Candidiasis,

budding cryptococcosis

Molds Multicellular, hyphae Aspergillus, Mucor Aspergillosis,

mucormycosis

Dimorphic fungi Yeast at 37°C, mold at Histoplasma, Systemic mycoses

25°C Blastomyces,

Coccidioides

Important Fungal Infections

Fungus Morphology Disease(s) Key Features / Diagnosis

Candida albicans Yeast with pseudohyphae Thrush, esophagitis, Germ tube positive; oral

vulvovaginitis thrush in

immunocompromised

Cryptococcus neoformans Encapsulated yeast Meningitis in AIDS India ink stain; latex

agglutination test

Aspergillus fumigatus Septate hyphae, acute Allergic Galactomannan antigen

angle branching bronchopulmonary test

aspergillosis, invasive

aspergillosis

Histoplasma capsulatum Intracellular yeast Histoplasmosis Ohio/Mississippi river

valley; macrophage filled

with yeast

Mucor, Rhizopus Broad, nonseptate Rhinocerebral Diabetic ketoacidosis risk

hyphae, right angle mucormycosis factor

branching

10. Parasitology

Protozoa

Parasite Transmission Disease Key Features / Diagnosis

Plasmodium spp. Anopheles mosquito Malaria Fever every 48-72 hrs;

ring forms in RBCs

Toxoplasma gondii Cat feces, undercooked Congenital toxoplasmosis Intracellular;

meat ring-enhancing brain

lesions

Trypanosoma brucei Tsetse fly African sleeping sickness Winterbottom sign

(posterior cervical

lymphadenopathy)

Giardia lamblia Contaminated water Giardiasis Frothy diarrhea;

trophozoites in stool

Entamoeba histolytica Fecal-oral Amebiasis Bloody diarrhea;

flask-shaped ulcers

Helminths

Parasite Type Transmission Disease Key Features

Enterobius Nematode Fecal-oral Pinworm infection Perianal pruritus;

vermicularis (roundworm) Scotch tape test

Ascaris Nematode Fecal-oral Intestinal Largest intestinal

lumbricoides obstruction roundworm

Schistosoma spp. Trematode (fluke) Snail intermediate Schistosomiasis Hematuria (S.

host haematobium),

portal hypertension

(S. mansoni)

Taenia solium Cestode (tapeworm) Undercooked pork Cysticercosis, Neurocysticercosis

taeniasis causes seizures

11. Antimicrobial Agents

Mechanism of Action & Resistance

Drug Class Target / Mechanism Examples Resistance Mechanism

Beta-lactams Inhibit cell wall synthesis Penicillins, Beta-lactamase

(PBPs) cephalosporins production, altered PBPs

Aminoglycosides Inhibit 30S ribosomal Gentamicin, amikacin Enzymatic modification,

subunit efflux pumps

Macrolides Inhibit 50S ribosomal Erythromycin, Methylation of 23S rRNA

subunit azithromycin

Fluoroquinolones Inhibit DNA Ciprofloxacin, Mutations in

gyrase/topoisomerase IV levofloxacin gyrase/topoisomerase

genes

Sulfonamides Inhibit dihydropteroate Sulfamethoxazole Increased PABA

synthase production

Tetracyclines Inhibit 30S ribosomal Doxycycline Efflux pumps, ribosomal

subunit protection

Common Antimicrobials Summary

Drug Spectrum Toxicity Notes

Penicillin G Gram-positive cocci, Hypersensitivity reactions DOC for syphilis

spirochetes

Vancomycin Gram-positive only Nephrotoxicity, red man MRSA treatment

syndrome

Aminoglycosides Aerobic gram-negative Nephrotoxicity, Synergistic with

rods ototoxicity beta-lactams

Macrolides Atypicals, gram-positive GI upset, prolonged QT Alternative to penicillin

cocci allergy

Fluoroquinolones Gram-negative rods, Tendon rupture, QT Avoid in pregnancy and

some gram-positive prolongation children

TMP-SMX Gram-negative rods, Megaloblastic anemia, Used for UTI, PCP

Pneumocystis rash prophylaxis

Mnemonics

Hypersensitivity Types

• ACID

• A: Type I = Allergy (IgE)

• C: Type II = Cytotoxic (IgG/IgM)

• I: Type III = Immune complex

• D: Type IV = Delayed (T cell)

Encapsulated Bacteria (Require spleen)

• SHiNE SKiS

• S. pneumoniae

• H. influenzae type b

• N. meningitidis

• E. coli

• Salmonella

• Klebsiella pneumoniae

• Streptococcus agalactiae

DNA Viruses

• HHAPPPPy

• Herpesviruses

• Hepadnavirus

• Adenovirus

• Papillomavirus

• Parvovirus

• Polyomavirus

• Poxvirus

Summary Tables

Comparison of Gram-Positive Cocci

Organism Gram Stain Catalase Coagulase Hemolysis Diseases Treatment

Staphylococc + + + Beta Skin Nafcillin

us aureus infections, (MSSA),

TSS, vancomycin

pneumonia (MRSA)

Staphylococc + + – None Prosthetic Vancomycin

us device

epidermidis infections

Streptococcu + – – Beta Pharyngitis, Penicillin

s pyogenes rheumatic

fever

Streptococcu + – – Beta Neonatal Penicillin

s agalactiae sepsis

Streptococcu + – – Alpha Pneumonia, Penicillin,

s meningitis ceftriaxone

pneumoniae

Key Viral Families and Diseases

Virus Family Genome Type Diseases Key Features

Herpesviridae dsDNA HSV, VZV, EBV, CMV Latency in neurons or B

cells

Retroviridae (+) ssRNA HIV Reverse transcriptase

Orthomyxoviridae (-) ssRNA segmented Influenza Antigenic shift and drift

Picornaviridae (+) ssRNA Poliovirus, Rhinovirus Acid stable (except

rhinovirus)

Flaviviridae (+) ssRNA HCV, Yellow fever Enveloped

Antimicrobial Mechanisms and Toxicities

Drug Class Mechanism Toxicity Resistance Mechanism

Beta-lactams Inhibit cell wall synthesis Hypersensitivity, Beta-lactamase

hemolytic anemia production

Aminoglycosides Inhibit 30S ribosome Nephrotoxicity, Enzymatic modification

ototoxicity

Drug Class Mechanism Toxicity Resistance Mechanism

Macrolides Inhibit 50S ribosome GI upset, QT Methylation of 23S rRNA

prolongation

Fluoroquinolones Inhibit DNA Tendon rupture, QT Mutations in gyrase genes

gyrase/topoisomerase prolongation

Sulfonamides Inhibit folate synthesis Stevens-Johnson Increased PABA

syndrome production

High-Yield Clinical Correlations

• Neutrophil chemotaxis defect: Leukocyte adhesion deficiency → delayed separation

of umbilical cord

• Complement deficiency (C5-C9): Recurrent Neisseria infections

• Bruton agammaglobulinemia: Absent B cells, recurrent bacterial infections after 6

months (loss of maternal IgG)

• DiGeorge syndrome: Thymic aplasia → decreased T cells → viral/fungal infections

• HIV infection: CD4+ T cell depletion → opportunistic infections (Pneumocystis

jirovecii, CMV retinitis)

• SLE: Anti-dsDNA antibodies → nephritis; anti-Smith antibodies diagnostic

• Rheumatic fever: Molecular mimicry → anti-streptococcal antibodies cross-react with

heart tissue

• Pseudomonas aeruginosa: Produces blue-green pigment (pyocyanin), causes

pneumonia in CF patients

• Histoplasma capsulatum: Intracellular yeast in macrophages; endemic to

Ohio/Mississippi river valleys

• Plasmodium falciparum: Causes severe malaria with cerebral involvement; ring forms

in RBCs

Summary

Mastering immunology and microbiology requires understanding immune mechanisms,

pathogen characteristics, and clinical presentations. Focus on:

• Innate vs adaptive immunity distinctions

• Hypersensitivity types and examples

• Primary immunodeficiencies and their clinical clues

• Autoimmune diseases and associated autoantibodies

• Vaccine types and indications

• Bacterial classification and key pathogens

• Viral families, genome types, and diseases

• Fungal and parasitic infections with geographic and clinical patterns

• Antimicrobial mechanisms, spectrum, and resistance

This high-yield framework supports rapid recall and clinical application on Step 1 and beyond.

Pathology & Pharmacology Basics

Overview

This section covers foundational concepts in pathology and pharmacology essential for

USMLE Step 1. It integrates mechanisms of disease with drug actions, emphasizing high-yield

facts, classic presentations, and mnemonics to aid rapid recall.

Table of Contents

1. Pathology Basics

2. Cell Injury & Death

3. Inflammation & Repair

4. Hemodynamics & Shock

5. Genetic & Pediatric Diseases

6. Neoplasia

7. Pharmacology Basics

8. Pharmacokinetics

9. Pharmacodynamics

10. Drug Metabolism & Interactions

11. Autonomic Pharmacology

12. Antibiotics & Antimicrobials

13. Cardiovascular Pharmacology

14. CNS Pharmacology

1. Pathology Basics

Cell Injury & Death

Types of Cell Injury

• Reversible Injury: Cellular swelling, fatty change

• Irreversible Injury: Membrane damage, mitochondrial dysfunction, nuclear changes

(pyknosis, karyorrhexis, karyolysis)

Mechanisms of Cell Injury

Mechanism Description Examples

ATP depletion Loss of energy → Na+/K+ pump Ischemia

failure

Mitochondrial damage Release of cytochrome c → Toxins, hypoxia

apoptosis

Ca2+ influx Activation of destructive enzymes Ischemia, toxins

Oxidative stress Free radical damage to lipids, Radiation, reperfusion injury

proteins, DNA

Membrane damage Loss of phospholipids, lipid ROS, toxins

peroxidation

DNA damage Mutations, strand breaks → Radiation, chemotherapy

apoptosis

Cell Death Types

Type Morphology Mechanism Clinical Example

Necrosis Cell swelling, membrane ATP depletion, MI, infarcts

rupture, inflammation membrane damage

Apoptosis Cell shrinkage, chromatin Caspase activation, DNA Physiologic cell turnover,

condensation, no fragmentation viral hepatitis

inflammation

Necrosis Patterns

Type Description Classic Example Buzzwords

Coagulative Architecture preserved, MI (except brain) “Ghost cells”

denatured proteins

Type Description Classic Example Buzzwords

Liquefactive Enzymatic digestion → Brain abscess, stroke “Cystic cavity”

pus formation

Caseous Granulomatous TB “Cheese-like”

inflammation, cheese-like

Fat Fat saponification with Pancreatitis “Soap bubbles”

Ca2+

Fibrinoid Immune complexes + Vasculitis “Bright pink” on H&E

fibrin in vessel walls

Gangrenous Coagulative necrosis + Lower limb ischemia “Wet” vs “dry” gangrene

superimposed infection

Inflammation & Repair

Acute Inflammation

• Key Cells: Neutrophils (PMNs)

• Vascular Changes: Vasodilation, increased permeability

• Mediators: Histamine, prostaglandins, leukotrienes, cytokines (TNF, IL-1)

• Signs: Rubor, calor, tumor, dolor, functio laesa

Steps of Leukocyte Extravasation

1. Rolling: Selectins (E-, P-selectin)

2. Adhesion: Integrins (CD11/CD18)

3. Transmigration: PECAM-1

4. Chemotaxis: C5a, LTB4, IL-8

Chronic Inflammation

• Key Cells: Macrophages, lymphocytes, plasma cells

• Granuloma: Aggregates of epithelioid macrophages + giant cells

• Causes: TB, sarcoidosis, foreign bodies

Mediators of Inflammation

Mediator Source Action Inhibited by

Histamine Mast cells Vasodilation, Antihistamines (H1

permeability blockers)

Prostaglandins COX pathway Pain, fever, vasodilation NSAIDs (COX

inhibitors)

Mediator Source Action Inhibited by

Leukotrienes 5-LO pathway Chemotaxis, Zileuton, montelukast

bronchospasm

TNF, IL-1 Macrophages Fever, leukocyte Anti-TNF agents

recruitment

C3a, C5a Complement cascade Anaphylaxis, chemotaxis Complement inhibitors

Tissue Repair

• Regeneration: Proliferation of residual cells + stem cells

• Scar Formation: Fibroblast proliferation, collagen deposition, angiogenesis

• Key Growth Factors: VEGF (angiogenesis), TGF-β (fibrosis), PDGF (fibroblast

growth)

Hemodynamics & Shock

Edema Mechanisms

Cause Mechanism Examples

Increased hydrostatic pressure Venous obstruction or CHF DVT, heart failure

Decreased oncotic pressure Hypoalbuminemia Nephrotic syndrome, cirrhosis

Lymphatic obstruction Impaired drainage Filariasis

Sodium retention Increased volume Hyperaldosteronism

Inflammation Increased vascular permeability Infection, allergy

Shock Types

Type Cause Hemodynamics Classic Features

Hypovolemic Hemorrhage, dehydration ↓ preload, ↓ CO Cold, clammy skin

Cardiogenic MI, arrhythmia ↓ CO, ↑ preload Pulmonary edema

Distributive Sepsis, anaphylaxis, ↓ SVR, ↑ CO Warm skin, hypotension

neurogenic

Obstructive PE, tamponade ↓ CO, ↑ preload Jugular venous distension

Genetic & Pediatric Diseases

Patterns of Inheritance

Pattern Description Examples

Autosomal dominant Vertical transmission, variable Marfan, Huntington

expressivity

Autosomal recessive Horizontal transmission, often CF, PKU

enzyme deficiencies

X-linked recessive Males affected, females carriers Duchenne MD, Hemophilia

Mitochondrial Maternal inheritance Leber hereditary optic neuropathy

Common Genetic Disorders

Disorder Gene/Mutation Key Features Inheritance

Marfan syndrome FBN1 mutation Tall, lens dislocation, AD

(fibrillin-1) aortic aneurysm

Cystic fibrosis CFTR mutation Recurrent lung infections, AR

pancreatic insufficiency

Duchenne muscular Dystrophin gene deletion Progressive muscle X-linked recessive

dystrophy weakness, Gower sign

Phenylketonuria (PKU) Phenylalanine Intellectual disability, AR

hydroxylase deficiency musty odor

Neoplasia

Definitions

• Benign: Well-differentiated, slow growth, no metastasis

• Malignant: Poor differentiation, rapid growth, metastasis

Hallmarks of Cancer (Hanahan & Weinberg)

1. Self-sufficiency in growth signals

2. Insensitivity to anti-growth signals

3. Evading apoptosis

4. Limitless replicative potential

5. Sustained angiogenesis

6. Tissue invasion and metastasis

Oncogenes vs Tumor Suppressor Genes

Gene Type Function Associated Cancer

RAS Oncogene GTPase, signal Pancreatic, colon cancer

transduction

MYC Oncogene Transcription factor Burkitt lymphoma

p53 Tumor suppressor DNA damage checkpoint Most cancers

RB Tumor suppressor G1/S cell cycle inhibitor Retinoblastoma,

osteosarcoma

Carcinogenesis Steps

• Initiation: DNA mutation

• Promotion: Clonal expansion

• Progression: Additional mutations, invasion

2. Pharmacology Basics

Pharmacokinetics (PK)

Key Parameters

Parameter Definition Formula/Notes

Absorption Movement from site → blood Bioavailability (F)

Distribution Movement from blood → tissues Vd = amount/plasma conc.

Metabolism Biotransformation (Phase I & II) Liver (CYP450)

Excretion Removal from body Kidney (GFR, secretion)

Clearance (Cl) Volume plasma cleared per time Cl = rate of elimination / plasma

conc.

Half-life (t½) Time to reduce plasma conc. by t½ = 0.7 × Vd / Cl

50%

Absorption Factors

• Increased by: High lipid solubility, large surface area, high blood flow

• Decreased by: First-pass metabolism, poor solubility, food

Volume of Distribution (Vd)

Vd (L) Interpretation Examples

<5 Mostly plasma Albumin

10-20 ECF Aminoglycosides

> 40 Total body water or fat Digoxin, lithium

Pharmacodynamics (PD)

Dose-Response Curves

• Potency: Drug concentration for effect (EC50)

• Efficacy: Maximal effect (Emax)

• Therapeutic index: TD50/ED50 (higher = safer)

Types of Drug-Receptor Interactions

Type Effect Example

Agonist Activates receptor Morphine (µ-opioid agonist)

Partial agonist Partial activation Buprenorphine

Antagonist Blocks receptor Naloxone

Inverse agonist Produces opposite effect β-carbolines (GABA receptor)

Drug Metabolism & Interactions

Phases of Metabolism

Phase Description Enzymes Effect

Phase I Oxidation, reduction, CYP450 Converts lipophilic →

hydrolysis polar

Phase II Conjugation Transferases Increases water solubility

(glucuronidation,

sulfation)

CYP450 Inducers & Inhibitors

Inducers Effect Inhibitors Effect

Rifampin, ↑ metabolism → ↓ drug Cimetidine, ↓ metabolism → ↑ drug

Carbamazepine, levels Ketoconazole, levels

Phenytoin, St. John’s Macrolides, Grapefruit

Wort juice

Autonomic Pharmacology

Neurotransmitters & Receptors

Neurotransmitter Receptor Type Location Effect

Acetylcholine (ACh) Nicotinic (N), Muscarinic NMJ, autonomic ganglia, Muscle contraction,

(M) parasympathetic effector parasympathetic effects

organs

Norepinephrine (NE) α1, α2, β1, β2 adrenergic Sympathetic target organs Vasoconstriction,

increased HR,

bronchodilation

Parasympathomimetics vs Parasympatholytics

Drug Class Mechanism Examples Clinical Use

Parasympathomimetics ACh agonists or AChE Pilocarpine, Neostigmine Glaucoma, myasthenia

inhibitors gravis

Parasympatholytics Muscarinic antagonists Atropine, Scopolamine Bradycardia, motion

sickness

Sympathomimetics vs Sympatholytics

Drug Class Mechanism Examples Clinical Use

Sympathomimetics α/β agonists Epinephrine, Albuterol Anaphylaxis, asthma

Sympatholytics α/β antagonists Propranolol, Prazosin Hypertension, BPH

Antibiotics & Antimicrobials

Antibiotic Classes & Mechanisms

Class Mechanism Examples Resistance Mechanism

β-lactams Inhibit cell wall synthesis Penicillins, β-lactamase production

Cephalosporins

Aminoglycosides Inhibit 30S ribosomal Gentamicin Enzymatic modification

subunit

Macrolides Inhibit 50S ribosomal Erythromycin Methylation of 23S rRNA

subunit

Fluoroquinolones Inhibit DNA gyrase Ciprofloxacin Mutation in gyrase

Sulfonamides Inhibit folate synthesis Sulfamethoxazole Increased PABA

production

Bactericidal vs Bacteriostatic

Drug Type Notes

Penicillins Bactericidal Time-dependent killing

Aminoglycosides Bactericidal Concentration-dependent

Tetracyclines Bacteriostatic Broad spectrum

Macrolides Bacteriostatic Good atypical coverage

Cardiovascular Pharmacology

Antiarrhythmics (Vaughan Williams Classification)

Class Mechanism Examples Use

I (Na+ channel blockers) Slow depolarization Ia: Quinidine; Ib: Arrhythmias

Lidocaine; Ic: Flecainide

II (β-blockers) ↓ SA/AV node Propranolol, Metoprolol SVT, post-MI

conduction

III (K+ channel blockers) Prolong repolarization Amiodarone, Sotalol VT, AF

IV (Ca2+ channel ↓ AV node conduction Verapamil, Diltiazem SVT, HTN

blockers)

Antihypertensives

Class Mechanism Examples Side Effects

ACE inhibitors ↓ Ang II production Lisinopril Cough, angioedema

ARBs Block Ang II receptor Losartan Hyperkalemia

Calcium channel blockers Vasodilation, ↓ Amlodipine, Verapamil Edema, constipation

contractility

Thiazide diuretics ↓ Na+ reabsorption in Hydrochlorothiazide Hypokalemia,

DCT hyperglycemia

CNS Pharmacology

Sedative-Hypnotics

Drug Mechanism Use Notes

Benzodiazepines ↑ GABA-A receptor Anxiety, seizures Dependence, respiratory

activity depression

Barbiturates Prolong GABA-A Anesthesia, seizures Narrow therapeutic

opening window

Antidepressants

Class Mechanism Examples Side Effects

SSRIs ↑ Serotonin Fluoxetine, Sertraline Sexual dysfunction,

serotonin syndrome

TCAs ↑ NE and 5-HT Amitriptyline Anticholinergic,

cardiotoxic

MAO inhibitors Inhibit monoamine Phenelzine Hypertensive crisis with

oxidase tyramine

Summary Tables

Table 1: Cell Death Types & Features

Feature Necrosis Apoptosis

Cell size Swelling Shrinkage

Nuclear changes Pyknosis, karyorrhexis, karyolysis Fragmentation

Membrane integrity Loss, leakage Intact

Inflammation Present Absent

Energy requirement Passive Active (ATP-dependent)

Physiologic/Pathologic Pathologic Both

Table 2: Pharmacokinetics Parameters

Parameter Definition Clinical Relevance

Bioavailability (F) Fraction absorbed into circulation Oral drug dosing

Volume of distribution (Vd) Theoretical volume for drug Determines loading dose

distribution

Clearance (Cl) Volume plasma cleared per time Determines maintenance dose

Half-life (t½) Time for plasma concentration to Dosing interval

halve

Table 3: Autonomic Drugs & Effects

Drug Receptor Target Effect Clinical Use

Atropine Muscarinic antagonist ↑ HR, ↓ secretions Bradycardia,

organophosphate

poisoning

Phenylephrine α1 agonist Vasoconstriction Nasal decongestant

Propranolol β1, β2 antagonist ↓ HR, HTN, angina

bronchoconstriction

Albuterol β2 agonist Bronchodilation Asthma

Mnemonics

• Cell Injury Mechanisms: “A MIC”

ATP depletion, Mitochondrial damage, Increased Ca2+, Cell membrane damage

• Acute Inflammation Mediators: “HOT T Bone”

Histamine, Oxygen radicals, TNF, TPA, Bradykinin, Oxygen radicals, Nitric oxide,

Eicosanoids

• CYP450 Inducers: “CRAP GPS”

Carbamazepine, Rifampin, Alcohol (chronic), Phenytoin, Griseofulvin, Phenobarbital, St.

John’s Wort

• Vascular Mediators of Edema: “CHIP”

Congestion (↑ hydrostatic pressure), Hypoproteinemia (↓ oncotic pressure),

Inflammation, Poor lymphatic drainage

Key High-Yield Points

• Ischemic injury → ATP depletion → Na+/K+ pump failure → cell swelling →

irreversible injury if prolonged.

• Neutrophils dominate acute inflammation; macrophages dominate chronic

inflammation.

• Granulomas are collections of macrophages with epithelioid appearance, seen in TB

and sarcoidosis.

• Vasodilation in inflammation is mediated by histamine and prostaglandins.

• Phase I metabolism involves CYP450 enzymes; phase II involves conjugation

reactions.

• Beta blockers decrease heart rate and contractility; non-selective blockers can cause

bronchospasm.

• Penicillins inhibit bacterial cell wall synthesis by binding penicillin-binding proteins.

• Apoptosis is energy-dependent and does not elicit inflammation, unlike necrosis.

• Volume of distribution helps determine loading dose; clearance and half-life guide

maintenance dosing.

• Sympathetic stimulation: α1 → vasoconstriction; β1 → increased HR; β2 →

bronchodilation.

This foundational knowledge integrates pathology and pharmacology principles critical for

understanding disease mechanisms and therapeutic interventions tested on USMLE Step 1.

Cardiovascular System

Overview

The cardiovascular system consists of the heart, blood vessels, and blood. It functions to

deliver oxygen and nutrients to tissues and remove waste products. Understanding

cardiovascular physiology, pathology, pharmacology, and clinical correlations is essential for

USMLE Step 1.

Cardiac Anatomy & Physiology

Heart Chambers & Valves

Structure Function Location/Notes

Right Atrium Receives deoxygenated blood from Contains SA node (pacemaker)

systemic veins (SVC, IVC)

Right Ventricle Pumps blood to lungs via Tricuspid valve (RA-RV)

pulmonary artery

Left Atrium Receives oxygenated blood from Bicuspid (mitral) valve (LA-LV)

pulmonary veins

Left Ventricle Pumps oxygenated blood to Thickest myocardium, highest

systemic circulation via aorta pressure

Cardiac Valves

• Atrioventricular valves: Tricuspid (right), Mitral (left)

• Semilunar valves: Pulmonary, Aortic

• Valve closure produces heart sounds:

• S1 = AV valve closure (beginning systole)

• S2 = Semilunar valve closure (beginning diastole)

Cardiac Cycle

Phase Description Pressure Changes

Isovolumetric contraction Ventricles contract, all valves Ventricular pressure rises, volume

closed constant

Ejection Semilunar valves open, blood Ventricular pressure >

ejected aortic/pulmonary artery pressure

Phase Description Pressure Changes

Isovolumetric relaxation Ventricles relax, all valves closed Ventricular pressure falls, volume

constant

Ventricular filling AV valves open, ventricles fill Ventricular pressure < atrial

pressure

Electrical Conduction System

Structure Location/Function Action Potential Characteristics

SA node Right atrium; primary pacemaker Phase 4 spontaneous depolarization

(funny current, If)

AV node Interatrial septum; delays impulse Slow conduction, allows atrial

contraction before ventricular

Bundle of His Interventricular septum Rapid conduction

Purkinje fibers Ventricular myocardium Rapid conduction, coordinates

contraction

Cardiac Action Potential Phases

Phase Description Ionic Currents

0 Rapid depolarization Na■ influx via fast Na■ channels

1 Initial repolarization Transient K■ efflux

2 Plateau Ca²■ influx (L-type channels), K■

efflux

3 Repolarization K■ efflux

4 Resting membrane potential Na■/K■ ATPase maintains

gradient

• Pacemaker cells (SA/AV nodes): Phase 0 is due to Ca²■ influx, slow upstroke.

Hemodynamics

Key Concepts

• Cardiac Output (CO): Volume of blood pumped per minute

[ CO = HR \times SV ]

• Stroke Volume (SV): Volume ejected per beat

• Ejection Fraction (EF):

[ EF = \frac{SV}{EDV} \times 100\% ]

• Blood Pressure (BP):

[ BP = CO \times TPR ]

• Total Peripheral Resistance (TPR): Resistance to blood flow in systemic circulation

Starling’s Law of the Heart

• Increased preload (end-diastolic volume) → increased stroke volume due to optimal

actin-myosin overlap.

Pressure-Volume Loop

• X-axis: LV volume

• Y-axis: LV pressure

• Phases: filling, isovolumetric contraction, ejection, isovolumetric relaxation

Cardiac Physiology: Important Parameters

Parameter Normal Value Clinical Significance

Heart Rate (HR) 60-100 bpm Tachycardia/bradycardia affect CO

Stroke Volume (SV) 70 mL Affected by preload, afterload,

contractility

Cardiac Output (CO) 5 L/min CO = HR × SV

Ejection Fraction (EF) 55-70% Reduced in systolic heart failure

Mean Arterial Pressure (MAP) ~90-100 mmHg MAP = CO × TPR; perfusion

pressure

Heart Sounds & Murmurs

Heart Sounds

• S1: Closure of AV valves (mitral, tricuspid)

• S2: Closure of semilunar valves (aortic, pulmonary)

• S3: Early diastolic sound; ventricular gallop (normal in children, pathologic in adults =

volume overload)

• S4: Late diastolic sound; atrial gallop (due to stiff ventricle, e.g., LV hypertrophy)

Murmur Characteristics

Feature Description Clinical Correlation

Timing Systolic, diastolic, continuous Helps localize valve pathology

Feature Description Clinical Correlation

Shape Crescendo, decrescendo, plateau Indicates severity and flow

dynamics

Location Auscultation site Identifies affected valve

Radiation Direction of sound transmission E.g., aortic stenosis radiates to

carotids

Maneuvers Change murmur intensity E.g., Valsalva decreases most

murmurs except HCM

Valvular Heart Disease

Valve Disease Etiology Murmur Classic Findings/Bu

Description zzwords

Aortic Valve Aortic Stenosis Age-related Crescendo-decresce Pulsus parvus et

calcification, ndo systolic tardus, LV

bicuspid valve ejection murmur, hypertrophy

radiates to carotids

Aortic Valve Aortic Rheumatic fever, Early diastolic Bounding pulses,

Regurgitation endocarditis, aortic decrescendo wide pulse pressure

root dilation murmur

Mitral Valve Mitral Stenosis Rheumatic heart Opening snap, Left atrial

disease diastolic rumbling enlargement, atrial

murmur at apex fibrillation

Mitral Valve Mitral Ischemic heart Holosystolic Volume overload,

Regurgitation disease, MVP blowing murmur at LA and LV dilation

apex, radiates to

axilla

Tricuspid Valve Tricuspid RV dilation, Holosystolic Jugular venous

Regurgitation endocarditis murmur, increases distension

with inspiration

Mitral Valve Prolapse (MVP)

• Etiology: Myxomatous degeneration of mitral valve

• Murmur: Mid-systolic click followed by late systolic murmur

• Maneuvers: Murmur increases with Valsalva (decreased preload)

Congenital Heart Defects

Defect Pathophysiology Clinical Associated

Features/Buzzwords Syndromes/Notes

Ventricular Septal Defect Left-to-right shunt Harsh holosystolic Most common congenital

(VSD) murmur at LLSB, CHF in heart defect

infants

Atrial Septal Defect Left-to-right shunt Wide fixed split S2, Ostium secundum most

(ASD) paradoxical emboli risk common

Patent Ductus Arteriosus Left-to-right shunt Continuous Associated with

(PDA) “machine-like” murmur congenital rubella

Tetralogy of Fallot (TOF) Right-to-left shunt Cyanosis, boot-shaped Pulmonary stenosis,

heart on CXR, squatting RVH, VSD, overriding

improves symptoms aorta

Transposition of Great Parallel circulation Severe cyanosis at birth, Associated with maternal

Arteries (TGA) requires PDA for survival diabetes

Ischemic Heart Disease (IHD)

Types

• Stable angina: exertional chest pain, relieved by rest or nitroglycerin

• Unstable angina: chest pain at rest, no myocardial necrosis

• NSTEMI: non-ST elevation MI, elevated troponins

• STEMI: ST elevation MI, transmural infarction

Pathophysiology

• Atherosclerosis → plaque rupture → thrombosis → ischemia/infarction

Clinical Presentation

Condition Chest Pain Characteristics ECG Findings Biomarkers

Stable Angina Exertional, relieved by ST depression during pain Normal

rest

Unstable Angina At rest, prolonged ST depression or T wave Normal

inversion

NSTEMI Similar to unstable angina ST depression or T wave Elevated troponin,

inversion CK-MB

STEMI Prolonged, severe ST elevation in leads Elevated troponin,

corresponding to infarct CK-MB

Infarct Locations & ECG Changes

Infarct Location Coronary Artery Involved ECG Leads Affected Clinical Features

Anterior wall LAD V1-V4 Most common, large

infarct

Lateral wall LCX I, aVL, V5-V6

Inferior wall RCA II, III, aVF Bradycardia, AV block

possible

Complications of MI

Time Post-MI Complication Features

0-24 hours Arrhythmias Vfib most common cause of death

1-3 days Fibrinous pericarditis Chest pain, friction rub

3-14 days Free wall rupture Cardiac tamponade, death

2-4 weeks Dressler syndrome Autoimmune pericarditis

Weeks-months Ventricular aneurysm Persistent ST elevation, risk of

thrombus

Heart Failure

Types

Type Definition Etiology Hemodynamics

Left-sided HF LV dysfunction → Ischemic heart disease, Increased PCWP,

pulmonary congestion HTN pulmonary edema

Right-sided HF RV dysfunction → Left-sided HF, cor Elevated JVP, peripheral

systemic venous pulmonale edema

congestion

High-output HF CO elevated but Anemia, thyrotoxicosis Low systemic vascular

insufficient resistance

Clinical Features

• Dyspnea, orthopnea, paroxysmal nocturnal dyspnea (PND)

• Pulmonary edema (left HF)

• Peripheral edema, hepatomegaly, ascites (right HF)

• S3 gallop, elevated JVP

Neurohormonal Activation

• RAAS activation → vasoconstriction, sodium retention

• Sympathetic activation → increased HR, contractility

• Natriuretic peptides (ANP, BNP) counteract volume overload

Cardiomyopathies

Type Description Etiology Clinical

Features/Buzzwords

Dilated Cardiomyopathy Dilated LV with systolic Alcohol, viral S3 gallop, biventricular

dysfunction myocarditis, genetic HF

Hypertrophic Asymmetric septal Autosomal dominant Sudden death in young

Cardiomyopathy hypertrophy, diastolic mutations (β-myosin athletes, systolic murmur

dysfunction heavy chain) increases with Valsalva

Restrictive Decreased compliance, Amyloidosis, sarcoidosis, Kussmaul sign, low

Cardiomyopathy diastolic dysfunction hemochromatosis voltage ECG

Pericardial Diseases

Disease Etiology Clinical Features Diagnostic Findings

Pericarditis Viral, uremia, Dressler Sharp pleuritic chest pain, Diffuse ST elevation, PR

syndrome worse with inspiration, depression

relieved by sitting up

Pericardial Effusion Infection, malignancy, Distant heart sounds, Electrical alternans on

trauma muffled ECG

Cardiac Tamponade Large pericardial effusion Beck triad (hypotension, Equalization of diastolic

JVD, muffled heart pressures on cath

sounds), pulsus

paradoxus

Vascular Pathology

Atherosclerosis

• Pathogenesis: Endothelial injury → LDL oxidation → macrophage foam cells → fatty

streak → fibrous plaque

• Risk factors: HTN, smoking, diabetes, hyperlipidemia, age, male sex

• Complications: MI, stroke, peripheral artery disease, aneurysm

Hypertension

Type Definition Causes Complications

Primary (essential) >140/90 mmHg, no Multifactorial LV hypertrophy, stroke,

identifiable cause renal failure

Secondary Due to identifiable cause Renal artery stenosis, Same as primary plus

hyperaldosteronism, underlying disease

pheochromocytoma

Aneurysms

Type Location Etiology Clinical Features

Abdominal Aortic Below renal arteries Atherosclerosis Pulsatile abdominal mass,

Aneurysm (AAA) rupture → hypotension

Thoracic Aortic Ascending aorta Hypertension, cystic Hoarseness (recurrent

Aneurysm medial necrosis laryngeal nerve),

dysphagia

Berry Aneurysm Circle of Willis Congenital, hypertension Subarachnoid

hemorrhage

Vasculitis Overview

Vasculitis Vessel Size Key Features Associated Antibodies

Giant Cell Arteritis Large arteries Temporal headache, jaw Elevated ESR, biopsy

claudication shows giant cells

Takayasu Arteritis Large arteries Pulseless disease, young Elevated ESR

Asian women

Polyarteritis Nodosa Medium arteries Hepatitis B association, Negative ANCA

renal and visceral infarcts

Granulomatosis with Small vessels Nasopharyngeal ulcers, c-ANCA (PR3)

Polyangiitis (Wegener) granulomas,

glomerulonephritis

Microscopic Polyangiitis Small vessels Pulmonary-renal p-ANCA (MPO)

syndrome

Pharmacology: Cardiovascular Drugs

Antiarrhythmics (Vaughan Williams Classification)

Class Mechanism of Examples Clinical Use Side Effects

Action

I (Na■ channel Slow phase 0 IA: Quinidine, IA: Atrial and IA: Cinchonism

blockers) depolarization Procainamide, ventricular (quinidine),

Disopyramide arrhythmias SLE-like

IB: Lidocaine, IB: Ventricular (procainamide)

Mexiletine arrhythmias IB: CNS toxicity

IC: Flecainide, post-MI IC: Proarrhythmic

Propafenone IC: SVT, afib

II (β-blockers) Decrease SA and Metoprolol, SVT, HTN, HF, Bradycardia, AV

AV node activity (↓ Atenolol, Esmolol post-MI block,

cAMP, Ca²■ bronchospasm

currents)

III (K■ channel Prolong Amiodarone, VT, afib Amiodarone:

blockers) repolarization Sotalol pulmonary fibrosis,

(phase 3) thyroid dysfunction

IV (Ca²■ channel Slow AV node Verapamil, SVT, HTN, angina Constipation, AV

blockers) conduction Diltiazem block

Antihypertensives

Drug Class Mechanism Clinical Use Side Effects

ACE inhibitors Block conversion of Ang HTN, HF, diabetic Cough, angioedema,

I → Ang II nephropathy hyperkalemia

ARBs Block Ang II receptor HTN, HF Hyperkalemia, no cough

Calcium channel blockers Dihydropyridines: HTN, angina Peripheral edema,

vasodilation constipation

Non-DHP: decrease HR

Thiazide diuretics Inhibit NaCl reabsorption HTN, HF Hypokalemia,

in DCT hyperuricemia

Beta blockers Decrease HR and HTN, angina, arrhythmias Bradycardia, fatigue

contractility

Nitrates

• Mechanism: Release NO → increase cGMP → smooth muscle relaxation →

venodilation > arteriolar dilation → decreased preload

• Use: Angina, acute coronary syndrome

• Side effects: Reflex tachycardia, hypotension, headache

• Tolerance: Avoid with nitrate-free intervals

Summary Tables

Comparison of Heart Failure Types

Feature Systolic HF Diastolic HF

EF ↓ (<40%) Normal (>50%)

LV Size Dilated Normal or thickened

Cause Ischemic heart disease, dilated Hypertension, hypertrophic

cardiomyopathy cardiomyopathy

Clinical Signs S3 gallop, pulmonary edema Pulmonary congestion, preserved

EF

Treatment ACE inhibitors, β-blockers, Control HTN, diuretics, β-blockers

diuretics

Comparison of Valvular Heart Disease Murmurs

Valve & Lesion Timing & Shape Location & Radiation Maneuvers Affecting

Murmur

Aortic Stenosis Systolic RUSB, radiates to Squatting ↑, Valsalva ↓

crescendo-decrescendo carotids

Mitral Regurgitation Holosystolic, blowing Apex, radiates to axilla Squatting ↓, Valsalva ↑

Mitral Stenosis Diastolic rumbling, Apex N/A

opening snap

Tricuspid Regurgitation Holosystolic, increases LLSB Inspiration ↑

with inspiration

High-Yield Mnemonics

• Causes of Dilated Cardiomyopathy: ABCCCD

Alcohol abuse, Beriberi, Coxsackie B virus, Cocaine, Chagas disease, Doxorubicin

• Tetralogy of Fallot: PROVe

Pulmonary stenosis, Right ventricular hypertrophy, Overriding aorta, VSD

• Heart Failure Signs: FACES

Fatigue, Activities limited, Chest congestion, Edema, Shortness of breath

• Vasculitis by Size:

Large: Giant Takayasu

Medium: Polyarteritis Nodosa

Small: Wegener, Microscopic Polyangiitis

Important Clinical Correlations

• Kussmaul sign: Increased JVP on inspiration; seen in constrictive pericarditis,

restrictive cardiomyopathy, right heart failure.

• Pulsus paradoxus: >10 mmHg drop in systolic BP during inspiration; seen in cardiac

tamponade, severe asthma.

• Electrical alternans: Alternating QRS amplitude; pathognomonic for large pericardial

effusion.

• Pulsus parvus et tardus: Weak, delayed carotid pulse; classic for aortic stenosis.

Practice Questions (Concept Reinforcement)

1. A 65-year-old man presents with exertional chest pain relieved by rest. ECG shows ST

depression during pain episodes. What is the most likely diagnosis?

Answer: Stable angina due to myocardial ischemia.

2. A young woman has a mid-systolic click followed by a late systolic murmur that

increases with Valsalva. Diagnosis?

Answer: Mitral valve prolapse.

3. A patient with a history of rheumatic fever presents with a diastolic rumbling murmur

and an opening snap. Which valve is affected?

Answer: Mitral stenosis.

This comprehensive cardiovascular system review covers essential anatomy, physiology,

pathology, pharmacology, and clinical correlations critical for USMLE Step 1 success.

Endocrine System

Overview

The endocrine system regulates physiological processes via hormones secreted by glands into

the bloodstream. Hormones act on distant target cells to modulate metabolism, growth,

reproduction, and homeostasis. Understanding hormone synthesis, regulation, receptor

signaling, and associated diseases is critical for USMLE Step 1.

Hormone Classification

Class Examples Synthesis Receptor Type Mechanism of

Action

Peptide/Protein Insulin, PTH, ADH, Preprohormone → Cell surface (GPCR Second messengers

ACTH prohormone → or RTK) (cAMP, IP3/DAG),

hormone tyrosine kinase

activation

Steroid Cortisol, Cholesterol → Intracellular Alter gene

Aldosterone, pregnenolone → (nuclear receptors) transcription (slow

Estrogen, steroid onset, long

Testosterone duration)

Amino Acid Thyroid hormones Tyrosine Thyroid: Thyroid: nuclear

Derivatives (T3/T4), modification intracellular; receptor;

Catecholamines Catecholamines: Catecholamines:

(Epi, NE) GPCR second messengers

Hypothalamic-Pituitary Axis

Hypothalamic Releasing/Inhibiting Hormones

Hormone Target Anterior Pituitary Hormone Effect on Target Hormone

Secretion

TRH (Thyrotropin-releasing TSH, Prolactin ↑ TSH → ↑ thyroid hormone; ↑

hormone) Prolactin

CRH (Corticotropin-releasing ACTH ↑ ACTH → ↑ cortisol

hormone)

GnRH (Gonadotropin-releasing LH, FSH ↑ LH, FSH → ↑ sex steroids

hormone)

GHRH (Growth hormone-releasing GH ↑ GH

hormone)

Hormone Target Anterior Pituitary Hormone Effect on Target Hormone

Secretion

Somatostatin GH, TSH ↓ GH, TSH

Dopamine Prolactin ↓ Prolactin

Pituitary Hormones and Functions

Hormone Source Target Organ/Cell Function Regulation

Anterior Pituitary

GH Somatotrophs Liver, many tissues ↑ IGF-1, growth, ↑ ↑ GHRH, ↓

blood glucose somatostatin

TSH Thyrotrophs Thyroid gland ↑ thyroid hormone ↑ TRH

synthesis

ACTH Corticotrophs Adrenal cortex ↑ cortisol secretion ↑ CRH

(zona fasciculata)

LH Gonadotrophs Ovary (theca cells), Ovulation, ↑ GnRH

Testis (Leydig testosterone

cells) synthesis

FSH Gonadotrophs Ovary (granulosa Follicle ↑ GnRH

cells), Testis development,

(Sertoli cells) spermatogenesis

Prolactin Lactotrophs Breast Milk production ↓ dopamine

Posterior Pituitary

ADH (Vasopressin) Synthesized in Kidney (collecting ↑ water ↑ plasma

hypothalamus, ducts) reabsorption (V2 osmolality, ↓

stored in PP receptor) volume

Oxytocin Synthesized in Breast, uterus Milk letdown, Suckling, cervical

hypothalamus, uterine contraction stretch

stored in PP

Hormone Receptor Signaling Pathways

Receptor Type Hormone Examples Second Effect

Messenger/Mechanism

GPCR (Gs) PTH, ACTH, TSH, LH, ↑ cAMP → PKA Phosphorylation of target

FSH, CRH, glucagon activation proteins

GPCR (Gi) α2-adrenergic receptors ↓ cAMP Inhibition of PKA

pathway

GPCR (Gq) GnRH, TRH, Oxytocin, ↑ IP3 → ↑ Ca²■, DAG Smooth muscle

ADH (V1 receptor) → PKC activation contraction, secretion

Receptor Type Hormone Examples Second Effect

Messenger/Mechanism

Receptor Tyrosine Insulin, IGF-1 Autophosphorylation → Metabolic effects, growth

Kinase (RTK) IRS → PI3K/Akt, MAPK

pathways

Nuclear Receptors Steroid hormones, thyroid Hormone-receptor Alters gene transcription

hormones complex binds DNA

Thyroid Gland

Hormone Synthesis

• Iodide trapping: Na■/I■ symporter transports iodide into follicular cells.

• Organification: Iodide oxidized by thyroid peroxidase (TPO) and attached to tyrosine

residues on thyroglobulin → MIT, DIT.

• Coupling: MIT + DIT = T3; DIT + DIT = T4.

• Storage: Thyroglobulin stored in colloid.

• Release: Endocytosis of thyroglobulin → lysosomal proteolysis → release T3 and T4.

Regulation

• TSH stimulates iodide uptake, TPO activity, and hormone release.

• Negative feedback by T3/T4 on hypothalamus and pituitary.

Thyroid Hormone Effects

• ↑ basal metabolic rate (via Na■/K■ ATPase)

• ↑ β-adrenergic receptor expression (↑ sensitivity to catecholamines)

• CNS development

• Bone growth and maturation

• ↑ gluconeogenesis, glycogenolysis, lipolysis

Disorders of the Thyroid

Disease Etiology/Pathogene Clinical Features/B Labs (TSH, T3/T4) Notes

sis uzzwords

Graves Disease Autoimmune (TSI Diffuse goiter, ↓ TSH, ↑ T3/T4 HLA-DR3,

stimulates TSH exophthalmos, HLA-B8;

receptor) pretibial myxedema orbitopathy due to

fibroblast activation

Disease Etiology/Pathogene Clinical Features/B Labs (TSH, T3/T4) Notes

sis uzzwords

Hashimoto Autoimmune Painless goiter, ↑ TSH, ↓ T3/T4 Most common

Thyroiditis destruction of hypothyroidism cause of

thyroid (anti-TPO, symptoms hypothyroidism in

anti-thyroglobulin iodine-sufficient

antibodies) areas

Subacute Post-viral Painful thyroid, ↑ ESR, variable Self-limited;

Granulomatous inflammation transient TSH/T3/T4 granulomatous

Thyroiditis (de hyperthyroidism inflammation

Quervain)

Riedel Thyroiditis Fibrous Hard, fixed Hypothyroidism Mimics anaplastic

replacement of “woody” thyroid carcinoma

thyroid

Thyroid Storm Severe Fever, tachycardia, Clinical diagnosis Life-threatening;

hyperthyroidism arrhythmia, treat with

(often Graves) agitation β-blockers, PTU,

steroids

Parathyroid Gland and Calcium Homeostasis

Hormones Regulating Calcium

Hormone Source Effect on Calcium and Mechanism

Phosphate

PTH Parathyroid glands ↑ serum Ca²■ (bone ↑ osteoclast activity

resorption, kidney (indirect via osteoblasts),

reabsorption), ↓ serum ↑ renal Ca²■

phosphate (renal reabsorption, ↑

excretion) 1α-hydroxylase in kidney

Vitamin D Kidney (activated form) ↑ intestinal absorption of Nuclear

(1,25-(OH)■D■) Ca²■ and phosphate receptor-mediated gene

transcription

Calcitonin Thyroid parafollicular ↓ serum Ca²■ (inhibits GPCR → inhibits

cells osteoclasts) osteoclasts

PTH Mechanism

• Binds PTH1 receptor (Gs and Gq coupled) on osteoblasts → RANKL expression →

osteoclast activation.

• In kidney: ↑ Ca²■ reabsorption in distal tubule; ↓ phosphate reabsorption in proximal

tubule.

• Stimulates 1α-hydroxylase → ↑ active vitamin D → ↑ Ca²■ absorption in gut.

Disorders of Calcium and PTH

Disorder Etiology/Pathogene Clinical Features/B Labs (Ca²■, PTH, Notes

sis uzzwords Phosphate)

Primary Hyperpar Parathyroid Stones (kidney), ↑ Ca²■, ↑ PTH, ↓ ↑ cAMP in urine;

athyroidism adenoma (most bones (osteitis phosphate “brown tumors” on

common), fibrosa cystica), bone biopsy

hyperplasia groans (abdominal

pain), psychiatric

overtones

Secondary Hyperp Chronic kidney Hypocalcemia ↓ Ca²■, ↑ PTH, ↑ Compensatory PTH

arathyroidism disease → ↓ symptoms, bone phosphate increase due to

vitamin D disease hypocalcemia

activation

Tertiary Hyperpar Autonomous PTH Hypercalcemia ↑ Ca²■, ↑ PTH Seen in renal

athyroidism secretion after despite correction transplant patients

prolonged of cause

secondary hyperpar

athyroidism

Hypoparathyroidi Surgical removal, Tetany, Chvostek ↓ Ca²■, ↓ PTH, ↑ Treat with calcium

sm autoimmune and Trousseau signs phosphate and vitamin D

destruction

Pseudohypoparath End-organ Short stature, round ↓ Ca²■, ↑ PTH, ↑ Albright hereditary

yroidism resistance to PTH face, subcutaneous phosphate osteodystrophy;

(Gs protein calcifications maternal imprinting

mutation)

Adrenal Gland

Anatomy and Zones

Zone Hormones Produced Regulation Function

Zona glomerulosa Mineralocorticoids RAAS, K■, ACTH Na■ retention, K■

(aldosterone) (minor) excretion

Zona fasciculata Glucocorticoids (cortisol) ACTH ↑ gluconeogenesis,

anti-inflammatory

Zona reticularis Androgens (DHEA, ACTH Secondary sex

androstenedione) characteristics

Medulla Catecholamines (Epi, Sympathetic nervous Fight or flight response

NE) system

Adrenal Steroid Synthesis Pathway

• Cholesterol → Pregnenolone (rate-limiting step)

• Pregnenolone → Progesterone → 11-Deoxycorticosterone → Aldosterone (zona

glomerulosa)

• Pregnenolone → 17-OH pregnenolone → 17-OH progesterone → 11-Deoxycortisol →

Cortisol (zona fasciculata)

• Pregnenolone → DHEA → Androgens (zona reticularis)

Key enzymes:

Enzyme Deficiency Effect Clinical Features

21-Hydroxylase ↓ Aldosterone, ↓ Cortisol, ↑ Salt wasting, hypotension,

Androgens virilization

11β-Hydroxylase ↓ Cortisol, ↑ Hypertension, virilization

11-deoxycorticosterone

17α-Hydroxylase ↓ Cortisol, ↓ Androgens, ↑ Hypertension, sexual infantilism

Aldosterone

Adrenal Disorders

Disease Etiology/Pathogene Clinical Features/B Labs (Cortisol, Notes

sis uzzwords ACTH,

Aldosterone)

Cushing ↑ cortisol Moon facies, ↑ cortisol; ACTH Dexamethasone

Syndrome (exogenous buffalo hump, depends on cause suppression test

steroids, central obesity, differentiates causes

ACTH-secreting purple striae,

pituitary adenoma, muscle weakness

adrenal adenoma)

Addison Disease Autoimmune Fatigue, ↓ cortisol, ↑ ACTH, Electrolyte

destruction of hypotension, ↓ aldosterone abnormalities

adrenal cortex hyperpigmentation, (hyponatremia,

weight loss hyperkalemia)

Primary Hyperald Aldosterone-secreti Hypertension, ↑ aldosterone, ↓ Resistant

osteronism (Conn ng adrenal adenoma hypokalemia, renin hypertension

Syndrome) or hyperplasia metabolic alkalosis

Congenital Enzyme Virilization, ↑ 17-OH Most common

Adrenal deficiencies in ambiguous progesterone cause of ambiguous

Hyperplasia steroid synthesis genitalia, salt (21-hydroxylase genitalia in

wasting (if deficiency) newborn females

21-hydroxylase

deficient)

Disease Etiology/Pathogene Clinical Features/B Labs (Cortisol, Notes

sis uzzwords ACTH,

Aldosterone)

Pheochromocytom Catecholamine-secr Episodic ↑ plasma and urine Rule out with

a eting tumor of hypertension, metanephrines clonidine

adrenal medulla headache, sweating, suppression test

palpitations

Pancreatic Endocrine Function

Islets of Langerhans

Cell Type Hormone Function Regulation

α-cells Glucagon ↑ blood glucose via ↓ glucose, ↑ amino acids

glycogenolysis,

gluconeogenesis

β-cells Insulin ↓ blood glucose via ↑ ↑ glucose, incretins

glucose uptake, glycogen (GLP-1)

synthesis

δ-cells Somatostatin Inhibits secretion of Paracrine feedback

insulin, glucagon, GH

PP cells Pancreatic polypeptide Regulates pancreatic Food intake

exocrine secretion

Insulin Synthesis and Action

• Synthesized as preproinsulin → proinsulin → insulin + C-peptide.

• Insulin receptor: RTK → autophosphorylation → IRS → PI3K/Akt pathway.

• Effects:

• ↑ GLUT4 translocation in muscle and adipose tissue → ↑ glucose uptake.

• ↑ glycogen synthesis (activates glycogen synthase).

• ↑ lipogenesis.

• ↓ gluconeogenesis.

Diabetes Mellitus

Type Pathogenesis Clinical Features/B Labs/Diagnostics Complications

uzzwords

Type 1 DM Autoimmune Polyuria, ↓ insulin, ↑ DKA,

destruction of polydipsia, glucose, + microvascular

β-cells polyphagia, weight anti-GAD complications

(HLA-DR3/4) loss antibodies

Type 2 DM Insulin resistance + Obesity, acanthosis ↑ insulin (early), ↑ Hyperosmolar

relative insulin nigricans glucose hyperglycemic

deficiency state, macrovascular

disease

Gestational DM Insulin resistance Usually ↑ glucose during Risk of

due to placental asymptomatic, pregnancy macrosomia,

hormones detected by glucose neonatal

tolerance test hypoglycemia

Diabetic Complications

Complication Pathogenesis Clinical Prevention/Treatment

Features/Buzzwords

Microvascular Nonenzymatic Retinopathy (cotton wool Tight glycemic control

glycosylation → spots,

basement membrane neovascularization),

thickening nephropathy

(Kimmelstiel-Wilson

nodules), neuropathy

(stocking-glove)

Macrovascular Accelerated CAD, peripheral artery Control lipids, BP,

atherosclerosis disease, stroke glucose

Infections Impaired neutrophil Mucormycosis, Candida, Glycemic control

function osteomyelitis

Diabetic Ketoacidosis Insulin deficiency → Kussmaul respirations, IV fluids, insulin, K■

(DKA) lipolysis → ketogenesis fruity breath, metabolic replacement

acidosis

Hormones of the Reproductive System

Hormone Source Target Organ/Cell Function Regulation

GnRH Hypothalamus Anterior pituitary Stimulates LH and Pulsatile secretion

FSH secretion

LH Anterior pituitary Leydig cells (testis), Testosterone GnRH

Theca cells (ovary) synthesis, ovulation

Hormone Source Target Organ/Cell Function Regulation

FSH Anterior pituitary Sertoli cells (testis), Spermatogenesis, GnRH

Granulosa cells follicle maturation

(ovary)

Testosterone Leydig cells Multiple Male secondary LH

sexual

characteristics

Estrogen Granulosa cells Multiple Female secondary FSH, LH

sexual

characteristics,

endometrial

proliferation

Progesterone Corpus luteum, Uterus Endometrial LH

placenta secretory phase,

pregnancy

maintenance

Inhibin Sertoli cells, Anterior pituitary Inhibits FSH Negative feedback

Granulosa cells secretion

Summary Tables

Comparison of Pituitary Adenomas

Adenoma Type Hormone Secreted Clinical Features Treatment

Prolactinoma Prolactin Galactorrhea, Dopamine agonists

amenorrhea, infertility (bromocriptine)

GH-secreting Growth hormone Gigantism (children), Octreotide, surgery

acromegaly (adults)

ACTH-secreting ACTH Cushing disease Surgery, ketoconazole

Nonfunctioning None Mass effect (headache, Surgery

bitemporal hemianopia)

Comparison of Diabetes Insipidus Types

Type Cause Urine Osmolality Serum Na■ Treatment

Central DI ↓ ADH secretion Dilute (<300 ↑ Desmopressin

(pituitary damage) mOsm/kg) (ADH analog)

Nephrogenic DI Renal insensitivity Dilute (<300 ↑ Thiazides, NSAIDs,

to ADH mOsm/kg) low salt

Psychogenic Excess water intake Dilute urine, low ↓ Water restriction

polydipsia serum Na■

High-Yield Mnemonics

• Hormones using cAMP as second messenger (Gs coupled): FLAT ChAMP

FSH, LH, ACTH, TSH, CRH, hCG, ADH (V2), MSH, PTH

• Steroid hormone synthesis enzymes:

“SCC” = Side Chain Cleavage (cholesterol → pregnenolone)

21-hydroxylase deficiency → salt wasting

11β-hydroxylase deficiency → hypertension

17α-hydroxylase deficiency → sexual infantilism

• Causes of hypercalcemia: “CHIMPANZEES”

Calcium supplementation, Hyperparathyroidism, Iatrogenic, Multiple myeloma, Paget

disease, Addison disease, Neoplasm, Zollinger-Ellison syndrome, Excess vitamin D,

Excess vitamin A, Sarcoidosis

• Signs of hypocalcemia: “CATS go numb”

Convulsions, Arrhythmias, Tetany, Spasms, numbness

Summary of Key Concepts

• Peptide hormones act via membrane receptors and second messengers; steroid

hormones act via nuclear receptors altering gene transcription.

• Hypothalamic-pituitary axis controls most endocrine glands via releasing/inhibiting

hormones.

• Thyroid hormone synthesis requires iodine and TPO; T3 is more active than T4.

• PTH increases serum calcium by bone resorption, renal reabsorption, and activating

vitamin D.

• Adrenal cortex produces mineralocorticoids, glucocorticoids, and androgens; medulla

produces catecholamines.

• Insulin lowers blood glucose by increasing cellular uptake and storage.

• Diabetes mellitus is characterized by hyperglycemia due to insulin deficiency or

resistance.

• Endocrine tumors often present with hormone excess syndromes and require

biochemical and imaging studies for diagnosis.

End of Endocrine System Section

Gastrointestinal System

Overview

The gastrointestinal (GI) system is responsible for digestion, absorption, and elimination of

food. It includes the oral cavity, esophagus, stomach, small and large intestines, liver,

pancreas, and biliary system. Understanding GI physiology, pathology, and pharmacology is

essential for the USMLE Step 1.

Anatomy & Physiology

Layers of the GI Tract (Inside → Outside)

Layer Description Function

Mucosa Epithelium + lamina propria + Absorption, secretion, barrier

muscularis mucosae

Submucosa Dense connective tissue with blood Nutrient transport, neural control

vessels, lymphatics, Meissner’s

plexus

Muscularis externa Inner circular + outer longitudinal Peristalsis, motility

muscle layers + Auerbach’s

(myenteric) plexus

Serosa (adventitia) Connective tissue + mesothelium Structural support, lubrication

GI Motility Control

• Enteric nervous system (ENS): Myenteric (Auerbach’s) plexus controls motility;

submucosal (Meissner’s) plexus controls secretion.

• Autonomic input: Parasympathetic (vagus nerve) stimulates motility/secretion;

sympathetic inhibits.

• Hormones: Gastrin, cholecystokinin (CCK), secretin, motilin regulate motility and

secretion.

GI Physiology

Digestion & Absorption

Nutrient Site of Digestion Enzymes Involved Absorption Site

Carbohydrates Mouth, small intestine Salivary amylase, Jejunum

pancreatic amylase, brush

border enzymes (maltase,

lactase, sucrase)

Proteins Stomach, small intestine Pepsin, trypsin, Jejunum

chymotrypsin,

carboxypeptidase, brush

border peptidases

Fats Small intestine Pancreatic lipase, bile Jejunum

salts

Vitamins Various (fat-soluble in – Fat-soluble: A, D, E, K in

ileum) ileum; Water-soluble in

jejunum/ileum

Iron Duodenum – Duodenum

Calcium Duodenum Vitamin D-dependent Duodenum

Gastric Secretions

Cell Type Location Secretions Function

Parietal cells Fundus/body stomach HCl, intrinsic factor Acidifies stomach, B12

absorption

Chief cells Fundus/body stomach Pepsinogen Protein digestion

G cells Antrum stomach Gastrin Stimulates acid secretion

Mucous cells Throughout stomach Mucus, bicarbonate Protects mucosa

D cells Antrum stomach Somatostatin Inhibits gastrin, acid

secretion

GI Hormones

Hormone Source Stimulus Action

Gastrin G cells (antrum) Protein, stomach ↑ HCl secretion, gastric

distension mucosa growth

Secretin S cells (duodenum) Acid in duodenum ↑ Pancreatic bicarbonate

secretion, ↓ gastric acid

Cholecystokinin (CCK) I cells Fat, protein in duodenum ↑ Pancreatic enzyme

(duodenum/jejunum) secretion, gallbladder

contraction, ↓ gastric

emptying

Hormone Source Stimulus Action

Motilin Small intestine Fasting ↑ GI motility (migrating

motor complex)

Somatostatin D cells (stomach, Acid, sympathetic ↓ Gastrin, insulin,

pancreas) stimulation glucagon secretion

GIP (Gastric inhibitory K cells Fat, glucose in small ↓ Gastric acid secretion,

peptide) (duodenum/jejunum) intestine ↑ insulin release

Common GI Diseases

Esophageal Disorders

Disease Pathophysiology Clinical Features Diagnosis Treatment

GERD ↓ LES tone → acid Heartburn, Clinical, endoscopy Lifestyle, PPIs, H2

reflux regurgitation, cough if alarm sx blockers

Barrett’s esophagus Squamous → Asymptomatic, risk Endoscopy + biopsy Surveillance,

intestinal of adenocarcinoma ablation,

metaplasia (acid esophagectomy

injury)

Achalasia Loss of myenteric Dysphagia (solids Barium swallow Pneumatic dilation,

plexus → LES fails & liquids), (bird-beak), myotomy

to relax regurgitation manometry

Esophageal varices Portal hypertension Hematemesis, Endoscopy Band ligation,

→ dilated shock octreotide, TIPS

submucosal veins

Gastric Disorders

Disease Pathophysiology Clinical Features Diagnosis Treatment

Peptic ulcer disease Imbalance Epigastric pain Endoscopy, urease PPI, antibiotics if H.

acid/defense (H. (worse with fasting test for H. pylori pylori

pylori, NSAIDs) or food)

Gastric Intestinal type (H. Weight loss, early Endoscopy + biopsy Surgery,

adenocarcinoma pylori, intestinal satiety, anemia chemotherapy

metaplasia), diffuse

type (signet ring

cells)

Menetrier disease Excess TGF-α → Protein-losing Endoscopy, biopsy Supportive,

hypertrophic gastric gastropathy, edema cetuximab

folds

Small Intestine Disorders

Disease Pathophysiology Clinical Features Diagnosis Treatment

Celiac disease Autoimmune Diarrhea, bloating, Anti-tTG Gluten-free diet

reaction to gluten malabsorption antibodies, biopsy

→ villous atrophy

Lactose intolerance ↓ Lactase enzyme Bloating, diarrhea Hydrogen breath Lactase enzyme

→ lactose after dairy test replacement, avoid

malabsorption lactose

Tropical sprue Unknown, Malabsorption, Biopsy, response to Antibiotics, folate

post-infectious → diarrhea antibiotics supplementation

villous atrophy

Whipple disease Tropheryma Diarrhea, weight PAS+ macrophages Ceftriaxone,

whipplei infection loss, arthralgia in biopsy TMP-SMX

→ macrophage

infiltration

Large Intestine Disorders

Disease Pathophysiology Clinical Features Diagnosis Treatment

Ulcerative colitis Autoimmune, Bloody diarrhea, Colonoscopy, 5-ASA, steroids,

mucosal tenesmus biopsy immunomodulators

inflammation

limited to colon

Crohn disease Transmural Abdominal pain, Endoscopy, biopsy Steroids, immunosu

inflammation, skip diarrhea, fistulas ppressants, surgery

lesions

Diverticulosis Outpouchings of Often CT scan if High-fiber diet,

mucosa/submucosa asymptomatic, LLQ diverticulitis antibiotics if

pain if inflamed inflamed

Colorectal cancer Adenoma-carcinom Change in bowel Colonoscopy, Surgery,

a sequence habits, bleeding biopsy chemotherapy

GI Microbiology & Infection

Organism Disease/Condition Key Features/Buzz Diagnosis Treatment

words

Helicobacter pylori Gastritis, PUD, Urease positive, Urea breath test, PPI +

gastric cancer curved stool antigen clarithromycin + a

gram-negative rod moxicillin/metronid

azole

Vibrio cholerae Cholera Rice-water diarrhea Stool culture Rehydration,

doxycycline

Clostridium Antibiotic-associate Pseudomembranous Stool toxin assay Oral vancomycin,

difficile d colitis colitis, diarrhea fidaxomicin

Organism Disease/Condition Key Features/Buzz Diagnosis Treatment

words

Entamoeba Amebiasis Bloody diarrhea, Stool O&P, Metronidazole

histolytica flask-shaped ulcers serology

Giardia lamblia Giardiasis Greasy, Stool antigen, O&P Metronidazole

foul-smelling

diarrhea

GI Pharmacology

Acid-Reducing Agents

Drug Class Examples Mechanism of Clinical Use Side Effects

Action

Proton pump Omeprazole, Irreversibly inhibit GERD, PUD, Increased risk of C.

inhibitors (PPIs) esomeprazole H+/K+ ATPase in Zollinger-Ellison difficile, pneumonia

parietal cells syndrome

H2 receptor Ranitidine, Block H2 receptors GERD, PUD Headache,

blockers famotidine on parietal cells → confusion (elderly)

↓ acid secretion

Antacids Mg(OH)2, Neutralize gastric Symptomatic relief Mg → diarrhea; Al

Al(OH)3, CaCO3 acid of dyspepsia → constipation

Prokinetic Agents

Drug Mechanism Clinical Use Side Effects

Metoclopramide D2 receptor antagonist → Gastroparesis, antiemetic Extrapyramidal

↑ ACh release → ↑ GI symptoms, tardive

motility dyskinesia

Erythromycin Motilin receptor agonist Gastroparesis GI upset, antibiotic

resistance

Antiemetics

Drug Class Examples Mechanism Clinical Use Side Effects

5-HT3 antagonists Ondansetron Block 5-HT3 Chemotherapy-indu Headache,

receptors in CTZ ced nausea constipation

and GI tract

Dopamine Metoclopramide, Block D2 receptors Nausea, vomiting Extrapyramidal

antagonists prochlorperazine in CTZ symptoms

Antihistamines Diphenhydramine, Block H1 receptors Motion sickness Sedation

meclizine

Drug Class Examples Mechanism Clinical Use Side Effects

Anticholinergics Scopolamine Block muscarinic Motion sickness Dry mouth,

receptors sedation

High-Yield Mnemonics

Causes of Acute Pancreatitis (I GET SMASHED)

• I: Idiopathic

• G: Gallstones

• E: Ethanol (alcohol)

• T: Trauma

• S: Steroids

• M: Mumps (and other infections)

• A: Autoimmune

• S: Scorpion sting

• H: Hypercalcemia, Hypertriglyceridemia

• E: ERCP (procedure-induced)

• D: Drugs (e.g., azathioprine, valproic acid)

Layers of GI Tract (MSMS)

• M: Mucosa

• S: Submucosa

• M: Muscularis externa

• S: Serosa/adventitia

GI Bleeding Sites & Causes

Location Common Causes Presentation

Upper GI (proximal to ligament of PUD, esophageal varices, Hematemesis, melena

Treitz) Mallory-Weiss tear

Lower GI (distal to ligament of Diverticulosis, ischemic colitis, Hematochezia

Treitz) colorectal cancer

GI Neoplasms

Esophageal Cancer

Type Risk Factors Location Histology Clinical Features

Squamous cell Smoking, alcohol, Upper/mid Keratin pearls, Dysphagia, weight

carcinoma hot liquids esophagus intercellular bridges loss

Adenocarcinoma Barrett’s esophagus, Lower esophagus Glandular Dysphagia, weight

GERD formation loss

Gastric Cancer

Type Risk Factors Histology Clinical Features

Intestinal type H. pylori, chronic Gland-forming Weight loss, early satiety,

gastritis, intestinal adenocarcinoma anemia

metaplasia

Diffuse type Signet ring cells, Poorly cohesive cells Linitis plastica (thickened

E-cadherin mutation infiltrating wall stomach)

Colorectal Cancer

Risk Factors Pathogenesis Screening Clinical Features

Adenomatous polyps, APC mutation → KRAS Colonoscopy starting at Change in bowel habits,

IBD, familial syndromes → p53 mutations 50 or earlier if risk bleeding, anemia

(FAP, HNPCC)

GI Physiology: Acid-Base & Electrolyte Imbalances

• Vomiting: Loss of gastric HCl → metabolic alkalosis, hypokalemia, hypochloremia.

• Diarrhea: Loss of bicarbonate → metabolic acidosis.

• Cholera toxin: Activates adenylate cyclase → ↑ cAMP → Cl- secretion → watery

diarrhea.

GI Histology: Key Features

Structure Histological Features Function

Esophagus Stratified squamous epithelium Protection

Stomach Simple columnar epithelium, Secretion

gastric pits with parietal/chief cells

Small intestine Villi, microvilli, crypts of Absorption

Lieberkühn

Colon No villi, many goblet cells Water absorption, mucus secretion

Summary Tables

Comparison of Inflammatory Bowel Diseases (IBD)

Feature Ulcerative Colitis Crohn Disease

Location Colon only, starts in rectum Any GI segment, skip lesions

Inflammation Mucosal and submucosal Transmural

Gross appearance Continuous lesions Cobblestone, fissures, fistulas

Histology Crypt abscesses, pseudopolyps Noncaseating granulomas

Clinical features Bloody diarrhea, tenesmus Abdominal pain, diarrhea,

malabsorption

Complications Toxic megacolon, colorectal cancer Strictures, fistulas, malabsorption

Smoking effect Protective Risk factor

Comparison of Diarrhea Types

Type Mechanism Examples Stool Osmotic Gap pH

Osmotic diarrhea Non-absorbable Lactose intolerance, >50 mOsm/kg Acidic

solutes draw water Mg-containing

antacids

Secretory diarrhea Active secretion of Cholera, VIPoma, <50 mOsm/kg Alkaline

electrolytes laxative abuse

Exudative diarrhea Mucosal damage → IBD, infections Variable Variable

pus, blood

Malabsorption Impaired nutrient Celiac disease, Variable Variable

diarrhea absorption pancreatic

insufficiency

Key Clinical Pearls

• Mallory-Weiss tear: Longitudinal mucosal lacerations at gastroesophageal junction due

to severe vomiting; presents with hematemesis.

• Zollinger-Ellison syndrome: Gastrin-secreting tumor → gastric acid hypersecretion →

refractory ulcers.

• Whipple disease: PAS+ macrophages in small intestine; systemic symptoms include

arthritis and cardiac involvement.

• Hepatic encephalopathy: Elevated ammonia → neuropsychiatric symptoms; treated

with lactulose (acidifies gut, traps NH4+).

• Gilbert syndrome: Mild unconjugated hyperbilirubinemia due to decreased

UDP-glucuronosyltransferase activity; benign.

Practice Questions (Sample)

1. A 45-year-old man presents with dysphagia to solids and liquids, regurgitation of

undigested food, and weight loss. Barium swallow shows a bird-beak appearance.

Diagnosis?

Answer: Achalasia.

2. A patient with chronic diarrhea and weight loss has anti-tissue transglutaminase

antibodies. Biopsy shows villous atrophy. Diagnosis?

Answer: Celiac disease.

3. A patient with cirrhosis develops hematemesis. Endoscopy reveals dilated veins in

the distal esophagus. Treatment?

Answer: Endoscopic band ligation and octreotide.

This comprehensive overview covers essential GI system concepts, diseases, and treatments

critical for USMLE Step 1 success. Mastery of these topics will aid in clinical reasoning and

exam performance.

Comprehensive Top 200 Drugs Reference

Brand Name Generic Name Category / Indication

Ambien zolpidem Sleep Aid (C-IV)

Amoxil amoxicillin Antibiotic

Augmentin amoxicillin + clavulanate Antibiotic

Glucophage metformin Antidiabetic

Lasix furosemide Diuretic/antihypertensive

Lipitor atorvastatin Cholesterol lowering

Lopressor metoprolol Antihypertensive

Microzide hydrochlorothiazide Diuretic/antihypertensive

Nexium esomeprazole Antacid (PPI)

Norvasc amlodipine Antihypertensive

Percocet oxycodone + APAP Analgesic (C-II)

Prilosec omeprazole Antacid (PPI)

Prinivil / Zestril lisinopril Antihypertensive

Synthroid levothyroxine Thyroid hormone replacement

Brand Name Generic Name Category / Indication

Tenormin atenolol Antihypertensive

Vicodin/ Lortab hydrocodone + APAP Analgesic (C-II)

Xanax alprazolam Antianxiety (C-IV)

Zithromax azithromycin Antibiotic

Zocor simvastatin Cholesterol lowering

Zoloft sertraline Antidepressant (SSRI)

Advil ibuprofen Analgesic (N.S.A.I.D)

Ativan lorazepam Antianxiety (C-IV)

Celexa citalopram Antidepressant (SSRI)

Cipro ciprofloxacin Antibiotic

Coumadin warfarin Anticlotting

Dyrenium triamterene Diuretic/antihypertensive

Flexeril cyclobenzaprine Muscle relaxer

Flonase fluticasone Anti-inflammatory steroid

Keflex cephalexin Antibiotic

Klonopin clonazepam Antianxiety (C-IV)

Lexapro escitalopram Antidepressant (SSRI)

Neurontin gabapentin Anticonvulsant

Plavix clopidogrel Anticlotting

Pravachol pravastatin Cholesterol lowering

ProAir / Ventolin albuterol Bronchodilator

Prozac fluoxetine Antidepressant (SSRI)

Septra sulfamethoxazole Antibiotic combination

Singulair montelukast Anti-asthmatic

Sterapred prednisone Anti-inflammatory steroid

Ultram tramadol Analgesic (narcotic-like)

Advair fluticasone +salmeterol Steroid + bronchodilator

Aleve naproxen Analgesic (N.S.A.I.D)

Zyrtec cetirizine Antihistamine (H1)

Coreg carvedilol Antihypertensive

Crestor rosuvastatin Cholesterol lowering

Brand Name Generic Name Category / Indication

Cymbalta duloxetine Antidepressant

Desyrel trazodone Antidepressant

Diflucan fluconazole Antifungal

Diovan valsartan Antihypertensive

Effexor venlafaxine Antidepressant

Elavil amitriptyline Antidepressant

Fosamax alendronate Bone strengthener

Klor-Con potassium chloride Electrolyte

Mevacor lovastatin Cholesterol lowering

Mobic meloxicam Analgesic (N.S.A.I.D.)

Paxil paroxetine Antidepressant (SSRI)

Valium diazepam Antianxiety (C-IV)

Vibramycin doxycycline Antibiotic

Minipress prazosin Antihypertensive

Bystolic nebivolol Antihypertensive

Actos pioglitazone Antidiabetic

Catapres clonidine Antihypertensive/sleep aid

Celebrex celecoxib Analgesic (N.S.A.I.D.)

Flomax tamsulosin Reduces enlarged prostate

Lantus insulin glargine Insulin

Levaquin levofloxacin Antibiotic

Medrol methylprednisolone Anti-inflammatory steroid

Oxycontin oxycodone Analgesic (C-II)

Phenergan promethazine Anti nausea/anti-emetic

Prevacid lansoprazole Antacid (PPI)

Edarbi azilsartan Antihypertensive

Seroquel quetiapine Antipsychotic

Soma carisoprodol Muscle relaxer (C-IV)

Tricor fenofibrate Cholesterol lowering

Tylenol 3 codeine + apap Analgesic (C-III)

Vasotec enalapril Antihypertensive

Brand Name Generic Name Category / Indication

Viagra sildenafil Erectile dysfunction

Focalin dexmethylphenidate ADHD (C-II)

Yaz ethinyl estradiol Birth control

Zyloprim allopurinol Antigout

Aldactone spironolactone Diuretic/antihypertensive

Altace ramipril Antihypertensive

Amaryl glimepiride Antidiabetic

Concerta methylphenidate ADHD (C-II)

Cozaar losartan Antihypertensive

Xyzal levocetirizine Antihistamine

Folvite folic acid Mineral supplement

Imdur isosorbide mononitrate Anti-angina (chest pain)

Lanoxin digoxin Treats heart failure/arrhythmia

Lyrica pregabalin Anticonvulsant/Anti nerve pain

(C-V)

Nasacort triamcinolone Anti-inflammatory steroid

Pristiq desvenlafaxine Antidepressant

Omnicef cefdinir Antibiotic

Levemir Insulin detemir Insulin – Antidiabetic

Xarelto rivaroxaban Anticoagulant

Restoril temazepam Sleep aid (C-IV)

Tamiflu oseltamivir Antiviral (Flu)

Valtrex valacyclovir Antiviral

Trandate labetalol Antihypertensive

Zetia ezetimibe Cholesterol lowering

Abilify aripiprazole Antipsychotic

Adderall amphetamine ADHD (C-II)

Adipex phentermine Appetite suppressant (C-IV)

Aricept donepezil Anti-Alzheimer’s

Benicar olmesartan Antihypertensive (ARB)

Cataflam diclofenac Analgesic (N.S.A.I.D.)

Zestoretic lisinopril + HCTZ Antihypertensive + diuretic

Brand Name Generic Name Category / Indication

Cleocin clindamycin Antimicrobial

Flagyl metronidazole Antimicrobial

Glucotrol glipizide Antidiabetic

Lamictal lamotrigine Anticonvulsant

Levoxyl levothyroxine Thyroid hormone replacement

Lopid gemfibrozil Cholesterol lowering

Lotensin benazepril Antihypertensive

Ortho Tri Cyclen ethinyl estradiol Birth Control

Reglan metoclopramide GI motility stimulant

Risperdal risperidone Antipsychotic

Spiriva tiotropium Reduces mucus

secretion/bronchodilator

Verelan verapamil Anti-arrhythmia

Vistaril hydroxyzine Antihistamine

Antivert meclizine Antivertigo

Buspar buspirone Antianxiety

Cardizem diltiazem Antihypertensive

Cardura doxazosin Reduces enlarged prostate

Depakote divalproex Anticonvulsant

Detrol tolterodine Urinary antispasmodic

Furadantin nitrofurantoin Antibiotic

Hyzaar losartan + HCTZ Antihypertensive + diuretic

Inderal propranolol Antihypertensive

Januvia sitagliptin Antidiabetic

Mirapex pramipexole Anti-tremor (Parkinson’s disease)

Eliquis apixaban Anticoagulant

Remeron mirtazapine Antidepressant

Robitussin guaifenesin Anti-mucus (expectorant)

Suboxone buprenorphine Opioid Recovery (C-III)

Topamax topiramate Anticonvulsant

Vyvanse lisdexamfetamine ADHD (C-II)

Wellbutrin bupropion Antidepressant

Brand Name Generic Name Category / Indication

Xalatan latanoprost Antiglaucoma

Zovirax acyclovir Antiviral

Accupril quinapril Antihypertensive

Aciphex rabeprazole Antacid (PPI)

Avapro irbesartan Antihypertensive

Bactroban mupirocin Topical antibacterial

Boniva ibandronate Bone strengthener

Combivent albuterol + ipratropium Bronchodilator/anti-mucus

Duragesic fentanyl Analgesic (C-II)

Myrbetriq mirabegron Overactive bladder

Fioricet butalbital/apap Antimigraine

Glycolax polyethylene glycol Laxative

Hytrin terazosin Antihypertensive

Imitrex sumatriptan Antimigraine

Tenex guanfacine Antihypertensive/ADHD

Tegratol carbamazepine Anticonvulsant

Tapazole methimazole Anti thyroid hormone

Pepcid famotidine Antacid

Procardia nifedipine Anti-arrhythmia

Proscar finasteride Reduces enlarged prostate

Rheumatrex methotrexate Antirheumatic

Tessalon Perles benzonatate Cough suppressant

Actonel risedronate Bone strengthener

Avalide irbesartan + HCTZ Antihypertensive + Diuretic

Bentyl dicyclomine Antispasmodic (intestines)

Biaxin clarithromycin Antibiotic

Chantix varenicline Smoking cessation

Evista raloxifene Estrogen modulator

Humalog insulin lispro Insulin (short acting)

Tresiba insulin degludec Insulin (long acting)

Namenda memantine Anti-Alzheimer’s

Brand Name Generic Name Category / Indication

NitroStat nitroglycerine Anti-angina

NovoLog insulin aspart Insulin

Trulicity dulaglutide Antidiabetic

Relafen nabumetone Analgesic (N.S.A.I.D.)

Requip ropinirole Anti-Parkinson’s

Robaxin methocarbamol Muscle relaxer

Temovate clobetasol Anti-inflammatory steroid

Zanaflex tizanidine Muscle relaxer

Zebeta bisoprolol Antihypertensive

Zofran ondansetron Anti nausea

Zyprexa olanzapine Antipsychotic

Apresoline hydralazine Antihypertensive

Avelox moxifloxacin Antibiotic

Avodart dutasteride Reduces enlarged prostate

Dyazide triamterene + HCTZ Antihypertensive (2 diuretics)

Cogentin benztropine Anti-Parkinson’s

Humira adalimumab Immunosuppressive

Dilantin phenytoin Anticonvulsant

Ditropan oxybutynin Overactive bladder

Keppra levetiracetam Anticonvulsant

Victoza liraglutide Antidiabetic

Lioresal baclofen Muscle relaxer

Trileptal oxcarbazepine Anticonvulsant

Nizoral ketoconazole Antifungal

Pamelor nortriptyline Antidepressant

Plaquenil hydroxychloroquine Arthritis/lupus

Protonix pantoprazole Antacid (PPI)

Pyridium phenazopyridine Analgesic (urinary)

Strattera atomoxetine ADHD (nonscheduled)

Janumet metformin + sitagliptin Antidiabetic combination

Jardiance empagliflozin Antidiabetic

Brand Name Generic Name Category / Indication

Brilinta ticagrelor Blood thinner / anticoagulant

Cialis tadalafil Erectile dysfunction

Colcrys colchicine Antigout

Daliresp roflumilast C.O.P.D.

Dexilant dexlansoprazole Antacid/ PPI

Exelon rivastigmine Antidementia

Feosol ferrous sulfate Iron supplement

Juxtapid lomitapide Cholesterol lowering

Latuda lurasidone Antipsychotic

Lunesta eszopiclone Sleep aid

Minocin minocycline Antibiotic

Multaq dronedarone Antiarrhythmic

Onglyza saxagliptin Antidiabetic

Pataday olopatadine Antihistamine (ophthalmic)

Pradaxa dabigatran Anticoagulant

Teveten eprosartan Antihypertensive (ARB)

Tussionex chlorpheniramine Antihistamine / analg

NBME Bacteria Q&A;

NBME/USMLE Bacteria Questions & Answers – Study Guide Question 1 A 34-year-old

woman presents to the emergency department with 2 days of dysuria, increased urinary

frequency, and suprapubic pain. Urinalysis shows: WBC: 50-100/hpf RBC: 0-2/hpf Bacteria:

Many Nitrites: Positive Leukocyte esterase: Positive Urine culture grows gram-negative rods

that are lactose-fermenting on MacConkey agar. What is the most likely causative organism?

A) Staphylococcus saprophyticus B) Escherichia coli C) Proteus mirabilis D) Pseudomonas

aeruginosa E) Enterococcus faecalis Answer: B) Escherichia coli Explanation: E. coli is

gram-negative rods that ferment lactose (pink on MacConkey) and produce nitrites. It’s the #1

cause of UTIs (80-90%). Staph saprophyticus is gram-positive, not gram-negative. Question 2

A 6-year-old boy is brought to the pediatrician with 3 days of sore throat, fever (39.2°C), and

difficulty swallowing. Physical exam reveals tonsillar exudate and tender anterior cervical

lymphadenopathy. No cough or rhinorrhea is present. Rapid strep test is positive. The bacteria

responsible for this infection would show which of the following on blood agar? A)

Alpha-hemolysis (green discoloration) B) Beta-hemolysis (clear zone) C) Gamma-hemolysis

(no hemolysis) D) Delta-hemolysis (double zone) E) Epsilon-hemolysis (cloudy zone)

Answer: B) Beta-hemolysis (clear zone) Explanation: Group A Strep (S. pyogenes) causes

strep throat and shows beta-hemolysis (complete/clear hemolysis on blood agar). Question 3 A

72-year-old man with COPD presents to the ED with fever, productive cough with rust-colored

sputum, and sharp chest pain that worsens with breathing. Chest X-ray shows right lower lobe

consolidation. Gram stain of sputum reveals gram-positive diplococci. This organism is likely

to show resistance to antibiotics through which mechanism? A) Beta-lactamase production B)

Altered penicillin-binding proteins C) Efflux pumps D) Ribosomal methylation E) Porin

mutations Answer: B) Altered penicillin-binding proteins Explanation: S. pneumoniae

(rust-colored sputum, gram-positive diplococci) typically develops resistance through altered

PBPs, not beta-lactamase production. Question 4 A 28-year-old woman develops severe

diarrhea 4 hours after eating potato salad at a picnic. She has nausea and vomiting but no fever.

The symptoms resolve within 24 hours. The responsible toxin was most likely produced by

bacteria growing in the food at what temperature? A) 4°C (refrigerator temperature) B) -20°C

(freezer temperature) C) 25-40°C (room temperature) D) 60°C (hot holding temperature) E)

100°C (boiling temperature) Answer: C) 25-40°C (room temperature) Explanation: This is

classic S. aureus food poisoning from preformed toxin. The toxin is produced when food

(especially mayo-based) sits at room temperature. Question 5 A 3-week-old infant is brought

to the ER with poor feeding, constipation, and weak cry. The mother mentions she recently

started giving the baby honey-sweetened pacifiers. On exam, the infant has decreased muscle

tone and weak gag reflex. What characteristic of the causative organism allows it to survive the

food processing? A) Capsule formation B) Spore formation C) Biofilm production D) Flagella

E) Pili formation Answer: B) Spore formation Explanation: Clostridium botulinum forms

spores that survive in honey. Causes infant botulism (“floppy baby syndrome”) by producing

toxin that blocks acetylcholine. Question 6 A 45-year-old construction worker steps on a rusty

nail that penetrates his work boot. Five days later, he develops difficulty opening his jaw and

painful facial muscle spasms. He mentions he “can’t remember” his last tetanus shot. The toxin

responsible for his symptoms travels to the CNS via: A) Bloodstream to cross the blood-brain

barrier B) Lymphatic system to cervical nodes C) Retrograde axonal transport in motor

neurons D) Direct extension through tissue planes E) CSF circulation after meningeal

penetration Answer: C) Retrograde axonal transport in motor neurons Explanation: Tetanus

toxin (tetanospasmin) travels backwards up motor neurons to reach the spinal cord, where it

blocks inhibitory neurons causing spasms. Question 7 A 19-year-old college student presents

with fever, headache, and a petechial rash that doesn’t blanch when pressed. CSF analysis

shows: Increased WBC (predominantly neutrophils) Decreased glucose Increased protein

Gram-negative diplococci Which virulence factor of this organism helps it avoid

complement-mediated lysis? A) Protein A B) M protein C) Polysaccharide capsule D) IgA

protease E) Lipooligosaccharide Answer: C) Polysaccharide capsule Explanation: N.

meningitidis uses its polysaccharide capsule to prevent complement deposition and avoid

complement-mediated lysis. Question 8 A 45-year-old gardener presents with a painless ulcer

on his forearm that started as a small papule 2 weeks ago. There’s a chain of non-tender

nodules extending up his arm along what appears to be lymphatic channels. He mentions

working with rose bushes and sphagnum moss. Initial bacterial cultures are negative. KOH

prep is negative. What special culture condition is needed to grow the most likely organism?

A) Chocolate agar at 42°C B) Lowenstein-Jensen medium at 37°C C) Sabouraud dextrose agar

at 25°C D) Charcoal yeast extract at 35°C E) Blood agar with 5% CO2 Answer: C) Sabouraud

dextrose agar at 25°C Explanation: This is sporotrichosis (rose gardener’s disease) caused by

Sporothrix schenckii. It requires room temperature culture on Sabouraud dextrose (sugar) agar.

Question 9 Three patients present to your clinic: Patient A: 4 hours after church potluck →

violent vomiting, no fever Patient B: 12 hours after the same potluck → watery diarrhea,

crampy pain Patient C: 48 hours after the same potluck → bloody diarrhea, fever Match each

patient to their likely pathogen: 1. Staph aureus 2. Clostridium perfringens 3. Salmonella

Answer: Patient A = 1 (Staph aureus) – 1-6 hours, preformed toxin, vomiting Patient B = 2 (C.

perfringens) – 8-16 hours, watery diarrhea Patient C = 3 (Salmonella) – 24-72 hours, invasive,

bloody diarrhea + fever Question 10 A 25-year-old medical student develops watery diarrhea

12 hours after eating leftover Chinese takeout that was left at room temperature overnight. No

blood or mucus is noted. She has crampy abdominal pain but no fever. Gram stain shows

gram-positive rods. Which test would differentiate between the two most likely causative

organisms? A) Motility at 25°C B) Hemolysis pattern C) Spore location D) Catalase test E)

Growth on mannitol salt agar Answer: A) Motility at 25°C Explanation: B. cereus (motile) vs

C. perfringens (non-motile) both cause similar food poisoning from reheated foods. Question

11 A 68-year-old man with poorly controlled diabetes presents with a rapidly spreading,

painful rash on his left leg. The affected area is warm, swollen, and has a characteristic “orange

peel” appearance. Fever is 39.1°C. Blood cultures grow gram-positive cocci in chains. What is

the most important virulence factor enabling this organism to spread rapidly through tissue? A)

Coagulase B) Hyaluronidase C) Protein A D) Lipase E) Catalase Answer: B) Hyaluronidase

Explanation: Group A Strep produces hyaluronidase (“spreading factor”) that breaks down

hyaluronic acid between cells, allowing rapid tissue spread in cellulitis. Question 12 A

30-year-old pregnant woman (32 weeks) presents with fever, myalgias, and diarrhea. She

mentions eating soft cheese from a farmer’s market 2 weeks ago. Blood cultures grow gram-

positive rods that show tumbling motility at room temperature. This organism can grow at

which temperature that most other pathogens cannot? A) -20°C B) 4°C C) 42°C D) 56°C E)

100°C Answer: B) 4°C Explanation: Listeria monocytogenes is the “refrigerator bug” – it can

grow at 4°C (fridge temp) while other bacteria cannot. Question 13 A 4-year-old boy presents

with honey-crusted lesions around his mouth and nose. The lesions started as small vesicles

that ruptured. Gram stain shows gram-positive cocci in clusters. The organism is catalase

positive and coagulase positive. What virulence factor specifically helps this organism resist

phagocytosis? A) M protein B) Protein A C) Leukocidin D) Alpha toxin E) Exfoliative toxin

Answer: B) Protein A Explanation: S. aureus (impetigo) uses Protein A to bind Fc portion of

IgG antibodies backwards, preventing opsonization and phagocytosis. Question 14 A

55-year-old alcoholic man presents with foul-smelling sputum and a chest X-ray showing a

cavitary lesion in the right lower lobe. He mentions “vomiting and then choking” after heavy

drinking last week. Gram stain of sputum shows mixed gram-positive and gram-negative

organisms. The bacteria most likely causing this infection are: A) Aerobic only B) Anaerobic

only C) Mixed aerobic and anaerobic D) Microaerophilic only E) Facultative anaerobes only

Answer: C) Mixed aerobic and anaerobic Explanation: Aspiration pneumonia typically

involves mixed aerobic and anaerobic mouth flora. The foul smell is from anaerobes. Question

15 A 22-year-old college student returns from spring break in Cancun with severe watery

diarrhea (“rice water stools”). She’s having 15-20 bowel movements per day and is severely

dehydrated. Stool microscopy shows comma-shaped gram-negative bacteria that are highly

motile. The toxin responsible for her symptoms acts by: A) Inhibiting protein synthesis B)

Increasing cAMP levels C) Disrupting cell membranes D) Blocking acetylcholine release E)

Inhibiting DNA synthesis Answer: B) Increasing cAMP levels Explanation: Vibrio cholerae

toxin permanently activates adenylyl cyclase, increasing cAMP, opening CFTR channels,

causing massive fluid loss. Question 16 A 32-year-old IV drug user presents with fever, new

heart murmur, and painful red nodules on his finger pads. Blood cultures grow gram-positive

cocci in clusters that are catalase positive but coagulase negative. Echocardiogram shows

vegetations on the tricuspid valve. Which organism is most likely responsible? A)

Staphylococcus aureus B) Staphylococcus epidermidis C) Streptococcus viridans D)

Enterococcus faecalis E) Streptococcus bovis Answer: B) Staphylococcus epidermidis

Explanation: Coagulase-negative staph (S. epidermidis) can cause endocarditis, especially with

prosthetic devices/IV drug use. Question 17 A 26-year-old woman presents with burning on

urination and white vaginal discharge. She mentions her boyfriend was recently treated for

urethritis. Wet mount shows motile organisms with jerky movements. No hyphae or clue cells

are seen. What is unique about this organism’s energy metabolism? A) Uses only aerobic

respiration B) Lacks mitochondria C) Cannot ferment glucose D) Requires CO2 for growth E)

Produces ATP via photosynthesis Answer: B) Lacks mitochondria Explanation: Trichomonas

vaginalis lacks mitochondria, using hydrogenosomes instead – very unusual for a eukaryote.

Question 18 A 7-year-old boy presents with facial swelling that’s worst in the morning,

tea-colored urine, and decreased urine output. His mother mentions he had a “skin infection” 2

weeks ago. Lab shows elevated ASO titers and low C3 levels. The bacteria that triggered this

condition contains which virulence factor in its cell wall? A) Teichoic acid B)

Lipopolysaccharide C) M protein D) Mycolic acid E) Peptidoglycan only Answer: C) M

protein Explanation: Post-streptococcal glomerulonephritis follows Group A Strep infection.

M protein is the major virulence factor. Question 19 A 28-year-old man with AIDS (CD4

count: 180) presents with multiple purple, raised skin lesions on his chest and arms. Biopsy

shows spindle cells and vascular proliferation. PCR of the lesion detects a DNA virus. This

virus is associated with which other malignancy? A) Hepatocellular carcinoma B) Burkitt

lymphoma C) Primary effusion lymphoma D) Nasopharyngeal carcinoma E) Cervical

carcinoma Answer: C) Primary effusion lymphoma Explanation: HHV-8 (KSHV) causes both

Kaposi sarcoma and primary effusion lymphoma in AIDS patients. Question 20 A 35-year-old

pig farmer presents with high fever, myalgias, and jaundice. He mentions several of his pigs

died recently after flooding on his farm. Physical exam reveals conjunctival suffusion and

hepatomegaly. Dark-field microscopy of blood shows spiral organisms. What is the most

likely portal of entry for this organism? A) Respiratory tract via inhalation B) GI tract via

ingestion C) Skin via minor abrasions D) Conjunctiva via direct contact E) Urogenital tract via

sexual contact Answer: C) Skin via minor abrasions Explanation: Leptospirosis enters through

breaks in skin when exposed to water contaminated with animal urine. Question 21 A

45-year-old diabetes patient is being treated for a foot ulcer with S. aureus. After 5 days of IV

nafcillin, he develops new fever and the wound looks worse. Culture now grows gram-positive

cocci that are catalase positive but don’t turn mannitol salt agar yellow. What’s the most likely

explanation? A) Original S. aureus developed resistance B) Superinfection with S. epidermidis

C) Lab error in original culture D) MRSA was present all along E) Contamination with

Micrococcus Answer: D) MRSA was present all along Explanation: Mixed MSSA/MRSA

population initially. Nafcillin killed MSSA, revealing mannitol-negative MRSA strain.

Question 22 A 62-year-old woman is hospitalized with severe community-acquired

pneumonia. Sputum shows gram-positive lancet-shaped diplococci. She’s started on penicillin

G but after 48 hours shows no improvement. Repeat culture confirms S. pneumoniae. MIC

testing reveals intermediate resistance to penicillin. What’s the best next step in management?

A) Increase penicillin G dose B) Add gentamicin for synergy C) Switch to vancomycin +

rifampin D) Switch to ceftriaxone E) Add azithromycin for atypical coverage Answer: D)

Switch to ceftriaxone Explanation: For penicillin-resistant S. pneumoniae, high-dose

ceftriaxone (3rd gen cephalosporin) often remains effective. Question 23 A 19-year-old

college freshman living in a dormitory presents with fever, headache, and petechial rash. You

suspect meningococcemia and start ceftriaxone immediately. CSF shows gram-negative

diplococci. However, the health department calls to report that 3 close contacts who received

standard ciprofloxacin prophylaxis have now developed similar symptoms. What’s the most

likely explanation? A) Prophylaxis was given too late B) Contacts had poor medication

compliance C) Fluoroquinolone-resistant strain D) Different organism than N. meningitidis E)

Hypersensitivity reaction mimicking infection Answer: C) Fluoroquinolone-resistant strain

Explanation: N. meningitidis fluoroquinolone resistance is increasing. Multiple prophylaxis

failures suggest resistant strain. Question 24 You admitted a 58-year-old man with diabetes for

cellulitis, starting him on vancomycin for presumed MRSA. The lab calls at 2 AM: “The blood

culture is growing gram-positive cocci in chains that are beta-hemolytic, but they’re

vancomycin RESISTANT. They’re also resistant to penicillin but sensitive to cephalosporins.”

What organism is most likely? A) Group A Streptococcus B) Streptococcus pneumoniae C)

Enterococcus faecium D) Streptococcus agalactiae (Group B) E) Streptococcus bovis Answer:

D) Streptococcus agalactiae (Group B) Explanation: Group B Strep has intrinsic vancomycin

tolerance (not true resistance) but remains sensitive to beta-lactams. Question 25 A 35-year-old

aid worker returns from Sudan with cyclical fevers every 48 hours, but her malaria smears are

negative 3 times. She mentions she’s been taking doxycycline prophylaxis religiously. Blood

cultures are negative. On day 5, during a fever spike, you order one more blood culture using

special lysis-centrifugation technique. It grows gram-negative coccobacilli that require

cysteine for growth. Wright-Giemsa stain of blood shows organisms within neutrophils.

What’s the most likely organism? A) Bartonella bacilliformis B) Francisella tularensis C)

Brucella species D) Burkholderia pseudomallei E) Yersinia pestis Answer: B) Francisella

tularensis Explanation: F. tularensis requires cysteine, is found in neutrophils, and needs

special culture techniques. Question 26 A 28-year-old woman at 20 weeks gestation presents

with flu-like symptoms and says she “can’t taste her food.” Her husband mentions she’s been

obsessively cleaning the cat’s litter box because “someone has to do it.” CBC shows atypical

lymphocytes. Her OB is worried about fetal complications. Serology shows: IgM: Positive

IgG: Negative IgG avidity: Not applicable What’s the approximate risk of fetal transmission at

this gestational age? A) <5% B) 15-20% C) 25-30% D) 50-60% E) >90% Answer: C) 25-30%

Explanation: Toxoplasmosis transmission risk increases with gestational age: 1st trimester

~15%, 2nd trimester ~25-30%, 3rd trimester ~60-70%. Question 27 A 45-year-old gardener

presents with a painless ulcer on his forearm that started as a small papule 2 weeks ago. There’s

a chain of non-tender nodules extending up his arm along what appears to be lymphatic

channels. He mentions working with rose bushes and sphagnum moss. Initial bacterial cultures

are negative. KOH prep is negative. What special culture condition is needed to grow the most

likely organism? A) Chocolate agar at 42°C B) Lowenstein-Jensen medium at 37°C C)

Sabouraud dextrose agar at 25°C D) Charcoal yeast extract at 35°C E) Blood agar with 5%

CO2 Answer: C) Sabouraud dextrose agar at 25°C Explanation: Sporothrix schenckii (rose

gardener’s disease) is dimorphic – grows as mold at 25°C on Sabouraud (sugar) agar. Question

28 A 16-year-old swimmer complains of severe ear pain and drainage. On exam, pulling the

ear causes significant pain. The discharge grows gram-negative rods that produce blue-green

pigment and have a fruity odor. Two days into treatment with polymyxin

B/neomycin/hydrocortisone drops, he returns WORSE with facial weakness on that side.

What’s the most likely explanation? A) Resistant organism B) Malignant otitis externa C)

Allergic reaction to neomycin D) Ototoxic reaction E) Undiagnosed cholesteatoma with

infection Answer: B) Malignant otitis externa Explanation: Pseudomonas can cause invasive

“malignant” otitis externa affecting cranial nerve VII (facial nerve). Question 29 A 34-year-old

man with Crohn’s disease on infliximab presents with fever and productive cough. Chest X-ray

shows upper lobe cavitation. PPD was negative before starting infliximab. Sputum AFB stain

is negative x3, but cultures are pending. While waiting for cultures, bronchoscopy is

performed. Transbronchial biopsy shows necrotizing granulomas. Silver stain reveals

narrow-based budding yeasts. What’s the most likely diagnosis? A) Mycobacterium

tuberculosis B) Mycobacterium avium complex C) Histoplasma capsulatum D) Coccidioides

immitis E) Aspergillus fumigatus Answer: C) Histoplasma capsulatum Explanation:

Histoplasma shows narrow-based budding (vs broad-based for Blasto), causes TB-like disease

in immunosuppressed. Question 30 A 6-month-old infant is brought in for failure to thrive and

recurrent bacterial infections. Mom mentions the baby has had “3 ear infections, 2 bouts of

pneumonia, and weird skin infections.” Labs show normal B cells and immunoglobulins but

severely decreased oxidative burst test. The child is at highest risk for serious infection from

which organism? A) Streptococcus pneumoniae B) Haemophilus influenzae C) Aspergillus

fumigatus D) Giardia lamblia E) Enterovirus Answer: C) Aspergillus fumigatus Explanation:

Chronic granulomatous disease (CGD) – can’t make oxidative burst. High risk for catalase-

positive organisms like Aspergillus. Question 31 Three patients present to your clinic: Patient

A: 4 hours after church potluck → violent vomiting, no fever Patient B: 12 hours after the

same potluck → watery diarrhea, crampy pain Patient C: 48 hours after the same potluck →

bloody diarrhea, fever All three ate the famous “mayo-heavy potato salad that sat out all day.”

Match each patient to their likely pathogen: 1. Staph aureus 2. Clostridium perfringens 3.

Salmonella Answer: Patient A = 1 (Staph aureus) Patient B = 2 (C. perfringens) Patient C = 3

(Salmonella) Question 32 A 55-year-old woman is treated for UTI with

trimethoprim-sulfamethoxazole. Three days later, she returns with worsening symptoms PLUS

a new diffuse rash and fever. Repeat urine culture shows: Original organism: E. coli (sensitive

to TMP-SMX) – now gone New organism: Gram-positive cocci in chains, alpha-hemolytic

What’s the most likely explanation? A) Treatment failure due to resistance B) Superinfection

during treatment C) Drug reaction with continued infection D) Laboratory contamination E)

Polymicrobial infection from the start Answer: B) Superinfection during treatment

Explanation: TMP-SMX killed E. coli but allowed Enterococcus (resistant to TMP-SMX) to

cause superinfection. Question 33 A 23-year-old medical student develops severe

gastroenteritis 6 hours after eating at a new sushi restaurant. She has profuse watery diarrhea

(10+ episodes), vomiting, and cramping. No fever. Her classmate who ate the exact same items

is completely fine. Further history reveals the affected student is taking omeprazole for GERD.

What best explains why only ONE person got sick? A) Different genetic susceptibility to

bacterial toxins B) Reduced stomach acid allowed bacterial survival C) Allergic reaction to

seafood D) Coincidental viral gastroenteritis E) Psychological food aversion Answer: B)

Reduced stomach acid allowed bacterial survival Explanation: PPIs reduce stomach acid,

allowing bacteria (like Vibrio from seafood) to survive passage to intestines. Question 34 A

67-year-old diabetic man is admitted for right foot cellulitis. Blood cultures grow methicillin-

sensitive S. aureus. He’s started on IV nafcillin. On day 3, the nurse reports his temperature is

now 39.5°C (was 37.2°C yesterday) and he has new confusion. Blood pressure is 85/50.

Repeat blood cultures are drawn. While waiting for results, you notice his IV site (placed on

admission) is slightly red. What’s the MOST likely source of his clinical deterioration? A)

Nafcillin-resistant S. aureus from the foot B) Hospital-acquired pneumonia C) Central

line-associated bloodstream infection D) Infected peripheral IV site E) Diabetic ketoacidosis

Answer: D) Infected peripheral IV site Explanation: Day 3 peripheral IV + “slightly red” +

septic shock = infected IV site. Should be changed q72-96h. Question 35 A 45-year-old

woman with no medical history presents with dysuria and frequency. Urinalysis shows: WBC:

20-50/hpf Bacteria: Many Nitrites: Negative Leukocyte esterase: Positive You prescribe

nitrofurantoin. She returns 3 days later WORSE with flank pain and fever. Urine culture comes

back showing >100,000 CFU/mL of gram-positive cocci in chains, catalase negative. What

characteristic of the causative organism explains the negative nitrite test? A) Lacks nitrate

reductase enzyme B) Produces urease C) Forms biofilms D) Slow growth rate E) Facultative

anaerobe Answer: A) Lacks nitrate reductase enzyme Explanation: Enterococcus lacks nitrate

reductase, so nitrite test is negative despite significant bacteriuria. Key Memory Tricks from

Our Session: “MRSA laughs at Methicillin, Nafcillin, and all their -cillin cousins!”

“BOTulinum BOTtles up the acetylcholine!” “TETanus Toxin Takes the nerve Train

upTown!” “Francisella is Finicky – needs cysteine” “LEPtospirosis LEAPs through skin in

flood water!” “Histo Has narrow Hips, Blasto has a Broad Butt!” “Cholera Causes cAMP

Catastrophe!” “ENTEROcoccus CAN’T ENTER the nitrate cycle!” “Protein A makes

Antibodies point Away!” “Strep Can’t Cut” (Catalase negative) vs “Staph Can Cut” (Catalase

positive)

UWorld Review Pearls

OK so we are going to start with phases of wound healing starting with hemostasis 0 to one

day platelets and damaged cells are gathered together and platelet derived growth factor as

well as tumor growth factor beta are implicated in the hemostasis next comes inflammation

which is anywhere between three and five days at this point macrophages platelet derived

growth factor vascular endothelial growth factor IL 1 tumor necrosis alpha and tumor necrosis

and tumor ohh tissue growth factor beta are implicated next we have proliferation which is 3 to

5 three days to five weeks and then proliferation fibroblasts are the dominant factor along with

the tumor growth factor beta fibroblast growth factor vascular endothelial growth factor and

the extracellular matrix next comes remodeling which is 3 weeks to two years and at this point

we have matrix metalloproteases type 3 collagen is laid down and eventually type 1 collagen is

laid down which is the same as skin and tendons.

Ataxia telangiectasia is autosomal recessive the pathophysiology is a defective DNA brake

repair features include presents in early childhood neurological dysfunction progressive

cerebellar ataxia uncoordinated head and eye movements telangiectasias on the face and

conjunctiva immune deficiency such as reoccurrence sinopulmonary infections and they have a

great risk for malignancy ohh mutation analysis we find that there is a defect in the ATM gene

or the ataxia telangiectasia mutated gene ATM kinase detects the DNA damage via

phosphorylation of various proteins which halt the cycle to allow for repair without ATM

kinase DNA that is impaired keeps building up

Bare lymphocyte syndrome is common is implicated by MHC Class 2 it’s defective so MHC

Class 2 is defective where it would normally be found on antigen presenting cells and present

foreign proteins to T helper cells defective MHC Class 2 expression impairs T cell immune

response as well as activation of B cells this syndrome presents an infancy with severe

infections.

Friedrich’s ataxia is due to a trinucleotide repeat GA affecting the mitochondrial protein

frataxin mitochondrial iron transport is impaired leading to progressive ataxia in adolescents as

well as kaipo scoliosis Pez cavus hammertoe cardiomyopathy and glucose intolerance

Leash nyhan syndrome is a disorder of purine catabolism it is a xlink recessive mutation in the

gene encoding for the hypoxanthine guanine phosphoribosyl phrase this defect leads to severe

hyperuricemia and gout typically patients exhibit self mutilation choreoathetoid movement and

spasticity.

Niemann pick is autosomal recessive there is a defect in sphingolipid degeneration or

regeneration due to a mutation in the sphingomyelinase signs and symptoms include motor

neuropathy hypotonia a reflexia hepatosplenomegaly and a cherry red macular spot.

Dimorphic fungi the species sporothrix kits shaneka is usually contracted through rosebud or

gardening the clinical presentation reveals postulates ulcers subcutaneous nodules that travel

along the lymphatics these are evident due to their cigar shaped shape and they are branching

hyphae in the cold

Coccidioides immitis is found in the southwestern United States mole through mold which is

present in the soil it is mainly associated with pulmonary flu like symptoms such as cough and

erythema nodosum along with disseminated effects on the bone skin and lungs this particular

fungus has hyphae it is thick walled filled with thick walled sphere rulers spherules spherules

spherules spherules with endospores inside of them.

Histoplasma capsulatum is found in the Ohio River Mississippi valley it’s found in soil bird

and bat chicken coops caves etcetera it manifests with pulmonary it looks like TB there is a

granulomatous calcification the disseminated lung to the spleen and the liver it is a high they’re

round Oval yeast cells within the macrophages so the most important thing is to look within

the macrophages for these particular mold.

Blastomyces dermatitis it’s also found in soil also presents with pulmonary pneumonia and it’s

disseminated form is common and severe it forms very large round broad based yeasts.

Paracoccidioides is found in the central and South of the United states it is mucocutaneous

ulcers that can actually go to the lymph nodes in the lungs these particular fungi are covered in

what we call blastocyte. Clinical features of cardiac tamponade include and malignancy and

radiation therapy can cause it. Infections such as viral tuberculosis HIV can cause it drugs like

hydralazine or isoniazid can cause cardiac tamponade connective tissue diseases such as lupus

erythematosus and rheumatoid arthritis can cause cardiac tamponade.

Clinical signs and symptoms symptoms relating to cardiac tamponade include the beck triad

which is jugular venous distension #1 #2 hypotension #3 diminished heart sounds there is also

pulses paradoxes and this is an abnormally large inspiratory decrease in systolic blood pressure

by 10mm of mercury.

The diagnosis of cardiac tamponade is usually typically seen with an EKG showing a low

voltage QRS complex electrical alternans chest X-ray will show an enlarged water bottle

shaped heart but clear lungs.

1.

the inferior vena cava which is being pointed out by the red arrow is formed from the union of

the common iliac veins and these are at the level of L4 and L5

1. A chancroid you will find an HIV positive sexually active people usually a typically a

1.5cm ulceration on the right side of the base of the penus it’s tender soft irregular ragged

borders covered in Gray exiting with palpable tender enlarged inguinal lymph nodes in

the right groin polymerase chain reaction testing for herpes will be negative dark field

microscopy will reveal no organisms therefore this is considered a chancroid. Now let us

take a look at some diagnostic features so a chancroid is caused by hemophilus ducreyi

the primary lesions are multiple deep ulcers they have grey to yellow base organisms

often tend to clump in long parallel strands IE school of fish the legion legion is very

painful.

Genital herpes: is caused by the herpes simplex virus one and two there are multiple grouped

ulcers shallow with arithmetic base they are composed of multinucleated giant cells and

intranuclear inclusion exclusions which are called cowdry bodies.

Granuloma inguinale or the donovanosis: is caused by the Organism klebsiella granulomatis:

the features of the lesion will be extensive and progressive ulcerative lesions without any

lymphadenopathy its base may have a granulation like tissue it is not painful. It stains gram

negative for intracytoplasmic cysts also called Donovan bodies.

Syphilis: caused by the Organism treponema Palladium. It presents as a single indurated well

circumscribed ulcer it is nonexudative at the base it is painless but there is also inguinal bag

nathy that is painless there are the Organism looks like thin delicate Corkscrew shaped

organisms on dark field microscopy.

Lymphoma granuloma venereum: is caused by the Organism chlamydia trachomatis it is also

not painful. It consists of small shallow ulcers large painful coalesced inguinal lymph nodes or

bubos which are painful and the intra cytoplasmic chlamydia inclusion bodies in the epithelial

cells and leukocytes. It is important to note that in the chlamydia trachomatis

lymphogranuloma venereum the ulcers themselves are not painful however the inguinal lymph

nodes that form bubos are indeed painful. Condyloma acuminata: AKA genital warts: caused

by the human papilloma virus present as skin colored white or Gray verruacus and filiform

papules usually in the penile glands and shaft of men and in the vulvo vaginal and cervical

areas and women.

Muscular contagiosum is a contagious disease caused by infection with a DNA pox virus the

lesions are smooth skin colored flimm somewhat clearly popular as that measure about two to

6mm and often have a central umbilication. Granuloma inguinale is characterized by painless

extensive ulcerative lesions without any lymphadenopathy.

Primary syphilis commonly presents as a painless single genital ulcer or a canker. The

diagnosis is established by identification of the organisms on darkfield microscopy, serologic

testing, or syphilis antibody testing. Secondary syphilis is also characterized by systemic

symptoms such as lymphadenopathy and grey mucus patches which are raised genital papules

or condo lomata lata with a diffuse rash involving the palms and soles. Note to self in critically

ill patients calculus: cystitis or an acute inflammation of the gallbladder in the absence of

gallstones frequently occurs especially those with sepsis severe burns, trauma or

immunosuppression clinical manifestations can be subtle especially in those who are sedated

or intubated with fever right upper quadrant pain and positive Murphy signs Leukocytosis and

a mild elevation and liver functions diagnostic study of choice is an ultrasound which may

show signs of a edematous and enlarged gallbladder without any gallstones. There are

numerous causes of gynecomastia in men physiological may be decreased T cell synthesis with

aging and increased aromatization of androgens and adipose tissue.

Hypogonadism can also cause low circulating T levels. Under uninterrupted adrenal

production of estrogen precursors can also do it.

In cirrhosis there is decreased hepatic clearance of estrogens so cirrhosis can cause

gynecomastia.

There is a plethora of medications that can cause gynecomastia and some are the following:

spironolactone, anti androgens like flutamide and cimetidine which is actually an androgen

receptor antagonist. 5A reductase inhibitors such as finasteride which decreases conversion of

testosterone to dihydrotestosterone. Kukana azole also decreases testosterone synthesis. Going

to tropen releasing hormone agonists suppress the pituitary gonadal axis. And androgenic

steroids can increase aromatization to estrogens.

Testicular tumors such as HCG secretion by a germ cell tumor can cause gynecomastia which

is due to impaired tea or testosterone production and increased aromatization in latex cells.

Hyperthyroidism can cause gynecomastia through the increase of LH secretion as well as an

increase of aromatization of androgens.

A male patient comes in with priapism treat the patient with an A1 adrenergic agonist. So here

is the explanation when the pennis is in a flaccid state tonic alpha adrenergic such as

norepinephrine sympathetic activity maintains a high vascular and trabecular smooth muscle

tone preventing the corpora from engorging with blood.

In an erection activation of the parasympathetic nerves S2 to S4 induces the relaxation of

smooth muscle in the cavernous arteries and trabeculae. The increased blood flow fills the

relaxed corpora which subsequently subsequently causes compression of the emissary veins

against the tunica albuginea. This blocks the outflow of blood and further increases pressure

within the corpora cavernosa.

In patients with sickle cell or people on Trazodone or utilizing cocaine it’s not unusual for

priapism to become idiopathic so treatment usually includes A penile junction injection of an

alpha adrenergic alpha adrenergic agonist such as phenylephrine which induces contraction of

the cavernous smooth muscle and result reduces venous obstruction by the engorged corpora

increasing venous outflow and promoting the two men’s methods. A1 antagonists such as

tamsulosin or doxazosin actually inhibit tonic sympathetic activity and can actually trigger a

priapism. Let’s take a look at what a pancoast tumor does a pancoast tumor is located in the

superior sulcus of the lung next to the mediastinum Horner syndrome which includes ptosis

myosis and anhidrosis are usually from non small cell lung cancers more along the lines of

squamous cell carcinoma or adenocarcinoma and they arise from the superior sulcus groove

that is produced by the subclavian artery. Compression and invasion of the brachial plexus can

cause ipsilateral shoulder pain and upper limb paresthesia and are reflexive arm weakness

which is due to motor lower neuron pattern of a peripheral nerve.

Involvement of the cervical sympathetic ganglia an autonomic ganglion in the lower neck that

carries sympathetic innervation to the eye may lead to partial ptosis and denervation of the

superior tarsal muscle as well as miosis or interruption of the sympathetic fibers to the dilator

pupula muscle. Pupil asymmetry is more prominent in dim light because the increased

sympathetic tone exacerbates the defect. Anhidrosis or loss of sweating completes the classic

corner syndrome triad. A patient with cancer that over expresses the her two new epidermal

growth factor is treated with chemotherapy as well as a monoclonal antibody that binds to the

extracellular domain of the growth factor receptor the response to the mild or monoclonal

antibody is that of natural killer cells and granzymes. Basically what this scenario is looking at

is a monoclonal antibody to treat cancer called tret subhumid which targets the HRT 2 surface

receptor and often results in tumor regression. Although antibody binding can trigger cancer

cell death through a variety of mechanisms mechanisms such as down regulation complement

deposition the majority of the response is due to antibody dependent cellular toxicity or ADC.

This involves the following number one. A naturally occurring or monoclonal IgG binds to a

complementary surface antigen on a holster foreign cell.

2. A patrolling natural killer cell binds the FC portion of

the attached IG using CD16.

Number three. This binding triggers natural killer cells to release its granules which contain

perforin and granzymes which are proteases that induce apoptosis or osmotic lysis of the

antibody bound cell.

4 although natural killer cells are derived from the same

lymphocyte lineages as B&T; cells they are considered part

of the innate immune system because they don’t engage

with the major histocompatibility complexes to

differentiate self from non self. Unlike sodium cytotoxic T

cells natural killer cells can often identify neoplasms and

viruses that have downregulated the surface expression of

MHC Class 1 molecules.

Think of an emergency situation when someone comes in and they’ve been binge drinking like

for three or four days straight what do you expect to see you expect to see a problem or

inhibition in the citric acid cycle from ethanol causing them to have very very low glucose like

35 milligrams per deciliter So what they’re missing is gluconeogenesis. It’s important to note

where alcohol inhibits the citric acid cycle one part is NAD plus to NADH which is the

thiamine dependent pyruvate dehydrogenase reaction to acetyl COA.

The other is where isocitrate goes to alpha ketoglutarate via isocitrate dehydrogenase and NAD

plus goes to an NADH.

The other is where alpha ketoglutarate via alpha ketoglutarate dehydrogenase complex which

is also thiamine dependent goes from NAD plus to NADH.

And the last one is malate to oxaloacetate through malate dehydrogenase which we have

another NAD plus going to NADH. All of these above reactions are needed and required for

gluconeogenesis. Benign prostatic hyperplasia: finasteride which prevents testosterone from

going into dihydrotestosterone which is basically a 5A reductase inhibitor is best used on men

with a predominance of epithelial cells causing their benign prostatic hyperplasia. Benign

prostatic hyperplasia that is mainly composed of smooth muscle in the prostate and bladder

base will benefit more from A1 blockers then they would finasteride. Benign prostatic

hyperplasia that consists mostly of collagen will not respond to finasteride nor A1 blockers.

Wernicke’s word salad it is usually due to an artery which is the middle cerebral artery. The

patient basically has fluent aphasia it’s a form of receptive aphasia and patients are typically

not even aware of how they sound just keep in mind that wernicke’s word salad occurs due to

destruction or some type of injury to the middle cerebral artery. SARCOIDOSIS; sarcoidosis is

heralded by the non caseating granulomas which are non necrotic aggregates of epithelioid

macrophages frequently with multinucleated giant cells.

A patient will display cough night sweats and bilateral hyoid adenopathy women are more

common than men and it occurs mostly in African Americans. Although any organ can be

affected by sarcoidosis the lungs will show reticular nodular infiltrates and lymph nodes skin

will have an asthmatic rash and the eyes will have anterior anterior uveitis. In addition to fever

fatigue and night sweats they will have weight loss and arthralgias are also common we also

call this vitamin D osis.

Hashimoto’s thyroiditis patients will exhibit antibodies to thyroid peroxidase they will have

weight gain fatigue Constipation and a diffuse goiter the peak incidence is between the ages of

45 and 65 and typically it’s related to a iodine sufficient region. All forms of primary

hypothyroidism labs will show a low serum T4 and an elevated TSH. Although in hashimoto’s

thyroiditis the anti thyroid peroxidase antibodies are usually elevated but they are not specific.

If the the diagnosis is uncertain that a biopsy will show infiltrate with the formation of

germinal centers. These regional centers are surrounded by herthel cells which are large cells

with granular eosinophilic eosinophilic cytoplasm these represent follicular epithelial cells that

have undergone metaplastic change in response to inflammation. Cerebral amyloid

angiopathy: patient will be elderly they will have multiple lobar hemorrhages at varying ages

in the occipital and parietal areas with a medium sized acute bleed or not this patient will not

have any head trauma and they will not tell you what their blood pressure is or if they do their

blood pressure will be normal. Aortic regurgitation: the diagnostic symptoms are bounding

femoral and carotid pulsations accompanied by head bobbing the patient may have mild

shortness of breath with exertion without chest pain. Aortic stenosis: patients with severe aortic

stenosis have a characteristic arterial pulse it’s basically a small amplitude we call it pulses

parvat at tardis it has a delayed peak and a slower upstroke of the arterial pulse so it’s parvus it

tardis it’s due to diminished stroke volume and prolonged ejection time because the ventricle

has to force the bicuspid valve of the aortic semi lunar valves open so it takes more pressure

for the ventricle to open the aortic valves.

An atrial septal defect: the presence of an atrial septal defect leads to left to right intracardiac

shanti which can cause a hyper dynamic right ventricular impulse it does not cause any

significant change in the arterial pulse character. In patients with mitral valve regurgitation

both the arterial pulse and pulse pressure and forward stroke volume remain normal however

arterial pulses are reduced in volume and amplitude in patients with mitral valve stenosis due

to decreased left ventricular and diastolic volume and stroke volume. . Question: someone with

COPD who needs long term oxygen use we’ll have a sudden decrease in stimulation of what

receptor once oxygen is begun. The answer? Is the carotid bodies. The corroded bodies are no

longer needed to be activated because the patient is not is getting exogenous oxygen. Think of

it this way at the carotid body at the bifurcation of the carotid artery there are chemoreceptors

there is a carotid sinus baroreceptor as we travel down the carotid artery to the aorta we have

chemoreceptors on the aorta and on the arch itself we have aortic arch barrel receptors so

there’s receptors along with corroded body bifurcation as well as the aortic body and arch and

the vagus nerve travels between them and the brachiocephalic region and farther up more

superior is the glossopharyngeal nerve which travels to the spinal cord. Now here’s the rub

once oxygen is given peripheral chemoreceptors found in the carotid and aortic bodies are

stimulated by hypoxemia but when supplemental oxygen is administered and there is a rapid

increase in the pressure of oxygen it basically reduces the peripheral chemosynthesis chemo

receptor stimulation and it decreases respiratory rate. The problem with the reduced respiratory

rate and someone with COPD is that the supplementary oxygen is a minor contributor to the

oxygen induced hypercapnia that occur in patients with COPD because there is an increased

ventilation perfusion mismatch triggered by the alleviation of pulmonary vasoconstriction and

poorly ventilated areas which is the major mechanism. Classic question as a patient is walking

down stairs they have to turn their head a certain way to be able to see why this is classic

trochlear nerve palsy and the trochlear nerve is which nerve right so so let’s look at the cranial

nerves cranial nerve one is the olfactory nerve, cranial nerve 2 is the optic nerve cranial nerve 3

is the ocular motor nerve, cranial nerve 4 is the trochlear nerve, etcetera etcetera etcetera

MARFAN SYNDROME: Think marFAN/Fibrillin/Mitral valve/Floppy/tgF

beta/Metalloprotinaases/MicroFibribials Gene implicated : FBN1 ENCODING FOR

FIBRILIN 1 FOLLICULAR LYMPHOMA: Small lymphoid Cells arranged in a follicular

pattern. /MOA DYSFUNCTION: BCL-2 GENE DYSFUNCTION. LOSS OF FUNCTION:

BCL2 FUNCTION AS INHIBITOR OF INTRINSIC MITOCHONDRIAL PATHWAY FOR

INDUCING APOPTOSIS RELEASE OF CYTOCHROME C. Translocation on chromosome

18 and the immunoglobin heavy chain gene on chromosome 14 = t(14:18) Over expression of

BCL 2 allowing for tumor cells to evade apoptosis,_____ CLASSIC CLINICAL

SCENARIOS: “Elderly patient with painless lymphadenopathy” “Waxing and waning lymph

nodes over months/years” “Asymptomatic patient with bulky abdominal mass” “Incidental

finding on CT scan” TRICKY DESCRIPTORS THEY’LL USE: 1. Histology buzzwords:

“Follicular pattern” (maintains normal architecture!) “Cleaved cells” (centrocytes) “BCL-2

positive” (blocks apoptosis) “t(14;18) translocation” (BCL-2 rearrangement) 2. Clinical

behavior tricks: “Indolent course” (slow-growing) “Watch and wait” approach initially

“Incurable but compatible with long survival” “May transform to aggressive lymphoma”

(DLBCL) 3. Age/demographics: “Median age 60” “More common in developed countries”

“Often presents as stage III/IV” (widespread) 4. Lab/imaging clues: “Multiple enlarged lymph

node regions” “Bone marrow involvement common” “Normal or mildly elevated LDH” (vs

aggressive lymphomas) raising coffee mug Memory trick: “Follicular = Following you

Forever, but Friendly pace!” grinning The BCL-2 and indolent behavior are CLASSIC testing

points! ■■ Ready for more lymphoma mayhem?

NANCY! Impaired ornithine transport – that’s

HYPERORNITHINEMIA-HYPERAMMONEMIA-HOMOCITRULLINURIA (HHH)

SYNDROME! adjusting imaginary reading glasses with biochemical focus HHH

SYNDROME – USMLE’S ORNITHINE TRANSPORT TRAP: TARDIS making analytical

sounds CLASSIC CLINICAL SCENARIOS: “Infant with failure to thrive and developmental

delay” “Episodic vomiting and lethargy after protein meals” “Progressive spastic paraplegia”

(unique feature!) “Intellectual disability with pyramidal signs” TRICKY BIOCHEMICAL

CLUES: “Elevated ornithine in blood/urine” “Hyperammonemia” (can’t make urea properly)

“Homocitrulline in urine” (pathognomonic!) “Normal citrulline levels” (vs other urea cycle

defects) SNEAKY WAYS THEY’LL TEST: 1. Mechanism confusion: Ornithine transporter

defect (ORNT1/SLC25A15) Can’t get ornithine INTO mitochondria Urea cycle dysfunction

(ornithine needed for cycle) 2. vs Other urea cycle defects: Citrullinemia: High citrulline

Argininemia: High arginine HHH: High ornithine + homocitrulline 3. Unique feature:

Progressive spasticity (distinguishes from other urea cycle defects) “Spastic paraplegia in teen

with mild intellectual disability” raising coffee mug Memory trick: “HHH = High ornithine,

High ammonia, Homocitrulline + sPasticity!” grinning The homocitrulline is

PATHOGNOMONIC! ■■

MAPLE SYRUP DISEASE: mmediately exploding with aromatic amino acid excitement

NANCY! MAPLE SYRUP URINE DISEASE – the “sweet-smelling metabolic emergency!”

adjusting imaginary reading glasses with urgency MSUD – USMLE’S BRANCHED-CHAIN

AMINO ACID DISASTER: TARDIS making intense analytical sounds CLASSIC CLINICAL

SCENARIOS: “Newborn with sweet, maple syrup-smelling urine” “Infant with poor feeding,

vomiting, lethargy” “Seizures and coma in first week of life” “Mennonite or Ashkenazi Jewish

heritage” (founder effect) TRICKY BIOCHEMICAL CLUES: “Elevated branched-chain

amino acids” (leucine, isoleucine, valine) “Elevated branched-chain ketoacids”

(alloisoleucine!) “Sweet, burnt sugar smell to urine/cerumen” “Ketosis without

hyperglycemia” SNEAKY WAYS THEY’LL TEST: 1. Enzyme defect: Branched-chain

α-ketoacid dehydrogenase complex deficiency “Cannot metabolize leucine, isoleucine, valine”

Multiple enzyme complex (like pyruvate dehydrogenase) 2. Clinical variants: Classic: Severe

neonatal presentation Intermediate: Milder, later onset Intermittent: Episodes during

stress/illness 3. Treatment tricks: “Protein restriction” (limit branched-chain AAs) “Thiamine

supplementation” (may help some variants) “Emergency dialysis” for acute crisis 4.

Pathognomonic finding: Alloisoleucine presence (only seen in MSUD!) raising coffee mug

Memory trick: “MSUD = Maple Syrup smell, can’t break down Leucine/Isoleucine/Valine!”

Grinning

Propionyl CoA carboxylase: NANCY! PROPIONYL-CoA CARBOXYLASE DEFICIENCY –

the “ketotic, acidotic nightmare!” adjusting imaginary reading glasses with metabolic precision

PROPIONYL-CoA CARBOXYLASE DEFICIENCY – USMLE’S ORGANIC ACIDURIA:

TARDIS making urgent analytical sounds CLASSIC CLINICAL SCENARIOS: “Newborn

with severe metabolic acidosis and ketosis” “Infant with vomiting, lethargy, and hypotonia”

“Episodes triggered by illness or protein intake” “Developmental delay and seizures” TRICKY

BIOCHEMICAL CLUES: “Elevated propionyl-CoA and methylmalonic acid” “Propionic acid

in urine” (organic aciduria!) “Ketosis with metabolic acidosis” “Hyperammonemia”

(secondary effect) SNEAKY WAYS THEY’LL TEST: 1. Enzyme pathway: Propionyl-CoA →

Methylmalonyl-CoA (this step broken!) Odd-chain fatty acids, branched AAs accumulate

“Cannot process valine, isoleucine, methionine, threonine” 2. vs Methylmalonic aciduria:

Propionyl-CoA deficiency: High propionic acid Methylmalonic aciduria: High methylmalonic

acid (next step down) Both: Can cause hyperammonemia 3. Treatment clues: “Protein

restriction” “Biotin supplementation” (cofactor for carboxylase!) “Carnitine supplementation”

“Avoid fasting” 4. Associated findings: “Neutropenia and thrombocytopenia”

“Cardiomyopathy” (from toxic metabolites) raising coffee mug Memory trick: “Propionyl =

Propionic acid piles up, needs Biotin!” grinning The biotin cofactor requirement is KEY! ■■

MEDIUM CHAIN ACYL COA DEHYDROGENASE DEFICIENCY immediately exploding

with fatty acid oxidation urgency NANCY! MCAD DEFICIENCY – the “fasting-induced

hypoglycemic crisis!” adjusting imaginary reading glasses with metabolic emergency precision

MCAD DEFICIENCY – USMLE’S FATTY ACID OXIDATION TRAP: TARDIS making

urgent analytical sounds CLASSIC CLINICAL SCENARIOS: “Toddler with hypoglycemic

seizures after fasting” “Child becomes lethargic during viral illness” “Sudden infant death

syndrome (SIDS) mimic” “Triggers: fasting, illness, stress, sleep” TRICKY BIOCHEMICAL

CLUES: “Hypoketotic hypoglycemia” (CLASSIC!) “Cannot make ketones during fasting”

“Medium-chain fatty acids in urine” (C6-C12) “Dicarboxylic aciduria” (adipic, suberic acids)

SNEAKY WAYS THEY’LL TEST: 1. Pathophysiology: “Cannot break down medium-chain

fatty acids” “Depleted glycogen + can’t use fat = hypoglycemia” “No ketone production” (can’t

get to acetyl-CoA) 2. Key clinical pearl: “Hypoketotic hypoglycemia” = think fatty acid

oxidation defect! Normal kids make ketones when hypoglycemic MCAD kids CAN’T make

ketones 3. Treatment tricks: “Avoid fasting” (frequent feeding) “Dextrose during illness”

“Cornstarch at bedtime” (slow-release glucose) “Medium-chain triglyceride (MCT) oil

CONTRAINDICATED!” 4. Newborn screening: “Most common fatty acid oxidation disorder”

“Detected by elevated C8-acylcarnitine” raising coffee mug Memory trick: “MCAD =

Medium-chain Can’t Access, Dangerous fasting!” grinning The hypoketotic hypoglycemia is

PATHOGNOMONIC NANCY! HOMOCYSTINURIA – the “tall, thrombotic, lens-dislocating

disaster!” adjusting imaginary reading glasses with biochemical precision

HOMOCYSTINURIA – USMLE’S METHIONINE METABOLISM MAYHEM: TARDIS

making focused analytical sounds CLASSIC CLINICAL SCENARIOS: “Tall, thin child with

lens dislocation” “Marfanoid habitus but with intellectual disability” “Young patient with

stroke or thromboembolism” “Fair-haired, blue-eyed child with developmental delay”

TRICKY CLINICAL FEATURES: “Downward lens dislocation” (vs Marfan’s upward!)

“Thrombotic events” (stroke, PE, DVT) “Osteoporosis and scoliosis” “Intellectual disability”

(distinguishes from Marfan!) SNEAKY WAYS THEY’LL TEST: 1. Enzyme defects:

Cystathionine β-synthase deficiency (classic, 90%) “Cannot convert homocysteine →

cystathionine” Methionine accumulates, homocysteine ↑↑ 2. Lab findings: “Elevated plasma

homocysteine” “Elevated methionine” “Homocystine in urine” (disulfide dimer) “Positive

cyanide-nitroprusside test” 3. Treatment pearls: “Pyridoxine (B6) supplementation” (works in

~50%) “Methionine-restricted diet” “Cysteine supplementation” (becomes essential) “Folate

and B12″ (remethylation pathway) 4. vs Marfan syndrome: Marfan: Upward lens, normal

intellect, no thrombosis Homocystinuria: Downward lens, intellectual disability, thrombotic

raising coffee mug Memory trick: “Homocystinuria = High Homocysteine, thrombosis, Down

lens, Dumb!” grinning The downward lens dislocation is CLASSIC The HIV envelope V3

loop region is crucial for coreceptor binding and determines CCR5 vs CXCR4 tropism.

Maraviroc, a CCR5 antagonist, becomes ineffective when mutations in the V3 region cause

tropism switching from CCR5-tropic (R5) to CXCR4-tropic (X4) or dual/mixed-tropic virus.

Key V3 Loop Mutations Affecting Maraviroc Efficacy Critical amino acid positions in V3

loop: Position 11 (K11R mutation common in X4 variants) Position 25 (D25K associated with

CXCR4 use) Overall charge changes – increased positive charge favors CXCR4 binding

Tropism prediction rules: R5-tropic: negatively charged, fewer basic residues X4-tropic:

positively charged, more lysine/arginine residues 11/25 rule: K at position 11 or K at position

25 strongly predicts X4 tropism USMLE-Style Clinical Scenarios Scenario 1:

Treatment-Experienced Patient A 45-year-old man with HIV on HAART for 8 years presents

with rising viral load despite good adherence. Genotype shows wild-type virus except for V3

loop mutations K11R and D25K. Tropism assay confirms CXCR4-tropic virus. Question: Why

would maraviroc be ineffective? Answer: V3 mutations shifted tropism from CCR5 to

CXCR4; maraviroc only blocks CCR5 Scenario 2: Treatment-Naive Patient A 35-year-old

woman with acute HIV infection. Baseline tropism testing shows dual-tropic virus with

significant X4 component. CD4+ count is 350 cells/µL. Question: What explains the rapid

CD4+ decline despite recent infection? Answer: X4-tropic virus preferentially infects naive

T-cells and causes faster progression Scenario 3: Virologic Failure A patient initially responds

well to maraviroc-containing regimen but develops virologic failure after 18 months. Repeat

tropism testing shows emergence of X4-tropic variants. Question: What mechanism explains

this treatment failure? Answer: Selection pressure led to outgrowth of pre-existing minority X4

variants Scenario 4: CNS Involvement A patient with HIV-associated neurocognitive disorder

has R5-tropic virus systemically but CSF analysis shows X4-tropic variants. Question: Why

might maraviroc have limited CNS efficacy here? Answer: Compartmentalized evolution in

CNS selected for X4 variants resistant to maraviroc Clinical Testing Implications Tropism

testing required before maraviroc: Phenotypic assays (Trofile) Genotypic prediction

algorithms Deep sequencing to detect minority variants Contraindications for maraviroc: Any

X4 or dual/mixed tropism Minority X4 variants >2-5% Previous maraviroc failure The key

concept is that V3 loop mutations changing viral tropism from CCR5 to CXCR4 render CCR5

antagonists like maraviroc completely ineffective, as the virus no longer requires the CCR5

coreceptor for cellular entry. Epiglottitis Overview Epiglottitis is a life-threatening

inflammatory condition of the epiglottis and surrounding supraglottic structures that can cause

rapid airway obstruction. Etiology and Epidemiology Pre-Hib vaccine era (before 1990s):

Haemophilus influenzae type b (Hib) was leading cause Peak incidence in children 2-4 years

old Post-Hib vaccine era (current): Streptococcus pyogenes, S. pneumoniae, Staphylococcus

aureus More common in adults than children Viral causes: parainfluenza, influenza A, EBV,

varicella Clinical Presentation Classic pediatric presentation (4 D’s): Drooling (cannot swallow

secretions) Dysphagia (painful swallowing) Distressed appearance Dysphonia (“hot potato” or

muffled voice) Additional signs: High fever (often >39°C/102°F) Sore throat Tripod

positioning (sitting upright, leaning forward) Inspiratory stridor Toxic appearance Adult

presentation: Often more indolent course Severe sore throat Odynophagia Voice changes Less

likely to have drooling or tripod positioning USMLE Clinical Scenarios Scenario 1: Classic

Pediatric Case A 3-year-old unvaccinated child presents with sudden onset high fever,

drooling, and refuses to lie down. Parents report child is sitting upright, leaning forward, and

has a muffled voice. No cough present. Key teaching: Absence of cough helps distinguish from

croup Scenario 2: Adult Case A 35-year-old adult presents with rapid onset severe sore throat,

fever, and “hot potato” voice. Examination shows pooled secretions and patient appears toxic.

Key teaching: Adult epiglottitis often has more gradual onset than pediatric Scenario 3:

Differential Diagnosis A 2-year-old with barking cough, low-grade fever, and stridor that

improves with cool mist therapy. Key teaching: This describes croup

(laryngotracheobronchitis), not epiglottitis Scenario 4: Emergency Management A child with

suspected epiglottitis arrives in ED. Resident wants to examine throat with tongue depressor.

Key teaching: NEVER examine throat directly – risk of precipitating complete airway

obstruction Diagnosis Clinical diagnosis primarily: High index of suspicion based on

presentation Avoid throat examination or procedures that may agitate child Imaging (if stable):

Lateral neck X-ray: “thumbprint sign” (swollen epiglottis) CT neck if diagnosis uncertain

Direct visualization: Only in controlled setting (OR) with airway management ready Fiberoptic

laryngoscopy shows cherry-red, swollen epiglottis Management Immediate priorities: Airway

assessment and management Avoid agitating the patient Keep child calm (parent present)

Have emergency airway equipment ready Airway management: If stable: close monitoring If

respiratory distress: immediate intubation in OR Have surgical airway

(cricothyrotomy/tracheostomy) ready Anesthesiologist and ENT surgeon should be present

Antibiotic therapy: Empiric: ceftriaxone or cefotaxime Add vancomycin if MRSA suspected

Duration: 7-10 days Switch to oral when able to swallow Supportive care: Humidified oxygen

Corticosteroids (controversial, may help reduce inflammation) IV fluids Pain management

Key USMLE Concepts High-yield differentials: Croup: barking cough, gradual onset,

responds to steroids/cool mist Bacterial tracheitis: toxic appearance but with productive cough

Foreign body aspiration: sudden onset, unilateral findings Retropharyngeal abscess: neck

stiffness, limited neck extension Critical management points: Never examine throat directly in

suspected epiglottitis Maintain child in position of comfort Emergency airway management

must be available Antibiotics should cover Hib even in vaccinated patients Complications:

Complete airway obstruction Pneumonia Sepsis Cardiac arrest from hypoxia The key USMLE

concept is recognizing epiglottitis as a medical emergency requiring immediate airway

assessment while avoiding any interventions that might precipitate complete obstruction. Retry

N please calify what you mean by antibiotics should never cover hib even in vaccinated

patients please. Edit I made an error in my statement – let me clarify that important point. I

wrote “Antibiotics should cover Hib even in vaccinated patients” but that’s misleading and

needs correction. Corrected Antibiotic Approach: In vaccinated patients (current era): Hib is

NOT a common cause due to effective vaccination Empiric antibiotics should target current

common pathogens: Streptococcus pyogenes Streptococcus pneumoniae Staphylococcus

aureus (including MRSA consideration) Empiric antibiotic choices: First-line: Ceftriaxone or

cefotaxime If MRSA concern: Add vancomycin or clindamycin Penicillin allergy:

Clindamycin or vancomycin The Hib consideration: In unvaccinated patients or

immunocompromised patients, Hib should still be considered In fully vaccinated,

immunocompetent patients, Hib is very unlikely Standard beta-lactams (ceftriaxone) do cover

Hib if present, but it’s not the primary target in vaccinated patients USMLE Teaching Point:

The antibiotic choice should be based on the patient’s vaccination status and most likely

pathogens for their demographic. In the post-Hib vaccine era, we’re primarily targeting

streptococcal and staphylococcal species in vaccinated children, not specifically targeting Hib.

Thank you for catching that error – it’s an important distinction for proper antibiotic

stewardship and understanding the changing epidemiology of epiglottitis. Haemophilus

influenzae type b (Hib) – USMLE Key Points Basic Microbiology Classification:

Gram-negative coccobacillus Facultative anaerobe Fastidious organism (requires special

growth factors) Family: Pasteurellaceae Morphology: Small, pleomorphic gram-negative rods

Often appears as short chains or clusters Non-motile Non-spore forming Growth Requirements

and Culture Growth factors (X and V factors): X factor: Hemin (found in blood) V factor:

NAD (nicotinamide adenine dinucleotide) Both factors required for growth Culture media:

Chocolate agar: Heat-lysed blood releases both X and V factors Blood agar alone: Will NOT

grow (V factor trapped inside intact RBCs) Satellite phenomenon: Grows around

Staphylococcus aureus on blood agar (S. aureus releases V factor) USMLE pearl: If organism

grows on chocolate agar but NOT on blood agar, think Haemophilus species Capsule and

Serotyping Capsular types: Types a through f (based on capsular polysaccharide) Type b

(Hib): Most virulent, causes invasive disease Non-typeable strains: Lack capsule, cause

mucosal infections Capsule composition: Type b capsule: Polyribosyl ribitol phosphate (PRP)

Capsule is major virulence factor Anti-capsular antibodies are protective Pathogenesis and

Virulence Virulence factors: Capsule: Antiphagocytic, most important virulence factor IgA

protease: Cleaves secretory IgA Outer membrane proteins: Adhesion and invasion

Lipooligosaccharide: Endotoxin activity Pathogenesis: Nasopharyngeal colonization Local

invasion or bloodstream invasion Crosses blood-brain barrier (neurotropic) Age-related

susceptibility due to maternal antibody waning Clinical Syndromes (Pre-vaccine Era) Invasive

diseases (encapsulated strains, especially type b): Meningitis: Most common cause in children

6 months-4 years Epiglottitis: Classic “cherry-red” swollen epiglottis Cellulitis: Characteristic

blue-purple facial cellulitis Pneumonia: Often with pleural effusion Septic arthritis Bacteremia

Non-invasive diseases (non-typeable strains): Otitis media: Second most common cause after

S. pneumoniae Sinusitis Bronchitis/COPD exacerbations USMLE Clinical Scenarios Scenario

1: Culture Identification Laboratory reports gram-negative coccobacilli that grow on chocolate

agar but not blood agar. Satellite phenomenon observed around S. aureus colonies. Answer:

Haemophilus influenzae (requires X and V factors) Scenario 2: Pre-vaccine Era Child

3-year-old with sudden onset high fever, neck stiffness, and altered mental status. CSF shows

gram-negative pleomorphic rods. Answer: H. influenzae type b meningitis Scenario 3: Adult

COPD Patient 65-year-old smoker with COPD exacerbation. Sputum shows gram-negative

coccobacilli. Answer: Non-typeable H. influenzae (common in adult respiratory infections)

Diagnostic Tests Direct detection: Gram stain: Small gram-negative coccobacilli CSF antigen

detection (capsular antigen) PCR (rapid, sensitive) Culture characteristics: Chocolate agar:

Small, smooth colonies Oxidase positive Catalase positive Requires X and V factors

Susceptibility: Ampicillin resistance common (β-lactamase production)

Ceftriaxone/cefotaxime: First-line for invasive disease Azithromycin: Alternative Prevention

Hib vaccine: PRP-conjugate vaccines: Conjugated to protein carriers Schedule: 2, 4, 6, 12-15

months Efficacy: >95% reduction in invasive Hib disease Herd immunity: Reduces

nasopharyngeal carriage Prophylaxis: Household contacts: Rifampin for unvaccinated children

<4 years Healthcare workers: Usually not needed unless intensive exposure Post-Vaccine Era

Changes Epidemiologic shift: Invasive Hib disease now rare in vaccinated populations

Non-typeable H. influenzae still causes mucosal infections Other encapsulated bacteria (S.

pneumoniae, group B strep) now more prominent Current relevance: Still important in

unvaccinated populations Immunocompromised patients remain susceptible Global health

concern in areas with poor vaccine coverage Key USMLE Mnemonics Growth requirements:

“Haemophilus Xpects Vitamins” (X and V factors) Satellite test: S. aureus acts as “helper” on

blood agar Age group: “Hib hits toddlers” (6 months to 4 years peak incidence) The most

testable concept is the growth factor requirements and the dramatic impact of vaccination on

disease epidemiology.

Haemophilus influenzae type b (Hib) – USMLE Key Points Basic Microbiology Classification:

Gram-negative coccobacillus Facultative anaerobe Fastidious organism (requires special

growth factors) Family: Pasteurellaceae Morphology: Small, pleomorphic gram-negative rods

Often appears as short chains or clusters Non-motile Non-spore forming Growth Requirements

and Culture Growth factors (X and V factors): X factor: Hemin (found in blood) V factor:

NAD (nicotinamide adenine dinucleotide) Both factors required for growth Culture media:

Chocolate agar: Heat-lysed blood releases both X and V factors Blood agar alone: Will NOT

grow (V factor trapped inside intact RBCs) Satellite phenomenon: Grows around

Staphylococcus aureus on blood agar (S. aureus releases V factor) USMLE pearl: If organism

grows on chocolate agar but NOT on blood agar, think Haemophilus species Capsule and

Serotyping Capsular types: Types a through f (based on capsular polysaccharide) Type b

(Hib): Most virulent, causes invasive disease Non-typeable strains: Lack capsule, cause

mucosal infections Capsule composition: Type b capsule: Polyribosyl ribitol phosphate (PRP)

Capsule is major virulence factor Anti-capsular antibodies are protective Pathogenesis and

Virulence Virulence factors: Capsule: Antiphagocytic, most important virulence factor IgA

protease: Cleaves secretory IgA Outer membrane proteins: Adhesion and invasion

Lipooligosaccharide: Endotoxin activity Pathogenesis: Nasopharyngeal colonization Local

invasion or bloodstream invasion Crosses blood-brain barrier (neurotropic) Age-related

susceptibility due to maternal antibody waning Clinical Syndromes (Pre-vaccine Era) Invasive

diseases (encapsulated strains, especially type b): Meningitis: Most common cause in children

6 months-4 years Epiglottitis: Classic “cherry-red” swollen epiglottis Cellulitis: Characteristic

blue-purple facial cellulitis Pneumonia: Often with pleural effusion Septic arthritis Bacteremia

Non-invasive diseases (non-typeable strains): Otitis media: Second most common cause after

S. pneumoniae Sinusitis Bronchitis/COPD exacerbations USMLE Clinical Scenarios Scenario

1: Culture Identification Laboratory reports gram-negative coccobacilli that grow on chocolate

agar but not blood agar. Satellite phenomenon observed around S. aureus colonies. Answer:

Haemophilus influenzae (requires X and V factors) Scenario 2: Pre-vaccine Era Child

3-year-old with sudden onset high fever, neck stiffness, and altered mental status. CSF shows

gram-negative pleomorphic rods. Answer: H. influenzae type b meningitis Scenario 3: Adult

COPD Patient 65-year-old smoker with COPD exacerbation. Sputum shows gram-negative

coccobacilli. Answer: Non-typeable H. influenzae (common in adult respiratory infections)

Diagnostic Tests Direct detection: Gram stain: Small gram-negative coccobacilli CSF antigen

detection (capsular antigen) PCR (rapid, sensitive) Culture characteristics: Chocolate agar:

Small, smooth colonies Oxidase positive Catalase positive Requires X and V factors

Susceptibility: Ampicillin resistance common (β-lactamase production)

Ceftriaxone/cefotaxime: First-line for invasive disease Azithromycin: Alternative Prevention

Hib vaccine: PRP-conjugate vaccines: Conjugated to protein carriers Schedule: 2, 4, 6, 12-15

months Efficacy: >95% reduction in invasive Hib disease Herd immunity: Reduces

nasopharyngeal carriage Prophylaxis: Household contacts: Rifampin for unvaccinated children

<4 years Healthcare workers: Usually not needed unless intensive exposure Post-Vaccine Era

Changes Epidemiologic shift: Invasive Hib disease now rare in vaccinated populations

Non-typeable H. influenzae still causes mucosal infections Other encapsulated bacteria (S.

pneumoniae, group B strep) now more prominent Current relevance: Still important in

unvaccinated populations Immunocompromised patients remain susceptible Global health

concern in areas with poor vaccine coverage Key USMLE Mnemonics Growth requirements:

“Haemophilus Xpects Vitamins” (X and V factors) Satellite test: S. aureus acts as “helper” on

blood agar Age group: “Hib hits toddlers” (6 months to 4 years peak incidence) The most

testable concept is the growth factor requirements and the dramatic impact of vaccination on

disease epidemiology.

Pancoast Tumor vs Superior Vena Cava (SVC) Syndrome – USMLE Differentiation These are

two distinct but potentially related conditions that can occur with lung cancer. Let me break

down the key differences and provide USMLE-style scenarios. Pancoast Tumor (Apical Lung

Tumor) Definition: Tumor at lung apex (superior sulcus) Invades local structures: brachial

plexus, sympathetic chain, ribs, vertebrae Classic presentation – Pancoast Syndrome: Horner’s

syndrome: Ptosis, miosis, anhidrosis (sympathetic chain invasion) Shoulder/arm pain:

Radiating down ulnar distribution (C8-T1 nerve roots) Hand weakness: Intrinsic hand muscles

(ulnar/median nerve involvement) Superior Vena Cava (SVC) Syndrome Definition:

Obstruction of SVC by tumor, clot, or external compression Impaired venous return from head,

neck, upper extremities Classic presentation: Facial/neck swelling: Especially morning, worse

when lying flat Upper extremity edema: Bilateral arm swelling Dilated chest wall veins:

Collateral circulation Stridor/dyspnea: If tracheal compression present Headache: Increased

intracranial pressure Key USMLE Differentiating Features USMLE Clinical Scenarios

Scenario 1: Classic Pancoast A 65-year-old smoker presents with 3 months of severe right

shoulder pain radiating down the medial arm. Physical exam shows right-sided ptosis, miosis,

and weakness of intrinsic hand muscles. Chest X-ray shows right apical mass. Question: What

nerve structure is most likely involved? Answer: Right sympathetic chain (causing Horner’s

syndrome) and lower trunk of brachial plexus (C8-T1) Scenario 2: Classic SVC Syndrome A

55-year-old man presents with 2 weeks of progressive facial swelling, worse in the morning.

He has bilateral arm edema and prominent dilated veins across his chest. He reports difficulty

breathing when lying flat. Question: What imaging finding would you expect? Answer:

Mediastinal mass compressing the superior vena cava Scenario 3: Combined Presentation A

60-year-old woman has both right shoulder pain with Horner’s syndrome AND facial swelling

with dilated chest veins. Question: What explains this combination? Answer: Large right upper

lobe tumor causing both Pancoast syndrome and SVC compression Scenario 4: Differential

Diagnosis A patient presents with unilateral arm swelling and chest pain but no facial

involvement or dilated chest veins. Question: What’s the most likely diagnosis? Answer: Deep

vein thrombosis or subclavian vein thrombosis (not SVC syndrome) Scenario 5: Emergency

Recognition A patient with known lung cancer develops acute onset facial swelling, stridor,

and altered mental status. Question: What’s the immediate concern? Answer: SVC syndrome

with laryngeal edema and cerebral edema – potential airway emergency Anatomical

Correlations for USMLE Pancoast tumor anatomy: T1 nerve root: Intrinsic hand muscles

weakness Sympathetic chain: Horner’s syndrome Subclavian artery: Possible arm claudication

First rib: Bone pain, possible fracture SVC syndrome anatomy: SVC drainage: Head, neck,

upper extremities, upper chest Collateral pathways: Azygos system, internal mammary veins

Obstruction level: Determines which collaterals develop Diagnostic Approach Pancoast tumor:

CT/MRI chest: Evaluate local invasion Brachial plexus MRI: Assess nerve involvement Bone

scan: Check for rib/vertebral involvement SVC syndrome: CT chest with contrast: SVC

obstruction, collaterals Venography: If CT inconclusive Echocardiogram: Rule out cardiac

causes Treatment Implications Pancoast tumor: Often requires multimodal therapy Surgery

challenging due to local invasion Radiation therapy important for local control SVC syndrome:

Urgent: High-dose steroids, radiation therapy Stenting: For immediate relief Chemotherapy: If

chemosensitive tumor Key USMLE Teaching Points Pancoast = Pain + Neurologic signs

(Horner’s + hand weakness) SVC = Swelling + Venous distention (face/arms + chest veins)

Both can occur together with large tumors SVC syndrome can be oncologic emergency if

airway compromise Pancoast often missed initially – think of lung cancer in chronic shoulder

pain The most testable concept is recognizing that these represent different patterns of local

invasion and compression by lung tumors, with distinct anatomical and clinical presentations.

Carcinoid Tumors and Lung Cancer – Important Distinctions Great question! There are some

important connections and distinctions to clarify for USMLE purposes. Carcinoid Tumors in

the Lung Classification: Typical carcinoid: Low-grade neuroendocrine tumor Atypical

carcinoid: Intermediate-grade neuroendocrine tumor Both are neuroendocrine tumors (NETs)

but distinct from classic lung cancers Location patterns: Central/endobronchial: More common

(especially typical carcinoids) Peripheral: Less common Can occur at lung apex but this is

NOT the same as Pancoast syndrome Key USMLE Distinctions Carcinoid vs Classic Lung

Cancers Important Clarifications Pancoast tumors are typically: Adenocarcinoma or squamous

cell carcinoma NOT carcinoid tumors Classical Pancoast syndrome is caused by non-small cell

lung cancer However, carcinoids CAN: Rarely occur at lung apex Cause local invasion (but

less aggressive) Usually do NOT cause classic Pancoast syndrome USMLE Clinical Scenarios

Scenario 1: Central Carcinoid A 35-year-old non-smoker presents with recurrent pneumonia

and hemoptysis. Bronchoscopy shows an endobronchial mass. Biopsy reveals uniform cells

with “salt-and-pepper” chromatin pattern. Question: What’s the most likely diagnosis? Answer:

Typical pulmonary carcinoid (central location, young non-smoker, characteristic histology)

Scenario 2: Carcinoid Syndrome A 45-year-old woman with known pulmonary carcinoid

develops episodic flushing, diarrhea, and tricuspid regurgitation. 24-hour urine shows elevated

5-HIAA. Question: What explains this presentation? Answer: Carcinoid syndrome from

serotonin production (requires liver metastases to bypass hepatic metabolism) Scenario 3:

Contrast with Pancoast A 65-year-old smoker has right apical lung mass with shoulder pain

and Horner’s syndrome. Biopsy shows poorly differentiated adenocarcinoma. Question: Is this

likely a carcinoid tumor? Answer: No – classic Pancoast presentation with adenocarcinoma in

smoker Scenario 4: Atypical Carcinoid A 50-year-old presents with peripheral lung nodule.

Biopsy shows neuroendocrine tumor with >2 mitoses per 10 HPF and focal necrosis. Question:

How does this differ from typical carcinoid? Answer: Atypical carcinoid (intermediate grade) –

higher mitotic rate and necrosis Neuroendocrine Tumor Spectrum in Lung Low grade → High

grade: Typical carcinoid (Grade 1 NET) <2 mitoses/10 HPF, no necrosis Excellent prognosis

Atypical carcinoid (Grade 2 NET) 2-10 mitoses/10 HPF or focal necrosis Intermediate

prognosis Large cell neuroendocrine carcinoma (Grade 3 NET) 10 mitoses/10 HPF, extensive

necrosis Poor prognosis, aggressive Small cell lung cancer (Grade 3 NET) Highest grade

neuroendocrine tumor Very aggressive, strong smoking association Key USMLE Points

Carcinoid syndrome requirements: Usually requires liver metastases Primary lung carcinoids

rarely cause syndrome Serotonin bypasses hepatic first-pass metabolism Diagnostic markers:

Chromogranin A: Neuroendocrine marker Synaptophysin: Neuroendocrine marker 5-HIAA:

Urine metabolite of serotonin Octreotide scan: Somatostatin receptor imaging Treatment

differences: Carcinoids: Often surgical resection if localized Classic Pancoast: Usually

requires multimodal therapy Carcinoid syndrome: Octreotide for symptom control Bottom

Line for USMLE Carcinoid tumors: Are NOT the typical cause of Pancoast syndrome Can

rarely occur at lung apex but behave differently Are neuroendocrine tumors with distinct

biology Usually occur in younger, non-smoking patients Have better prognosis than classic

lung cancers Classic Pancoast tumors: Are typically adenocarcinoma or squamous cell

carcinoma Occur in older smokers Cause characteristic neurologic syndrome Have aggressive

local invasion patterns The key distinction is that while both can occur at the lung apex, they

represent completely different tumor types with different presentations, prognoses, and

treatments. IgA Vasculitis (Henoch-Schönlein Purpura) – Complete USMLE Review Overview

and Classification Definition: Small-vessel vasculitis with IgA immune complex deposition

Most common systemic vasculitis in children Formerly called Henoch-Schönlein purpura

(HSP) Classification: ANCA-negative vasculitis Affects small vessels (capillaries, venules,

arterioles) Immune complex-mediated (Type III hypersensitivity) Pathophysiology

Mechanism: IgA immune complexes deposit in vessel walls Complement activation and

neutrophil infiltration Leukocytoclastic vasculitis pattern Unknown trigger (possibly infectious

or environmental) Immunology: Elevated serum IgA levels (50-75% of patients) IgA deposits

in skin, kidney, GI tract Often follows upper respiratory infection Clinical Presentation –

Classic Tetrad 1. Purpuric Rash (100% of patients) Non-thrombocytopenic purpura

Distribution: Lower extremities and buttocks (gravity-dependent) Characteristics: Palpable

purpura, petechiae, ecchymoses Evolution: Red → purple → brown, may become bullous 2.

Arthritis/Arthralgia (75% of patients) Pattern: Knees, ankles most common Characteristics:

Painful, swollen, non-deforming Duration: Usually transient (days to weeks) Age pattern:

More common in older children 3. Gastrointestinal Involvement (65% of patients) Symptoms:

Crampy abdominal pain, nausea, vomiting GI bleeding: Melena, hematochezia Complications:

Intussusception (ileocolic most common) Severity: Can mimic acute abdomen 4. Renal

Involvement (40% of patients) Onset: Usually within 6 months of rash Manifestations:

Hematuria, proteinuria, hypertension Severity: Ranges from microscopic hematuria to

nephritic syndrome Long-term: Most important prognostic factor USMLE Clinical Scenarios

Scenario 1: Classic Pediatric Presentation A 6-year-old boy develops purpuric rash on legs and

buttocks 2 weeks after upper respiratory infection. He complains of knee pain and crampy

abdominal pain. Platelet count is normal. Question: What’s the most likely diagnosis? Answer:

IgA vasculitis (Henoch-Schönlein purpura) Scenario 2: Renal Complications A 8-year-old girl

with recent IgA vasculitis presents with gross hematuria, proteinuria, and hypertension 3

months after initial rash resolved. Question: What’s the most concerning long-term

complication? Answer: Chronic kidney disease/ESRD (renal involvement determines

prognosis) Scenario 3: GI Emergency A 5-year-old with known IgA vasculitis develops severe

abdominal pain, vomiting, and a sausage-shaped abdominal mass. Question: What

complication should you suspect? Answer: Intussusception (ileocolic most common in IgA

vasculitis) Scenario 4: Differential Diagnosis A 4-year-old with petechial rash on legs, but

platelet count is 15,000/µL and no other systemic symptoms. Question: How does this differ

from IgA vasculitis? Answer: This suggests thrombocytopenic purpura (ITP) – IgA vasculitis

has normal platelet count Scenario 5: Adult Presentation A 25-year-old adult develops similar

presentation but with more severe renal involvement and persistent symptoms. Question: How

does adult IgA vasculitis differ from pediatric? Answer: Adults have worse prognosis, more

severe renal disease, more chronic course Diagnostic Criteria and Workup Clinical diagnosis

primarily: Palpable purpura (mandatory criterion) Plus 1+ of: abdominal pain, arthritis, renal

involvement, skin biopsy showing IgA Laboratory tests: CBC: Normal platelet count (key

differentiator) Urinalysis: Hematuria, proteinuria, RBC casts Serum IgA: Elevated in 50-75%

Complement: Usually normal (unlike SLE) ANCA: Negative Skin biopsy (if diagnosis

unclear): Leukocytoclastic vasculitis IgA deposits on immunofluorescence Fibrinoid necrosis

of vessel walls Renal biopsy (if severe renal involvement): Mesangial IgA deposits Similar to

IgA nephropathy Helps determine prognosis Age-Related Patterns Peak incidence: 4-6 years

old Seasonal: Fall/winter (post-infectious pattern) Age differences: Younger children: More GI

involvement, intussusception risk Older children/adults: More severe renal disease Adults:

Worse overall prognosis Differential Diagnosis Thrombocytopenic purpura: ITP, TTP, HUS

Key difference: Low platelet count Other vasculitides: Polyarteritis nodosa: Medium vessels,

ANCA-negative Microscopic polyangiitis: ANCA-positive, more renal involvement

Hypersensitivity vasculitis: Drug-induced, limited to skin Systemic diseases: SLE: ANA

positive, low complement Infective endocarditis: Blood cultures positive Inflammatory bowel

disease: GI symptoms but different pattern Management Supportive care (mainstay): Rest

during acute phase Adequate hydration Pain management with acetaminophen Avoid NSAIDs

(renal toxicity risk) Corticosteroids: Indications: Severe abdominal pain, severe joint pain

Renal disease: Controversial benefit Typical dose: Prednisone 1-2 mg/kg/day Duration: Short

course (1-2 weeks) Severe renal disease: ACE inhibitors for proteinuria/hypertension

Immunosuppressives (cyclophosphamide, mycophenolate) Consider in crescentic

glomerulonephritis Complications management: Intussusception: Surgical or pneumatic

reduction Severe GI bleeding: Supportive care, rarely surgery Hypertension: ACE inhibitors,

calcium channel blockers Prognosis and Follow-up Overall prognosis: Excellent in children

Most recover completely within weeks to months Recurrence rate: 30-40% within first year

Renal prognosis factors: Good: Microscopic hematuria only Poor: Nephrotic syndrome,

crescents on biopsy, persistent proteinuria Long-term monitoring: Urinalysis: Monthly for 6

months, then periodic Blood pressure: Regular monitoring Renal function: If abnormal initially

Adult outcomes: Higher risk of chronic kidney disease More likely to require

immunosuppression Overall worse prognosis than children Key USMLE Pearls Classic triad to

remember: Palpable purpura (legs/buttocks) Normal platelet count Post-infectious timing Most

tested concepts: Intussusception as GI complication Normal platelets vs thrombocytopenic

purpura Renal involvement determines long-term prognosis IgA deposits on

immunofluorescence Treatment pearls: Supportive care is mainstay Steroids for severe

symptoms, not routine Avoid NSAIDs due to renal risk Monitor kidneys long-term The most

important USMLE concept is recognizing IgA vasculitis as non-thrombocytopenic purpura in a

child following infection, with the understanding that renal involvement determines long-term

outcomes.

TTP (Thrombotic Thrombocytopenic Purpura)/HUS/ITP TTP, ITP, and HUS – Complete

USMLE Breakdown These three conditions form a classic triad of thrombocytopenic disorders

with overlapping but distinct presentations. Let me break them down systematically. Idiopathic

Thrombocytopenic Purpura (ITP) Pathophysiology Autoimmune destruction of platelets

Antiplatelet antibodies (usually IgG against GPIIb/IIIa) Splenic sequestration and destruction

Normal bone marrow with increased megakaryocytes Clinical Presentation Bleeding

manifestations: Petechiae and purpura (especially legs) Mucosal bleeding (epistaxis, gingival

bleeding) Menorrhagia in women NO hepatosplenomegaly (key point) Two forms: Acute ITP:

Children, post-viral, self-limited Chronic ITP: Adults (especially women 20-40), persistent

Laboratory Findings Isolated thrombocytopenia (<100,000, often <30,000) Normal RBC and

WBC counts Large platelets on smear (young platelets) Negative antiplatelet antibody tests

(not routinely done) Thrombotic Thrombocytopenic Purpura (TTP) Pathophysiology

ADAMTS13 deficiency (metalloprotease) Inability to cleave von Willebrand factor Large

vWF multimers cause platelet aggregation Microthrombi formation in small vessels Classic

Pentad (rarely complete) Thrombocytopenia Microangiopathic hemolytic anemia (MAHA)

Neurologic symptoms Fever Renal dysfunction Clinical Presentation Neurologic (most

common): Altered mental status, confusion Headache, seizures, focal deficits Fluctuating

symptoms (key feature) Hematologic: Bleeding from thrombocytopenia Pallor from anemia

Laboratory Findings Severe thrombocytopenia (<30,000) Hemolytic anemia with schistocytes

Elevated LDH (hemolysis marker) Low haptoglobin ADAMTS13 activity <10% Normal

coagulation studies (PT/PTT) Hemolytic Uremic Syndrome (HUS) Pathophysiology Two

main types: Typical (D+ HUS): Post-infectious, usually E. coli O157:H7 Atypical (D- HUS):

Complement dysregulation Mechanism: Shiga toxin damages glomerular endothelium

Complement activation and microthrombi Primarily affects kidneys Clinical Presentation

Classic triad: Thrombocytopenia Microangiopathic hemolytic anemia Acute kidney injury

Typical HUS: Bloody diarrhea 5-10 days before Children most commonly affected E. coli

O157:H7 exposure (undercooked beef) Atypical HUS: No diarrheal prodrome Any age

(including adults) Worse prognosis Laboratory Findings Thrombocytopenia (usually >30,000)

Hemolytic anemia with schistocytes Elevated creatinine/BUN Proteinuria, hematuria Stool

culture: E. coli O157:H7 (if typical) USMLE Clinical Scenarios Scenario 1: Classic ITP A

35-year-old woman presents with 2 weeks of easy bruising and heavy menstrual bleeding.

Physical exam shows petechiae but no splenomegaly. CBC shows platelets 15,000, normal

Hgb and WBC. Question: What’s the most likely diagnosis? Answer: Chronic ITP (isolated

thrombocytopenia in adult woman, no organomegaly) Scenario 2: TTP Emergency A

28-year-old woman presents with confusion, fever, and purpura. Labs show platelets 20,000,

Hgb 7 g/dL with schistocytes, LDH 800. PT/PTT normal. Question: What’s the most urgent

treatment? Answer: Plasmapheresis (TTP is medical emergency requiring immediate plasma

exchange) Scenario 3: Typical HUS A 4-year-old develops bloody diarrhea after eating at a

barbecue. One week later, develops oliguria, pallor, and petechiae. Creatinine elevated with

schistocytes on smear. Question: What’s the likely pathogen? Answer: E. coli O157:H7

(classic post-infectious HUS) Scenario 4: Differential Challenge A patient has

thrombocytopenia, hemolytic anemia with schistocytes, but normal neurologic exam and

normal kidney function. Question: How do you differentiate TTP vs HUS? Answer: Could be

early TTP (neurologic symptoms may develop) or need ADAMTS13 level Scenario 5:

Atypical HUS A 30-year-old with no diarrheal illness develops acute kidney injury,

thrombocytopenia, and hemolytic anemia. Family history of kidney disease. Question: What

suggests atypical HUS? Answer: No diarrheal prodrome, adult onset, family history

(complement gene mutations) Key Differentiating Features Laboratory Comparison Treatment

Approaches ITP Treatment First-line: Corticosteroids: Prednisone 1 mg/kg/day IVIG: For

severe bleeding or pre-procedure Anti-D (WinRho): In Rh+ patients Second-line:

Splenectomy: Refractory cases Rituximab: Anti-CD20 monoclonal TPO agonists:

Romiplostim, eltrombopag TTP Treatment Emergency management: Plasmapheresis: Remove

antibodies, replace ADAMTS13 Corticosteroids: High-dose methylprednisolone Rituximab:

For refractory cases Caplacizumab: Anti-vWF antibody (newer agent) HUS Treatment Typical

HUS: Supportive care: Fluid management, dialysis if needed NO antibiotics: May worsen

toxin release NO platelets: Risk of thrombosis Atypical HUS: Complement inhibition:

Eculizumab (anti-C5) Plasmapheresis: May be helpful Long-term monitoring: High recurrence

risk Prognosis ITP: Acute (children): 80% spontaneous remission Chronic (adults): May need

long-term treatment TTP: Untreated: >90% mortality Treated: 80-90% survival with

plasmapheresis Relapse: 30-40% risk HUS: Typical: Good recovery in children (>95%)

Atypical: Poor prognosis, high recurrence Key USMLE Pearls ITP: Isolated thrombocytopenia

+ no splenomegaly Large platelets on smear Bone marrow biopsy rarely needed TTP:

ADAMTS13 <10% is diagnostic Neurologic symptoms distinguish from HUS Plasmapheresis

is life-saving HUS: Post-diarrheal (typical) vs no diarrhea (atypical) Kidney involvement

predominates Don’t give antibiotics in typical HUS All three: Normal PT/PTT (distinguishes

from DIC) Avoid platelet transfusions in TTP/HUS Schistocytes only in TTP/HUS, not ITP

The most testable concept is using the clinical context (age, associated symptoms, lab pattern)

to differentiate these three thrombocytopenic conditions and knowing the appropriate urgent

treatments. Retry N can you help me to understand why and where the shistocytes are coming

from please? Edit Schistocytes – Formation and Significance Excellent question!

Understanding schistocyte formation is crucial for USMLE and helps explain why they appear

in some conditions but not others. What Are Schistocytes? Definition: Fragmented red blood

cells (RBC fragments) Helmet cells, triangle shapes, bite cells Result from mechanical

shearing of RBCs Indicate microangiopathic hemolytic anemia (MAHA) Mechanism of

Schistocyte Formation The Basic Process Normal RBCs are flexible and deformable Abnormal

microvasculature creates physical obstacles RBCs get sheared as they try to squeeze through

Fragments circulate as schistocytes Hemolysis occurs (intravascular) What Creates the

“Shearing Forces”? Fibrin strands in microvasculature: Abnormal clot formation in small

vessels RBCs hit fibrin meshwork and fragment Like “cheese wire” cutting through RBCs

Abnormal vessel walls: Damaged endothelium Irregular vessel surfaces Turbulent blood flow

Why Schistocytes Form in TTP and HUS TTP (Thrombotic Thrombocytopenic Purpura)

Mechanism: ADAMTS13 deficiency → can’t cleave von Willebrand factor Ultra-large vWF

multimers accumulate Excessive platelet aggregation in microvasculature Microthrombi

formation throughout small vessels RBCs shear against fibrin strands in these microthrombi

Location: Systemic microvasculature (brain, kidneys, etc.) HUS (Hemolytic Uremic

Syndrome) Mechanism: Shiga toxin (from E. coli) damages glomerular endothelium

Complement activation and endothelial injury Microthrombi formation primarily in renal

microvasculature RBCs fragment as they pass through damaged glomerular capillaries

Location: Primarily renal microvasculature Why NO Schistocytes in ITP ITP Mechanism

Antiplatelet antibodies destroy platelets in spleen No microthrombi formation No fibrin

deposition in vessels Normal microvasculature RBCs pass through normally → no

fragmentation Key point: ITP affects platelet number, not vessel architecture USMLE Clinical

Correlations Scenario 1: Understanding the Pattern A patient has thrombocytopenia and

anemia. Blood smear shows schistocytes. Question: What does this suggest about the

pathophysiology? Answer: Microangiopathic process with microthrombi formation

(TTP/HUS, not ITP) Scenario 2: Laboratory Interpretation Two patients with

thrombocytopenia: Patient A: Normal RBC morphology, no schistocytes Patient B:

Schistocytes present, elevated LDH Question: Which patient likely has TTP? Answer: Patient

B – schistocytes indicate microangiopathic hemolysis Scenario 3: Mechanism Understanding A

patient with TTP has ADAMTS13 deficiency. Question: How does this lead to schistocyte

formation? Answer: Large vWF multimers → platelet aggregation → microthrombi → RBC

shearing Other Conditions Causing Schistocytes DIC (Disseminated Intravascular

Coagulation) Mechanism: Widespread activation of coagulation cascade Fibrin deposition

throughout microvasculature RBC fragmentation against fibrin meshwork Key difference:

Abnormal PT/PTT (unlike TTP/HUS) Mechanical Heart Valves Mechanism: High shear

forces across prosthetic valves Direct mechanical trauma to RBCs Chronic low-level

hemolysis Location: High-flow areas around valve Malignant Hypertension Mechanism:

Severe hypertension damages vessel walls Fibrinoid necrosis of arterioles Microthrombi

formation Clinical: Very high BP (>180/120) with end-organ damage HELLP Syndrome

Mechanism: Pregnancy-related microangiopathy Endothelial dysfunction Microthrombi in

hepatic sinusoids Clinical: Hemolysis, Elevated Liver enzymes, Low Platelets Laboratory

Markers of Hemolysis When schistocytes are present, expect: Direct evidence: Elevated LDH

(released from lysed RBCs) Low haptoglobin (binds free hemoglobin) Elevated indirect

bilirubin (from RBC breakdown) Blood smear findings: Schistocytes (helmet cells, fragments)

Polychromasia (young RBCs/reticulocytes) Decreased RBC count Key USMLE Concepts

Pattern Recognition Schistocytes present = Microangiopathic process Think: TTP, HUS, DIC,

mechanical causes NOT: ITP, autoimmune hemolysis, nutritional anemia Diagnostic

Approach See schistocytes → microangiopathic hemolysis Check PT/PTT → if normal, think

TTP/HUS Clinical context → neurologic (TTP) vs renal (HUS) ADAMTS13 level → confirms

TTP Treatment Implications Schistocytes = Urgent evaluation needed TTP requires immediate

plasmapheresis HUS requires supportive care Don’t give platelets in microangiopathic

conditions Memory Aid for USMLE “Schistocytes = Shearing” Shearing forces in

microvasculature Caused by fibrin strands or vessel damage Hemolysis (intravascular)

Indicates microangiopathic process Seen in TTP/HUS/DIC, NOT ITP Treatment depends on

underlying cause Key Rule: If you see schistocytes + thrombocytopenia + normal coagulation

studies → think TTP/HUS immediately The most important concept is that schistocytes

indicate mechanical RBC damage from abnormal microvasculature, which immediately

narrows your differential and has urgent treatment implications.

Corynebacterium diphtheriae – Complete USMLE Review Basic Microbiology Classification:

Gram-positive rod (bacillus) Non-spore forming Non-motile Facultative anaerobe

Pleomorphic appearance Morphology: “Chinese letter” arrangement on Gram stain

Club-shaped rods (wider at one end) Metachromatic granules (volutin granules) with

methylene blue stain Palisading pattern (parallel arrangement) Culture Characteristics Growth

requirements: Tellurite agar (selective medium) Loeffler’s serum medium (enhances

metachromatic granules) Blood agar (also grows, but less specific) Colony appearance:

Gray-black colonies on tellurite agar Small, dry colonies Catalase positive Non-hemolytic on

blood agar Pathophysiology and Virulence Diphtheria Toxin (Primary Virulence Factor) Toxin

production: Lysogenic bacteriophage carries tox gene Only toxigenic strains cause severe

disease Iron-poor conditions enhance toxin production Mechanism of Action:

ADP-ribosylation of elongation factor-2 (eEF-2) Inhibits protein synthesis in host cells Cell

death occurs Systemic toxicity affects heart, nerves, kidneys Toxin structure: Fragment A:

Enzymatic activity (ADP-ribosyltransferase) Fragment B: Binding and translocation Clinical

Syndromes Respiratory Diphtheria (Classic) Pharyngeal/tonsillar diphtheria: Pseudomembrane

formation (gray-white, adherent) “Bull neck” appearance (cervical lymphadenopathy)

Bleeding when membrane removed Foul-smelling breath Low-grade fever Laryngeal

diphtheria: Hoarseness, stridor Croup-like symptoms Risk of airway obstruction Cutaneous

Diphtheria Chronic, non-healing ulcers More common in tropics Less systemic toxicity Can

still cause complications Systemic Complications Cardiac (myocarditis): Week 2-6 of illness

Heart block, arrhythmias Heart failure Leading cause of death Neurologic: Week 2-10 of

illness Cranial nerve palsies (especially CN IX, X) Peripheral neuropathy Guillain-Barré-like

syndrome Renal: Acute tubular necrosis Proteinuria USMLE Clinical Scenarios Scenario 1:

Classic Presentation A 7-year-old unvaccinated child presents with sore throat, low-grade

fever, and difficulty swallowing. Physical exam reveals a gray, adherent membrane on the

tonsils that bleeds when removal is attempted. Cervical lymphadenopathy gives “bull neck”

appearance. Question: What organism is most likely responsible? Answer: Corynebacterium

diphtheriae (classic pseudomembrane + bull neck) Scenario 2: Cardiac Complications A

patient with recent diphtheria infection develops heart block and ventricular arrhythmias 3

weeks after initial symptoms. Question: What’s the mechanism of cardiac involvement?

Answer: Diphtheria toxin causes myocarditis through inhibition of protein synthesis Scenario

3: Neurologic Complications A child recovering from diphtheria develops difficulty

swallowing and nasal speech 6 weeks later. Question: What nerve is most likely affected?

Answer: Cranial nerves IX and X (glossopharyngeal and vagus) – classic diphtheria

neuropathy Scenario 4: Laboratory Identification Gram stain shows gram-positive rods in

“Chinese letter” arrangement with metachromatic granules. Question: What medium should be

used for isolation? Answer: Tellurite agar (selective for Corynebacterium diphtheriae)

Scenario 5: Toxin Testing A patient has clinical diphtheria but cultures are negative for toxin

production. Question: What’s the significance of non-toxigenic strains? Answer:

Non-toxigenic strains cause local infection only, no systemic complications Diagnostic Testing

Direct microscopy: Gram stain: Gram-positive rods, Chinese letter pattern Methylene blue:

Metachromatic granules Albert stain: Enhanced visualization Culture: Tellurite agar: Selective

medium, gray-black colonies Loeffler’s medium: Enhances morphology Catalase test: Positive

Toxin detection: Elek test: In vitro toxin production PCR: For tox gene Cell culture assay:

Cytotoxicity testing Serology: Antitoxin levels: Protective immunity Not useful for acute

diagnosis Treatment Antitoxin Therapy (Priority #1) Diphtheria antitoxin (DAT) Horse

serum-derived (risk of serum sickness) Neutralizes circulating toxin Must give early (within

48-72 hours) Dosage: Based on severity and site Test for horse serum allergy first Antibiotic

Therapy First-line options: Penicillin G: IV for severe cases Erythromycin: Oral or IV, good

alternative Azithromycin/Clarithromycin: Also effective Duration: 14 days Goal: Eradicate

organism, prevent transmission Supportive Care Airway management: May need tracheostomy

Cardiac monitoring: For heart block/arrhythmias Bed rest: Especially with cardiac

involvement Isolation: Until cultures negative Prevention Vaccination (Primary Prevention)

DTaP/Tdap vaccines: Diphtheria toxoid (formaldehyde-inactivated toxin) Primary series: 2, 4,

6, 15-18 months, 4-6 years Boosters: Every 10 years (Tdap/Td) Pregnancy: Tdap during each

pregnancy Post-Exposure Prophylaxis Close contacts: Antibiotics: Erythromycin × 7 days or

single-dose azithromycin Vaccination: Update if needed Surveillance: Monitor for 7 days

Epidemiology Global distribution: Endemic in developing countries Rare in developed

countries (vaccination) Outbreaks in unvaccinated populations Risk factors: Unvaccinated

status Crowded living conditions Poor hygiene Immunocompromised state Key USMLE

Concepts Microbiology Pearls “Chinese letter” arrangement = pathognomonic Metachromatic

granules = characteristic finding Tellurite agar = selective medium Toxigenic vs non-toxigenic

strains Clinical Pearls Pseudomembrane that bleeds when removed Bull neck appearance

Cardiac complications = leading cause of death Cranial nerve palsies weeks later Treatment

Pearls Antitoxin first (neutralizes toxin) Antibiotics second (eradicate organism) Early

treatment crucial (toxin already bound won’t be neutralized) Prevention Pearls Toxoid vaccine

prevents disease Herd immunity important Post-exposure prophylaxis for contacts Differential

Diagnosis Infectious causes of pharyngitis: Streptococcal pharyngitis: Exudate but no true

membrane EBV/CMV: Lymphocytosis, monospot positive Candidiasis: White plaques, easily

removed Other membrane-forming conditions: Vincent’s angina: Necrotizing, foul odor

Bacterial tracheitis: Productive cough Memory Aids for USMLE “DIPHTHERIA” mnemonic:

Diphtheria toxoid vaccine prevents Inhibits protein synthesis (eEF-2) Pseudomembrane (gray,

adherent) Heart block (myocarditis) Tellurite agar (culture medium) Horse serum antitoxin

Erythromycin (antibiotic) Respiratory obstruction risk Immunization prevents

ADP-ribosylation mechanism Key Clinical Rule: Pseudomembrane + bull neck + unvaccinated

= diphtheria until proven otherwise The most testable concepts are toxin mechanism

(ADP-ribosylation of eEF-2), characteristic morphology (Chinese letters), and the critical

importance of early antitoxin therapy.

Key Medical Terms – Definitions and Examples to Prevent Mix-ups Membrane vs Exudate vs

Other Throat Findings Pseudomembrane Definition: Thick, adherent, fibrinous coating that

bleeds when removed Composition: Fibrin, dead tissue, inflammatory cells, bacteria Key

feature: Firmly attached to underlying tissue Examples: Diphtheria: Gray-white

pseudomembrane on tonsils/pharynx Pseudomembranous colitis (C. diff): Yellow plaques in

colon USMLE Pearl: If it bleeds when you try to remove it = pseudomembrane Exudate

Definition: Inflammatory fluid with high protein content, easily wiped away Composition:

Mostly inflammatory fluid, some cells Key feature: Not firmly attached Examples: Strep

throat: White/yellow patches that wipe off easily Bacterial tonsillitis: Purulent material in

crypts USMLE Pearl: If it wipes off easily = exudate Plaques Definition: Raised, discrete

patches, consistency varies Key feature: Well-demarcated areas Examples: Oral thrush

(Candida): White plaques, easily scraped off Oral hairy leukoplakia (EBV): White plaques that

don’t scrape off Leukoplakia: White patches (premalignant) Toxic vs Septic vs Ill-appearing

Toxic Appearance Definition: Severe systemic illness with multiple organ dysfunction

Features: Altered mental status, poor perfusion, respiratory distress Examples: Toxic shock

syndrome: High fever + rash + hypotension + organ dysfunction Severe sepsis: Infection +

organ failure Kawasaki disease: Child with prolonged fever + multiple system involvement

Septic Definition: Infection + systemic inflammatory response (SIRS criteria) SIRS criteria:

2+ of: Temp >38°C or <36°C, HR >90, RR >20, WBC >12K or <4K Examples: Bacterial

pneumonia with fever + tachycardia + elevated WBC UTI with systemic symptoms Cellulitis

with fever and systemic signs Ill-appearing Definition: Subjective assessment of being unwell

but stable Features: Looks sick but no immediate life threat Examples: Viral syndrome: Looks

tired, decreased appetite, but stable vitals Mild dehydration: Appears unwell but not critically

ill Hemolysis Types Intravascular Hemolysis Definition: RBC destruction within blood vessels

Lab findings: Free hemoglobin in plasma, hemoglobinuria, low haptoglobin Examples:

TTP/HUS: Mechanical destruction by microthrombi Transfusion reaction:

Complement-mediated lysis PNH: Complement sensitivity Mechanical heart valves: Physical

trauma USMLE Pearl: Hemoglobinuria (dark urine) = intravascular Extravascular Hemolysis

Definition: RBC destruction in spleen/liver (reticuloendothelial system) Lab findings: Indirect

bilirubin elevated, jaundice, NO hemoglobinuria Examples: Hereditary spherocytosis: Splenic

sequestration Autoimmune hemolytic anemia: Antibody-coated RBCs removed by spleen

Sickle cell disease: Abnormal RBCs cleared by spleen USMLE Pearl: Jaundice without dark

urine = extravascular Inflammation Types Acute Inflammation Definition: Rapid onset

(minutes to hours), short duration Features: Heat, redness, swelling, pain, loss of function

Cells: Neutrophils predominate Examples: Acute appendicitis: Sudden onset abdominal pain

Acute MI: Immediate inflammatory response Bacterial pneumonia: Rapid onset with

neutrophilic infiltrate Chronic Inflammation Definition: Prolonged (weeks to months),

persistent Features: Tissue destruction and repair occur simultaneously Cells: Lymphocytes,

macrophages, plasma cells Examples: Rheumatoid arthritis: Ongoing joint inflammation

Crohn’s disease: Chronic bowel inflammation Chronic hepatitis: Persistent liver inflammation

Granulomatous Inflammation Definition: Specialized chronic inflammation with epithelioid

cells and giant cells Features: Organized collection of activated macrophages Examples:

Tuberculosis: Caseating granulomas Sarcoidosis: Non-caseating granulomas Crohn’s disease:

Non-caseating granulomas in bowel Infection Patterns Acute Infection Definition: Recent

onset (days), rapid progression Features: High fever, elevated WBC, positive cultures

Examples: Acute bacterial meningitis: Hours to days onset Acute pyelonephritis: Sudden onset

flank pain + fever Acute endocarditis: Rapid valve destruction Chronic Infection Definition:

Prolonged course (weeks to months) Features: Indolent progression, may have systemic

symptoms Examples: Tuberculosis: Months of symptoms Chronic osteomyelitis: Persistent

bone infection Chronic sinusitis: Symptoms >12 weeks Latent Infection Definition: Organism

present but no active disease Features: Positive tests but asymptomatic Examples: Latent TB:

Positive TB skin test, normal chest X-ray CMV latency: Virus dormant, reactivates with

immunosuppression HSV latency: Virus in nerve ganglia Quick Reference Memory Tricks

Membrane Removal Test: Bleeds when removed = Pseudomembrane (Diphtheria) Wipes off

easily = Exudate (Strep throat) Scrapes off = Plaques (Thrush) Hemolysis Location:

INTRAvascular = INTRAvenous hemoglobin (dark urine) EXTRAvascular = EXTRA

hemoglobin goes to liver (jaundice) Inflammation Timing: Acute = Always Arrives quickly

(neutrophils) Chronic = Continuous Cellular infiltrate (lymphocytes) Appearance Severity:

Toxic = Threatening multiple organs Septic = Systemic infection signs Ill = Indefinite concern

but stable USMLE Application Examples Scenario: Throat examination findings Gray

membrane that bleeds when removed = Diphtheria pseudomembrane White patches that wipe

off = Streptococcal exudate White plaques that scrape off = Oral thrush Scenario: Hemolysis

pattern Dark urine + low haptoglobin = Intravascular (think TTP/mechanical) Jaundice +

normal urine = Extravascular (think spherocytosis/autoimmune) Scenario: Patient appearance

Multiple organ dysfunction = Toxic Fever + tachycardia + infection = Septic Looks tired but

stable vitals = Ill-appearing These distinctions are absolutely crucial for USMLE success! The

key is using the specific features (bleeding, timing, location) to differentiate rather than just

memorizing lists.

Bacterial Genetic Exchange and Viral Reassortment – USMLE Concepts Ah! Now I

understand perfectly! You’re asking about the mechanisms of genetic transfer and whether the

changes are heritable to progeny. This is a crucial USMLE concept. Let me break this down

systematically. Bacterial Genetic Exchange Mechanisms Transformation Definition: Uptake of

free DNA from environment by competent bacteria Mechanism: Naked DNA enters through

cell wall/membrane Inheritance: YES – PERMANENT genetic change passed to progeny

Examples: Streptococcus pneumoniae: Classic Griffith experiment (rough → smooth)

Haemophilus influenzae: Naturally competent Laboratory: Heat shock E. coli to take up

plasmids USMLE Pearl: Free DNA + competent bacteria = permanent change Conjugation

Definition: Direct transfer of plasmid DNA through pilus between bacteria Mechanism: F+

donor → F- recipient via sex pilus Inheritance: YES – PERMANENT (recipient now has

plasmid) Examples: F plasmid transfer: F+ × F- → two F+ cells R plasmid transfer: Antibiotic

resistance genes Hfr conjugation: Chromosomal DNA transfer USMLE Pearl: Cell-to-cell

contact + pilus = permanent transfer Transduction Definition: DNA transfer via bacteriophage

(virus) Two types: Generalized vs Specialized Inheritance: YES – PERMANENT genetic

change Generalized transduction: Mechanism: Phage accidentally packages host DNA

Example: P1 phage in E. coli Result: Any bacterial gene can be transferred Specialized

transduction: Mechanism: Prophage excision includes adjacent host genes Example: Lambda

phage transfers gal or bio genes Result: Only specific genes near prophage site USMLE Pearl:

Virus-mediated = permanent DNA transfer Plasmid Concepts Plasmids Definition:

Extrachromosomal circular DNA that replicates independently Inheritance: YES –

PERMANENT (passed to daughter cells) Loss: Can be lost under selective pressure Types: F

plasmid: Fertility, enables conjugation R plasmid: Resistance genes (antibiotics) Col plasmid:

Colicin production Virulence plasmids: Toxin genes Examples: E. coli R plasmid: Multiple

antibiotic resistance Bacillus anthracis pXO1: Anthrax toxin genes Yersinia pestis: Virulence

factors Viral Genetic Exchange Reassortment (Segmented Viruses) Definition: Exchange of

whole genome segments between viruses Requirement: Segmented genome viruses only

Inheritance: YES – PERMANENT in progeny virions Examples: Influenza A: 8 RNA

segments can reassort Rotavirus: 11 RNA segments Reovirus: 10-12 RNA segments

Mechanism: Co-infection of same cell by two different strains Genome segments mix during

assembly New combinations in progeny viruses Antigenic shift results USMLE Example:

Human influenza H1N1 + Avian H5N1 → Novel H5N1 with human transmission

Recombination (Non-segmented Viruses) Definition: Crossing over between viral genomes

Requirement: DNA viruses or RNA viruses with long genomes Inheritance: YES –

PERMANENT genetic change Examples: HSV-1 and HSV-2: Recombination creates variants

HIV: High recombination rate Poliovirus: Vaccine-derived recombinants Phenotypic Mixing

Definition: Proteins from one virus package genome of another Key point: NO genetic change

• only one generation affected Inheritance: NO – TEMPORARY (progeny revert to original

phenotype) Mechanism: Co-infection by two viruses Viral proteins mix in infected cell One

virus genome gets packaged with other virus proteins Next generation reverts to original

genotype Example: HIV + HTLV co-infection: HIV genome in HTLV envelope Progeny:

Normal HIV (no permanent change) USMLE Pearl: Phenotypic mixing = temporary coat,

permanent genome Complementation Definition: Defective virus rescued by helper virus

functions Key point: NO genetic exchange – just functional rescue Inheritance: NO –

TEMPORARY (still defective) Examples: Hepatitis D: Requires hepatitis B envelope proteins

Adeno-associated virus: Requires adenovirus helper functions Defective interfering particles:

Need helper virus USMLE Clinical Scenarios Scenario 1: Antibiotic Resistance Spread

Hospital outbreak of multi-drug resistant E. coli. All isolates have identical resistance pattern

on same plasmid. Question: What mechanism explains rapid spread? Answer: Conjugation – R

plasmid transfer between bacteria (permanent) Scenario 2: Influenza Pandemic Novel

influenza strain emerges with avian H5 and human N1 proteins. Question: What mechanism

created this strain? Answer: Reassortment between avian and human influenza (permanent

genetic change) Scenario 3: Pneumococcal Transformation Laboratory experiment shows

rough S. pneumoniae becomes smooth after exposure to heat-killed smooth strain. Question:

What genetic mechanism occurred? Answer: Transformation – uptake of free DNA from dead

smooth bacteria (permanent) Scenario 4: Viral Co-infection Patient co-infected with two

viruses. Initial isolates show mixed properties, but subsequent isolates revert to original

characteristics. Question: What explains this pattern? Answer: Phenotypic mixing – temporary

protein mixing, no genetic change Summary Table: Permanent vs Temporary Key USMLE

Memory Points Permanent genetic changes: Transformation: “Permanently transformed”

Conjugation: “Conjugal union is permanent” Transduction: “Viral delivery is permanent”

Reassortment: “New combinations stick” Temporary changes: Phenotypic mixing: “Just

wearing someone else’s clothes” Complementation: “Borrowing functions temporarily” The

Rule: If DNA/RNA changes, it’s permanent. If only proteins mix, it’s temporary. This concept

is huge for understanding antibiotic resistance spread, vaccine development, and viral

evolution – all major USMLE themes!

Antiepileptic Drug Mechanisms – Complete USMLE Breakdown Absolutely! Let me break

down these mechanisms systematically. Understanding MOA is crucial for USMLE side

effects and drug interactions. GABA-A vs GABA-B Receptors First GABA-A Receptor

Structure: Ligand-gated chloride channel (ionotropic) Subunits: α, β, γ, δ subunits (pentameric

structure) Mechanism: GABA binding → chloride influx → hyperpolarization → inhibition

Binding sites: GABA site: Where GABA binds Benzodiazepine site: Between α and γ subunits

Barbiturate site: Different location Alcohol site: Overlaps with other sites Result: Fast

inhibitory neurotransmission (milliseconds) GABA-B Receptor Structure: G-protein coupled

receptor (metabotropic) Mechanism: GABA binding → G-protein activation → potassium

efflux + calcium channel inhibition Result: Slow inhibitory neurotransmission (seconds)

USMLE Pearl: GABA-A = Acute, Anion (Cl-) channel GABA-B = Baclofen receptor, Big

G-protein response Antiepileptic Drug Mechanisms Benzodiazepines (Lorazepam, Diazepam,

Clonazepam) MOA: GABA-A receptor positive allosteric modulator Mechanism: Binds to

benzodiazepine site on GABA-A receptor Increases frequency of chloride channel opening

Does NOT bind GABA site directly Requires GABA to be present (can’t work alone) USMLE

Pearl: Increases frequency, not duration of channel opening Clinical use: Status epilepticus

(first-line), anxiety, muscle relaxation Phenobarbital MOA: GABA-A receptor positive

allosteric modulator + direct agonist Mechanism: Binds to barbiturate site on GABA-A

receptor Increases duration of chloride channel opening Can directly activate receptor (doesn’t

require GABA) Higher doses: Direct membrane effects USMLE Pearl: Increases duration of

channel opening, can work without GABA Clinical use: Neonatal seizures, refractory epilepsy

Levetiracetam (Keppra) MOA: SV2A protein inhibition (synaptic vesicle protein) Mechanism:

Binds to SV2A in presynaptic terminals Inhibits vesicle exocytosis Reduces neurotransmitter

release Unique mechanism among AEDs USMLE Pearl: Novel target – SV2A protein, broad

spectrum efficacy Clinical use: Broad spectrum, well-tolerated, IV available Valproic Acid

MOA: Multiple mechanisms (the “Swiss Army knife”) Mechanisms: Sodium channel blockade

(high-frequency firing) GABA transaminase inhibition → increased GABA T-type calcium

channel blockade Histone deacetylase inhibition (epigenetic effects) USMLE Pearl: Multiple

MOAs explain broad spectrum activity Clinical use: Broad spectrum, bipolar disorder,

migraine prophylaxis Ethosuximide MOA: T-type calcium channel blockade Mechanism:

Selectively blocks T-type (Cav3.1) calcium channels Thalamic neurons depend on T-type

channels Prevents 3-Hz spike-wave generation Specific for absence seizures USMLE Pearl:

T-type specific = absence seizure specific Clinical use: ONLY absence seizures (very specific

indication) Phenytoin MOA: Voltage-gated sodium channel blockade (use-dependent)

Mechanism: Binds to inactivated state of sodium channels Preferentially blocks

high-frequency firing Use-dependent blockade (more block with more activity) Stabilizes

inactive conformation USMLE Pearl: Use-dependent = blocks abnormal high-frequency firing

more than normal Clinical use: Tonic-clonic seizures, status epilepticus Carbamazepine MOA:

Voltage-gated sodium channel blockade (similar to phenytoin) Mechanism: Use-dependent

sodium channel blockade Stabilizes inactivated state Reduces repetitive firing Also adenosine

reuptake inhibition USMLE Pearl: Similar to phenytoin but better tolerated Clinical use:

Partial seizures, trigeminal neuralgia, bipolar disorder Gabapentin MOA: Voltage-gated

calcium channel blockade (α2δ subunit) Mechanism: Binds to α2δ subunit of calcium

channels Reduces calcium influx at nerve terminals Decreases neurotransmitter release Does

NOT directly affect GABA (despite name) USMLE Pearl: Name is misleading – doesn’t

directly affect GABA Clinical use: Neuropathic pain, partial seizures USMLE Clinical

Scenarios Scenario 1: Status Epilepticus Patient in status epilepticus receives lorazepam,

which terminates seizure rapidly. Question: Why is lorazepam effective for status epilepticus?

Answer: GABA-A positive allosteric modulation increases inhibitory tone rapidly Scenario 2:

Absence Seizures 8-year-old with 3-Hz spike-wave complexes and staring spells. Question:

What’s the drug of choice and why? Answer: Ethosuximide – specifically blocks T-type

calcium channels in thalamus Scenario 3: Neonatal Seizures Newborn with seizures refractory

to other medications responds to phenobarbital. Question: Why might phenobarbital work

when others fail? Answer: Can directly activate GABA-A receptors without requiring GABA

Scenario 4: Drug Interaction Patient on phenytoin has subtherapeutic levels despite good

compliance. Question: What explains this? Answer: Phenytoin induces its own metabolism

(autoinduction) – zero-order kinetics Mechanism-Based Side Effects GABA Enhancement

(Benzos, Barbiturates) Sedation, ataxia, confusion Respiratory depression (especially

barbiturates) Tolerance and dependence Sodium Channel Blockade (Phenytoin,

Carbamazepine) Diplopia, ataxia (cerebellar effects) Cardiac conduction defects Hyponatremia

(carbamazepine) Calcium Channel Effects (Gabapentin, Ethosuximide) Dizziness, somnolence

Weight gain (gabapentin) GI upset (ethosuximide) Quick Reference Table Memory Aids

GABA receptor types: GABA-A = Acute Anion (chloride) channel GABA-B = Baclofen, Big

slow response Benzodiazepines vs Barbiturates: BenZos = increase Zero (frequency)

Barbiturates = Bigger Duration Absence seizure treatment: Ethosuximide for Epileptogenic

T-type channels Sodium channel blockers: PHenytoin = PHrequency dependent

CARBAmazepine = CAR needs good BAM (sodium channels) The key concept is matching

mechanism to seizure type and understanding why certain drugs work for specific indications!

GABA-A and GABA-B Receptors – Physiological Functions Great question! Understanding

their normal functions helps explain why drugs targeting these receptors have specific effects.

GABA: The Brain’s “Brake Pedal” GABA (γ-aminobutyric acid) is the primary inhibitory

neurotransmitter in the CNS 30-40% of all synapses in the brain use GABA Counterbalances

glutamate (the main excitatory neurotransmitter) Essential for preventing seizures and

maintaining normal brain function GABA-A Receptor Functions Primary Role: Fast Synaptic

Inhibition Millisecond responses to stop overexcitation Immediate “braking” of neural activity

Prevents runaway excitation that could cause seizures Specific Functions: 1. Seizure

Prevention Primary mechanism preventing epileptic activity Balances excitatory input from

glutamate Loss of GABA-A function → seizures 2. Sleep Regulation Promotes sleep initiation

Sleep-wake cycle control Different GABA-A subtypes in sleep centers 3. Anxiety Control

Limbic system modulation (amygdala, hippocampus) Reduces fear/anxiety responses

Benzodiazepines work here for anxiety 4. Motor Control Spinal cord interneurons use

GABA-A Prevents excessive muscle activity Motor coordination and muscle tone regulation 5.

Cognitive Function Working memory regulation Attention and focus by filtering irrelevant

signals Learning and memory consolidation Anatomical Distribution: Cerebral cortex:

Cognitive functions Hippocampus: Memory formation Amygdala: Fear/anxiety Thalamus:

Sensory gating Spinal cord: Motor control Brainstem: Sleep/wake, vital functions GABA-B

Receptor Functions Primary Role: Slow, Prolonged Inhibition Seconds to minutes of inhibitory

effects Fine-tuning neural circuits Presynaptic and postsynaptic modulation Specific

Functions: 1. Presynaptic Modulation Autoreceptors on GABA terminals Feedback inhibition

of GABA release Heteroceptors on glutamate terminals Reduces excitatory neurotransmitter

release 2. Muscle Tone Regulation Spinal cord functions Baclofen targets GABA-B for

spasticity Reduces muscle hyperactivity 3. Pain Modulation Spinal cord pain pathways

Descending inhibition from brainstem Chronic pain conditions involve GABA-B dysfunction

4. Mood and Behavior Long-term mood regulation Addiction pathways (reward system

modulation) Depression may involve GABA-B dysfunction 5. Respiratory Control Brainstem

respiratory centers Long-term breathing pattern regulation Sleep-related breathing disorders

Key Differences in Function: Clinical Correlations GABA-A Dysfunction: Epilepsy: Loss of

fast inhibition Anxiety disorders: Reduced limbic inhibition Insomnia: Sleep center

dysfunction Alcohol withdrawal: GABA-A downregulation GABA-B Dysfunction: Spasticity:

Loss of muscle tone control Chronic pain: Reduced spinal inhibition Addiction: Altered

reward pathways Depression: Mood regulation problems USMLE Clinical Examples Scenario

1: Alcohol Withdrawal Chronic alcoholic stops drinking and develops seizures. Explanation:

Alcohol enhances GABA-A function. Chronic use leads to GABA-A downregulation.

Withdrawal removes alcohol enhancement → relative GABA deficiency → seizures Scenario

2: Benzodiazepine for Anxiety Patient with panic attacks responds to lorazepam. Explanation:

GABA-A receptors in amygdala normally control fear responses. Anxiety disorders may have

reduced GABA-A function. Benzodiazepines enhance GABA-A → reduced anxiety Scenario

3: Baclofen for Spasticity Multiple sclerosis patient with spasticity improves with baclofen.

Explanation: GABA-B receptors in spinal cord normally control muscle tone. MS damages

inhibitory pathways. Baclofen enhances GABA-B → reduced spasticity Scenario 4:

Barbiturate Coma ICU patient in barbiturate coma for refractory status epilepticus.

Explanation: Massive GABA-A enhancement creates profound inhibition, stopping all seizure

activity but requiring mechanical ventilation Developmental Aspects GABA-A changes with

age: Neonates: Immature GABA-A function Children: Developing inhibitory circuits Adults:

Mature balanced excitation/inhibition Elderly: May have declining GABA function Clinical

relevance: Neonatal seizures may need different drugs Febrile seizures in children (immature

inhibition) Age-related anxiety/sleep disorders Key USMLE Concepts GABA-A = Acute

Control: Seizure prevention (primary mechanism) Immediate anxiety relief Rapid sleep

induction Emergency inhibition GABA-B = Chronic Control: Sustained muscle tone

Long-term pain modulation Mood regulation Fine-tuning circuits Clinical Pearl: Most

psychiatric and neurologic drugs that enhance inhibition target GABA-A (benzos, barbiturates,

alcohol), while GABA-B drugs are more specialized (baclofen for spasticity). The bottom line:

GABA-A keeps your brain from going haywire moment-to-moment, while GABA-B

fine-tunes how your nervous system works over longer periods.

ZERO ORDER KINETICS: ETHO, ASA AND PHENYTOIN Zero-Order vs First-Order

Kinetics Graphs I’ll create visual graphs to show you the key differences between these kinetic

patterns! Zero-Order vs First-Order Kinetics Comparison Interactive artifact Perfect! These

graphs show the key visual differences between zero-order and first-order kinetics: Key Graph

Interpretations for USMLE: Graph 1: Concentration vs Time First-order (blue):

Curved/exponential decay – gets steeper as concentration drops Zero-order (red): Straight line –

same amount eliminated each hour Graph 2: Elimination Rate vs Concentration First-order

(blue): Sloped line – higher concentration = faster elimination Zero-order (red): Flat line – same

elimination rate regardless of concentration (Vmax reached) Graph 3: Semi-Log Plot

First-order (blue): Straight line on log scale (easy half-life calculation) Zero-order (red):

Curved on log scale (unpredictable) USMLE Clinical Recognition: When you see these

patterns in questions: Disproportionate response to dose changes → Think zero-order

Unpredictable drug levels → Think zero-order Need for frequent monitoring → Think

zero-order “Small dose increase caused toxicity” → Think phenytoin (zero-order) “Cannot

eliminate alcohol faster” → Think ethanol (zero-order) The visual key: Zero-order kinetics

create straight lines on regular plots but curved lines on log plots – the opposite of first-order

kinetics! This is exactly why phenytoin dosing is so tricky and why you can’t “sober up” faster

no

Half-Life Calculations – The Classic USMLE Method! YES! I absolutely know this method –

it’s one of the most tested pharmacology concepts on USMLE! This is the “Rule of Half-Lives”

and it’s pure gold for quick calculations. The Classic Half-Life Pattern The Magic Numbers: 1

half-life: 50% eliminated (50% remaining) 2 half-lives: 75% eliminated (25% remaining) 3

half-lives: 87.5% eliminated (12.5% remaining) 4 half-lives: 93.75% eliminated (6.25%

remaining) 5 half-lives: ~97% eliminated (~3% remaining) = “Essentially gone” For Steady

State (opposite direction): 1 half-life: 50% of steady state reached 2 half-lives: 75% of steady

state reached 3 half-lives: 87.5% of steady state reached 4 half-lives: 93.75% of steady state

reached 5 half-lives: ~97% = “Steady state achieved” USMLE-Style Questions (With Sugar

and Strawberries! ■) Question 1: Classic Elimination A patient receives a single IV dose of a

drug with a half-life of 6 hours. The initial plasma concentration is 40 mg/L. What will the

concentration be after 18 hours? A) 10 mg/L B) 5 mg/L C) 2.5 mg/L D) 20 mg/L E) 15 mg/L

Question 2: Steady State Achievement A patient starts daily dosing of a medication with a

half-life of 12 hours. Approximately when will steady state be achieved? A) 24 hours B) 36

hours C) 48 hours D) 60 hours E) 72 hours

Question 3: Clinical Scenario – Digoxin An 80-year-old patient with heart failure is started on

digoxin (half-life = 36 hours). After how many days should you check the first steady-state

level? A) 2 days B) 4 days C) 7 days D) 10 days E) 14 days

Question 4: Toxicity Resolution A patient accidentally takes 10x the normal dose of a drug

with a half-life of 8 hours. Assuming no additional doses, when will the drug concentration

return to the normal therapeutic range? A) 16 hours B) 24 hours C) 32 hours D) 40 hours E) 48

hours

Question 5: Loading Dose Scenario A patient needs rapid therapeutic levels of a drug with a

long half-life of 48 hours. Without a loading dose, when would therapeutic levels be reached?

A) 2 days B) 4 days C) 6 days D) 8 days E) 10 days

Question 6: Two-Compartment Thinking A patient stops taking a medication with a half-life of

4 hours. After 12 hours, what percentage of the original dose remains in the body? A) 25% B)

12.5% C) 6.25% D) 3.125% E) 1.5%

Question 7: Clinical Decision Making A patient on warfarin (half-life = 40 hours) needs

emergency surgery. How long after the last dose should you wait for the anticoagulant effect to

be essentially gone? A) 2 days B) 4 days C) 6 days D) 8 days E) 10 days

Quick Reference Table for USMLE Memory Tricks “50-75-87.5-94-97” – the elimination

percentages “Half, quarter, eighth, sixteenth, thirty-second” – the remaining fractions Clinical

Rules: Check steady state levels: 5 half-lives after starting Drug essentially gone: 5 half-lives

after stopping Dose adjustment effects: Wait 5 half-lives to see full effect USMLE Pearls

Always convert time to half-lives first 5 half-lives = steady state OR essentially eliminated

Loading doses bypass the 5 half-life rule Works for first-order kinetics only (not phenytoin,

ethanol, aspirin at high doses) This method will save you SO much time on the USMLE – no

complex calculations needed! ■ Basic Epidemiology Rates – USMLE Simplified Absolutely!

These “simple” statistics questions are NOTORIOUS for tripping people up because they seem

easy but have subtle differences. Let me break down the big three that USMLE loves to test:

The Big Three Rates Attack Rate Definition: Proportion of people who develop disease after a

specific exposure in a defined time period Formula: (Number who got sick after exposure) ÷

(Total number exposed) × 100 Key features: Outbreak/epidemic situations Specific exposure

(food poisoning, infectious disease) Short time frame (hours to weeks) Closed population

(wedding, school, etc.) Incidence Rate Definition: Rate of new cases developing in a

population over a specified time period Formula: (New cases during time period) ÷

(Population at risk × time period) Key features: New cases only (not existing cases) Population

at risk (excludes those who already have disease) Expressed per unit time (per year, per 1000

person-years) Chronic diseases, general populations Prevalence Rate Definition: Proportion of

population that has the disease at a specific point in time Formula: (Total cases at specific

time) ÷ (Total population) × 100 Key features: All cases (new + existing) Point in time

(snapshot) No time component in denominator “How common is this disease?” USMLE-Style

Questions Question 1: Food Poisoning Outbreak At a wedding reception with 200 guests, 50

people ate the salmon, and 30 of those who ate salmon developed food poisoning. What is the

attack rate for salmon consumption? A) 15% B) 25% C) 30% D) 60% E) 75%

Question 2: Diabetes Study A 5-year study follows 10,000 healthy adults. During the study,

500 people develop diabetes. What is the incidence rate of diabetes? A) 5% B) 10 per 1,000

person-years C) 50 per 1,000 person-years D) 100 per 1,000 person-years E) 500 per 1,000

person-years

Question 3: Hypertension Screening A community health screening of 5,000 adults finds that

1,000 people currently have hypertension. What is the prevalence of hypertension? A) 10% B)

15% C) 20% D) 25% E) Cannot be determined

Question 4: Tricky Scenario In a dormitory of 400 students, 40 students had influenza at the

beginning of the semester. During the semester, 60 additional students developed influenza.

What is the prevalence of influenza at the end of the semester (assuming no one recovered)?

A) 10% B) 15% C) 20% D) 25% E) 30%

Question 5: Attack Rate vs Incidence During a norovirus outbreak on a cruise ship with 1,000

passengers, 200 people became ill over 3 days. What should this be called? A) Incidence rate

of 20% B) Attack rate of 20% C) Prevalence of 20% D) Case fatality rate of 20% E) Both A

and B are correct

Quick Recognition Guide When to think ATTACK RATE: Keywords: Outbreak, epidemic,

food poisoning, wedding, school, cruise ship Timeframe: Hours to weeks Population: Specific

exposure group Question asks: “What’s the attack rate of…” When to think INCIDENCE

RATE: Keywords: New cases, develops disease, person-years Timeframe: Months to years

Population: General population at risk Question asks: “What’s the incidence rate of…” When to

think PREVALENCE: Keywords: Currently has, screening study, point in time Timeframe:

Snapshot (no time in calculation) Population: Everyone surveyed Question asks: “What’s the

prevalence of…” Memory Tricks Attack Rate: “Attack = After specific exposure” Incidence:

“Incidence = Incoming new cases” Prevalence: “Prevalence = Picture at one point in time” The

Restaurant Analogy: Attack rate: “How many people who ate the bad oysters got sick?”

Incidence: “How many new food poisoning cases occur per year in this city?” Prevalence:

“How many people currently have food poisoning right now?” These distinctions are HUGE

on USMLE – once you nail the pattern recognition, these become easy points! ■ Basic

Epidemiology Rates – USMLE Simplified Absolutely! These “simple” statistics questions are

NOTORIOUS for tripping people up because they seem easy but have subtle differences. Let

me break down the big three that USMLE loves to test: The Big Three Rates Attack Rate

Definition: Proportion of people who develop disease after a specific exposure in a defined

time period Formula: (Number who got sick after exposure) ÷ (Total number exposed) × 100

Key features: Outbreak/epidemic situations Specific exposure (food poisoning, infectious

disease) Short time frame (hours to weeks) Closed population (wedding, school, etc.)

Incidence Rate Definition: Rate of new cases developing in a population over a specified time

period Formula: (New cases during time period) ÷ (Population at risk × time period) Key

features: New cases only (not existing cases) Population at risk (excludes those who already

have disease) Expressed per unit time (per year, per 1000 person-years) Chronic diseases,

general populations Prevalence Rate Definition: Proportion of population that has the disease

at a specific point in time Formula: (Total cases at specific time) ÷ (Total population) × 100

Key features: All cases (new + existing) Point in time (snapshot) No time component in

denominator “How common is this disease?” USMLE-Style Questions Question 1: Food

Poisoning Outbreak At a wedding reception with 200 guests, 50 people ate the salmon, and 30

of those who ate salmon developed food poisoning. What is the attack rate for salmon

consumption? A) 15% B) 25% C) 30% D) 60% E) 75%

Question 2: Diabetes Study A 5-year study follows 10,000 healthy adults. During the study,

500 people develop diabetes. What is the incidence rate of diabetes? A) 5% B) 10 per 1,000

person-years C) 50 per 1,000 person-years D) 100 per 1,000 person-years E) 500 per 1,000

person-years

Question 3: Hypertension Screening A community health screening of 5,000 adults finds that

1,000 people currently have hypertension. What is the prevalence of hypertension? A) 10% B)

15% C) 20% D) 25% E) Cannot be determined

Question 4: Tricky Scenario In a dormitory of 400 students, 40 students had influenza at the

beginning of the semester. During the semester, 60 additional students developed influenza.

What is the prevalence of influenza at the end of the semester (assuming no one recovered)?

A) 10% B) 15% C) 20% D) 25% E) 30%

Question 5: Attack Rate vs Incidence During a norovirus outbreak on a cruise ship with 1,000

passengers, 200 people became ill over 3 days. What should this be called? A) Incidence rate

of 20% B) Attack rate of 20% C) Prevalence of 20% D) Case fatality rate of 20% E) Both A

and B are correct

Quick Recognition Guide When to think ATTACK RATE: Keywords: Outbreak, epidemic,

food poisoning, wedding, school, cruise ship Timeframe: Hours to weeks Population: Specific

exposure group Question asks: “What’s the attack rate of…” When to think INCIDENCE

RATE: Keywords: New cases, develops disease, person-years Timeframe: Months to years

Population: General population at risk Question asks: “What’s the incidence rate of…” When to

think PREVALENCE: Keywords: Currently has, screening study, point in time Timeframe:

Snapshot (no time in calculation) Population: Everyone surveyed Question asks: “What’s the

prevalence of…” Memory Tricks Attack Rate: “Attack = After specific exposure” Incidence:

“Incidence = Incoming new cases” Prevalence: “Prevalence = Picture at one point in time” The

Restaurant Analogy: Attack rate: “How many people who ate the bad oysters got sick?”

Incidence: “How many new food poisoning cases occur per year in this city?” Prevalence:

“How many people currently have food poisoning right now?” These distinctions are HUGE

on USMLE – once you nail the pattern recognition, these become easy points! ■ Retry N

questions 2, 3 and 4 tripped me up. I don’t understand the 1 person per year = 10 per 1000 if

you could please explain that. Also I never know when to subtract people from the total. lol

Edit Breaking Down Those Tricky Calculations! I TOTALLY get why these tripped you up –

these are the exact calculations that make students want to throw their pencils! Let me break it

down step by step. Question 2: The Person-Years Mystery The Setup: 10,000 people followed

for 5 years, 500 develop diabetes Step 1: Calculate Person-Years Person-years = Population ×

Time 10,000 people × 5 years = 50,000 person-years Think of it this way: If you follow 1

person for 50,000 years OR 50,000 people for 1 year OR 10,000 people for 5 years – it’s all the

same “exposure time” Step 2: Calculate Rate Incidence = 500 new cases ÷ 50,000 person-years

= 0.01 cases per person-year Step 3: Convert to “Per 1,000” 0.01 per person-year × 1,000 = 10

per 1,000 person-years Why multiply by 1,000? Because 0.01 is a tiny decimal –

epidemiologists like whole numbers! The Easy Way to Think About It: Rate = Cases ÷ (People

× Years) 500 ÷ (10,000 × 5) = 500 ÷ 50,000 = 0.01 Convert to “per 1,000”: 0.01 × 1,000 = 10

Question 3: Why No Subtraction Here The Setup: 5,000 adults screened, 1,000 have

hypertension Prevalence = 1,000 ÷ 5,000 = 20% Why no subtraction? Because prevalence is a

snapshot – we’re asking “Of everyone we looked at, what percentage currently has the

disease?” We include EVERYONE in the denominator. Question 4: The Tricky Addition The

Setup: 400 students total 40 had flu at beginning 60 developed flu during semester Prevalence

at END = (40 + 60) ÷ 400 = 100 ÷ 400 = 25% Why add them? Prevalence = ALL cases at a

specific time point (old cases + new cases) When TO Subtract vs When NOT To When TO

Subtract (Population at Risk): Example: Study of 1,000 people for heart disease, but 100

already have heart disease Population at risk = 1,000 – 100 = 900 Only the 900 without disease

can develop “new” heart disease Incidence = New cases ÷ Population at risk When NOT to

Subtract (Total Population): Prevalence calculations: Always use total population screened

Attack rates: Use total exposed population Let Me Show You With Examples: Example A:

When to Subtract 1,000 factory workers studied for lung cancer over 10 years. 50 already had

lung cancer at start. During study, 30 developed lung cancer. Incidence = 30 ÷ (950 × 10) = 30

÷ 9,500 person-years Why subtract? The 50 with existing cancer can’t develop “new” cancer

Example B: When NOT to Subtract Same factory: What’s the prevalence of lung cancer at the

end? Prevalence = (50 + 30) ÷ 1,000 = 80 ÷ 1,000 = 8% Why not subtract? We want total

disease burden in the population Quick Decision Tree: Is the question asking about: NEW

cases developing? → Incidence Denominator: Population at risk (subtract existing cases)

Formula: New cases ÷ (People without disease × time) ALL cases at one time? → Prevalence

Denominator: Total population (don’t subtract) Formula: All cases ÷ Total population Specific

exposure outbreak? → Attack Rate Denominator: Total exposed (don’t subtract) Formula:

Cases after exposure ÷ Total exposed Person-Years Made Simple: Think of person-years like

“exposure time”: 1 person for 10 years = 10 person-years 10 people for 1 year = 10

person-years 5 people for 2 years = 10 person-years It’s just: Number of people × Number of

years = Person-years The “per 1,000” part is just to make the numbers easier to read (like

saying “per capita” instead of tiny decimals). Does this help clarify the tricky parts? The

subtraction decision is really about “Who is AT RISK of developing the disease?” vs “Who do

we want to count in our total?”

Let Me Clear Up This Confusion – You’re Thinking Like a Clinician! You’re absolutely

RIGHT to be confused because you’re thinking like a doctor, not a statistician! Let me explain

this without the confusing “rule in/rule out” nonsense. Question 4: “Rarely Misses Disease”

“Rarely misses disease” = If someone HAS the disease, the test will catch it Let’s use a

concrete example: Cancer Screening Scenario: 1,000 people get screened 100 actually have

cancer Test finds 95 of the 100 cancers Test misses 5 cancers The test “rarely missed” disease

because it caught 95/100 = 95% sensitivity Why NOT PPV? PPV asks a different question: “If

the test is positive, what’s the chance they really have cancer?” But PPV depends on how many

FALSE POSITIVES you get, which depends on the population you’re testing! Same test,

different populations: Population A (high-risk): 100 have cancer, test finds 95, gives 50 false

positives Sensitivity: 95/100 = 95% (same) PPV: 95/(95+50) = 65.5% Population B (low-risk):

10 have cancer, test finds 9, gives 200 false positives Sensitivity: 9/10 = 90% (almost same)

PPV: 9/(9+200) = 4.3% (terrible!) The test’s ability to “rarely miss disease” stayed the same

(sensitivity), but PPV changed dramatically! Question 5: Confirmatory Test You want to avoid

FALSE POSITIVES in confirmatory testing Why This Matters: After screening, you’re saying

“We think you might have HIV, let’s confirm.” Bad confirmatory test: Gives lots of false

positives Tells healthy people they have HIV Causes psychological trauma, unnecessary

treatment Good confirmatory test: Rarely gives false positives (high specificity) If it says

positive, you can trust it Few healthy people get told they’re sick Sensitivity vs Specificity in

Context: Screening (cast wide net): High sensitivity = catch most disease (few false negatives)

Accept some false positives (will confirm later) Confirmation (be very sure): High specificity

= few false positives If positive, really trust it Question 6: Prevalence Effect This is the BIG

“aha!” moment that trips everyone up! Why Higher Prevalence = Higher PPV: Imagine 1,000

people tested: High prevalence area (10% have disease): 100 people have disease, 900 don’t

Test finds 90 (sensitivity 90%), misses 10 Test gives 90 false positives (specificity 90%) PPV

= 90/(90+90) = 50% Low prevalence area (1% have disease): 10 people have disease, 990

don’t Test finds 9 (sensitivity 90%), misses 1 Test gives 99 false positives (specificity 90%)

PPV = 9/(9+99) = 8.3% Same test, same accuracy, but way more false positives overwhelm the

true positives in low-prevalence populations! Let’s Forget “Rule In/Rule Out” – Think

Practically: Sensitivity = “Disease Detection Power” High sensitivity = If disease is there, test

will probably find it Low sensitivity = Test misses lots of disease Specificity = “Healthy

Person Protection” High specificity = If person is healthy, test won’t falsely alarm Low

specificity = Test falsely alarms lots of healthy people PPV = “Positive Test Trustworthiness”

High PPV = If test says positive, probably really have disease Low PPV = Lots of positive

tests are false alarms NPV = “Negative Test Reassurance” High NPV = If test says negative,

probably really don’t have disease Low NPV = Lots of negative tests miss disease Clinical

Translation: For screening: You want high sensitivity (catch the disease) For confirmation:

You want high specificity (don’t falsely diagnose) For trust: You want high PPV (positive

means something) For reassurance: You want high NPV (negative means something) Does this

make way more sense now? The key is thinking about what each number actually tells you in

real clinical practice! Retry N yes, but i am wondering where you came up with the numbers in

the 10% and 1% hiv population. enlighten me:) Edit Great Catch! Let Me Show You Where

Those Numbers Came From You’re absolutely right to question this – I need to show you the

exact math! Let me break down how I calculated those HIV population examples. The Original

HIV Test Data (From Questions 1-3): 1,000 people total 100 have HIV (10% prevalence)

Sensitivity = 90% (finds 90 of 100 HIV+ people) Specificity = 94.4% (correctly identifies 850

of 900 HIV- people) Population A: 10% Prevalence (This was our original data) Starting with

1,000 people: HIV+: 100 people (10%) HIV-: 900 people (90%) Test Results: True Positives:

100 × 0.90 = 90 people False Negatives: 100 × 0.10 = 10 people True Negatives: 900 × 0.944

= 850 people False Positives: 900 × 0.056 = 50 people PPV = 90/(90+50) = 90/140 = 64.3%

(same as Question 3!) Population B: 1% Prevalence (NEW calculation with same test) Starting

with 1,000 people: HIV+: 10 people (1%) HIV-: 990 people (99%) Using SAME sensitivity

(90%) and specificity (94.4%): True Positives: 10 × 0.90 = 9 people False Negatives: 10 × 0.10

= 1 person True Negatives: 990 × 0.944 = 935 people False Positives: 990 × 0.056 = 55 people

PPV = 9/(9+55) = 9/64 = 14.1% Wait – I Made an Error in My Previous Example!

Sensitivity, Specificity & Predictive Values – USMLE Gold Let me hit you with the 2×2 table

that rules all of medical testing! The Magic 2×2 Table Where: TP = True Positive (correctly

identified disease) FP = False Positive (incorrectly said disease present) FN = False Negative

(missed the disease) TN = True Negative (correctly said no disease) The Big Four Calculations

Sensitivity (True Positive Rate) Definition: Ability to detect disease when present Formula: TP

÷ (TP + FN) = A ÷ (A + C) Think: “Of all people WITH disease, what % tested positive?”

Memory: SNout = Sensitivity rules out (high sensitivity = few false negatives) Specificity

(True Negative Rate) Definition: Ability to rule out disease when absent Formula: TN ÷ (TN +

FP) = D ÷ (B + D) Think: “Of all people WITHOUT disease, what % tested negative?”

Memory: SPin = Specificity rules in (high specificity = few false positives) Positive Predictive

Value (PPV) Definition: If test is positive, what’s the chance you actually have disease?

Formula: TP ÷ (TP + FP) = A ÷ (A + B) Think: “Of all positive tests, what % truly have

disease?” Negative Predictive Value (NPV) Definition: If test is negative, what’s the chance

you’re truly disease-free? Formula: TN ÷ (TN + FN) = D ÷ (C + D) Think: “Of all negative

tests, what % truly don’t have disease?” USMLE-Style Questions Question 1: HIV Screening

A new HIV test is evaluated in 1,000 patients: 100 patients have HIV 90 of the HIV+ patients

test positive 850 of the HIV- patients test negative What is the sensitivity of this test? A) 85%

B) 90% C) 94.4% D) 98.8% E) Cannot be determined

Question 2: Same HIV Test Using the same data from Question 1, what is the specificity? A)

85% B) 90% C) 94.4% D) 98.8% E) Cannot be determined

Question 3: PPV Calculation Same HIV test data. What is the positive predictive value? A)

64.3% B) 85% C) 90% D) 94.4% E) 98.8%

Question 4: Screening Strategy You want a screening test that rarely misses disease. Which

characteristic is most important? A) High sensitivity B) High specificity C) High positive

predictive value D) High negative predictive value E) Low cost

Question 5: Confirmatory Test After a positive screening test, you want a confirmatory test

that rarely gives false positives. Which is most important? A) High sensitivity B) High

specificity C) High positive predictive value D) High negative predictive value E) Low cost

Question 6: Prevalence Effect The same HIV test is used in two populations: Population A:

HIV prevalence = 10% Population B: HIV prevalence = 1% Assuming identical sensitivity and

specificity, in which population will the PPV be higher? A) Population A (10% prevalence) B)

Population B (1% prevalence) C) PPV will be the same in both D) Cannot be determined E)

Depends on the specificity

Quick Memory Tricks Sensitivity vs Specificity: Sensitivity = Sees disease (finds the sick)

Specificity = Spots the healthy (finds the well) SNout vs SPin: SNout: High Sensitivity rules

out (negative test = probably don’t have disease) SPin: High Specificity rules in (positive test =

probably do have disease) PPV vs NPV: PPV: “If Positive, Probably have it?” NPV: “If

Negative, No disease?” The Prevalence Connection Key USMLE concept: PPV and NPV

change with disease prevalence, but sensitivity and specificity don’t! High prevalence →

Higher PPV, Lower NPV Low prevalence → Lower PPV, Higher NPV This is why screening

tests work differently in different populations!

You caught me! In my previous explanation, I used 90% specificity instead of the 94.4% from

our original data. Let me recalculate correctly: Corrected Low Prevalence Calculation:

Population B: 1% prevalence, 94.4% specificity False Positives: 990 × 0.056 = 55 people (not

99!) PPV = 9/(9+55) = 14.1% (not 8.3%) The Key Point Remains the Same: Even with my

corrected math, the pattern holds: Higher prevalence → Higher PPV Lower prevalence →

Lower PPV Why This Happens: In high prevalence populations: More true disease cases Same

number of false positives True positives “outnumber” false positives In low prevalence

populations: Very few true disease cases Same number of false positives False positives

“overwhelm” true positives The Formula Connection: PPV = True Positives ÷ (True Positives

+ False Positives) When prevalence drops: True Positives drop (fewer diseased people) False

Positives stay roughly the same (depends on specificity) PPV drops because denominator stays

large while numerator shrinks Thanks for keeping me honest with the math! The principle is

rock solid, but you’re absolutely right to check my calculations. This attention to detail is

exactly what makes a great physician! ■ Retry N in question 6 there is no mention of how

many people in the population. That’s where I am confused. Edit You’re ABSOLUTELY Right

• Question 6 is Missing Key Information! You caught a huge flaw in my question! Question 6

doesn’t give us: Total population size Actual sensitivity/specificity values Number of people

tested So technically, the answer should be “Cannot be determined” without more information!

Let Me Fix This With a Proper Question 6: Question 6 (Corrected): Prevalence Effect The HIV

test from Questions 1-3 (sensitivity 90%, specificity 94.4%) is used in two different

populations of 1,000 people each: Population A: HIV prevalence = 10% (100 people have

HIV) Population B: HIV prevalence = 1% (10 people have HIV) In which population will the

positive predictive value (PPV) be higher? A) Population A (10% prevalence) B) Population B

(1% prevalence) C) PPV will be the same in both D) Cannot be determined E) Depends on the

specificity

The General Principle (Without Specific Numbers): Even without exact calculations, you can

reason: When prevalence is higher: More people actually have the disease More true positives

in your positive results Higher PPV When prevalence is lower: Fewer people actually have the

disease False positives start to overwhelm true positives Lower PPV Your Critical Thinking is

Spot-On! You’re absolutely right to call out insufficient information in questions. On the real

USMLE, if a question doesn’t give you enough data to calculate an answer, “Cannot be

determined” is often the correct choice. This kind of careful analysis – checking whether you

actually have all the information needed – is exactly what separates good test-takers from great

ones. You’re thinking like a scientist, not just a memorizer! Thanks for keeping me honest! ■

Should I give you some better, more complete statistics questions to practice with?

17 year old, SVC syndrome, large mediastinal mass with pleural effusion, In adolescences look

for T cell leukemias, CD2, CD3, CD4, CD5, 7, 8 USUSALLY LESS THAN 10. BLASTS in

pleural fluid are ALL. Usually TdT CD3

Classic hodgkins is CD15 and CD30 can have mediastinal mass and SVC syn With Reed

sTernberge cells.

B-ALL usually occur in early childhood

CD33 and myeloperoxidase are maker for myeloid

Nitroprusside over infustion= aka cyanide toxicity = electron transport chain termination

MELANOMA: Pt. female, crusty, itchy breast lesion, ulcerated, erthyematous,

hyperpigmentation S-100 and HMB 45 + this Is neural crest cell origin markers

Appendicities acute = obstruction of the appendiceal lume

Pleural effusion: sterile exudate: due to normal glucose, normal pH even though the light

criteria for exudative effiusion is met, it is not considered complicated.

Newborne 1 month old, taking formula made with cows milk Develops loose stools: reason:

allergy: si

Baby develops loose stools after starting cows milk formula: histo: Eosinophilic infiltration in

the distal colon.

Person coming back from Mexico, ANOREXIA, DARK URINE, ,NAUSEA, FEVER, RT UQ

ABD PAIN = HEP A= HEPAOTCYTE SWELLING OR AKA BALLONING

DEGENERATION. CARDIOGENIC SHOCK: INC CAPILLARY WEDGE PRESSURE,

INC CVP, DEC CORONARY PERFUSION 2ND GENERATION ANTIPSYCHOTICS:

DOPAMINE 2 ANTAGONIST, AND A SEROTONIN 2A RECEPTOR ANTAGONIST.

GESTATIONAL/HEREDITARY DIABETES TYPE 2 OF THE YOUNG/ GENETIC

DEFECT IN GLUCOKINASE CLL = CD20 STREP = M PROTEIN =RESIST

PHAGOCYTOSIS HAEMOPHILUS INFLUENZE CAN CAUSE MENNIGITIS IS NOT

VACCINATED PT WITH JAUNDICE, N/V, ABD PAIN, INC TOTAL BILI, INC ALK

PHOS, INC AST/ALT + ANIT SMOOTH MUSCLE ANTIBODY = AUTOIMMUNE

HEPATITIS

MEASUREMENT OF BRONCHIAL WALL THICKNESS: = C/C+B+D ADRENAL MASS

LABS: HCO3- HIGH/K LOW/Na NORMAL

ABLATING THE CRISA TERMINALIS IN THE RT ATRIUM CAN CAUSE THE

PHRENIC ERVE TO BE SERVERED AND CAUSE A HIGHT HEMIDIAPHRAGM OR

ELEVATED RIGHT DIAPHARM.

IV NITRO: WHAT IT DOES: LVEDP INC/PERIPHERAL VENOUS CAPACITANCE, INC/

SYSTEMIC VAS RESISITANCE: DEC

AXONS: IF SEVERED DUE TO TRAUM PRESENT WITH AN AXONAL REACTION:

WALLERIAN DEGENERATION: CELL SWELLING, DISPERSIONOF THE NISSL

SUBSTANCE TO THE PERIPHERY OF THE CELL.

HERPES MENINGITIS: TEMPORAL LOBE SIGNIFICANT IN DX.

AUTOIMMUNE GASTRITIS: SERUM GASTRIN INC/GASTRIC PH INC GASTRIC

PARIETAL CELL MASS, DECREASED.

METOLAZONE: THIAZIDE DIURETIC, INC SODIUM DELIVERY TO DCT

IDOPATHIC PULMONARY FIBROSIS: TREAT WITH TRANSFORMING GROWTH

FACTOR BETA INHIBITORS IE: PIRFENIDONE IDOPATHIC PULMONARY FIBROSIS

CAN ALSO BE TREATED WITH : NINTEDANIB, A TYROSINE KINASE INHIBITOR

THAT INHIBITS PDGE, FGF AND VEGF. IPF: CHONIC, PROGRESSIVE FIBROTIC

LUNG DISEASE, PERSISTENT INFLAMMATIO, HYPERPLASIA OF TYPE 2

PNEUMOCYTES. RIGHT CORONARY ARTERY IN 90% OF PATIENT SUPPIES

BLOOD TO THE AV NODE, AND THE RIGHT VENTRICLE AND INFERIOR PORTION

OF THE LEFT VENTRICLE, AND THE SA NODE: IN AN MI WITH BRADYCARDIA,

THINK RCA

LEFT ANTERIOR DECENDING AKA LAD, SUPPLIES BLOOD TO L AND R BB AND

BUNDLE OF HIS. MI IN THE LAD CAUSES AV BLOCK MOBIZ TYPE II 2ND DEG/

LEFT MAIN CORONARY BIFURCATES INTO THE LAD AND LEFT CIRCUMFLEX

AND SUPPLIES THE LFT. LATERAL VENTRICLE. IN 40% THE LEFT CIRCUMFLEX

SUPPLIES THE SA NODE. BUT THE AV NODE ONLY 10 % OF THE TIME

COLCHINCIN: IS ADMINISTERED INITIALLY AT THE FIRST SIGNS OF GOUT

FLARE AND CAN BE REPEATED AN HOUR LATER. COLCHICINE BIND TO

TUBULIN AND INHIBITS ITS POLYMERIZATION INTO MICROTUBULES. IT

DISRUTS THE CYTOSKELETAL DEPENDENT FUNCTIONS SUCH AS CHEMOTAXIS

AND PHAGOCYTOSIS.

PT TREATED WITH BETA LACTAM, SULFONAMIDE, RIFAMPIN, PPI’S NASAID,

DIURETIC OR MCOYPLSAM AND LEGIONELLA CAN GET RASH, FEVER, DUE TO

NEW DRUG EXPOSURE ACUTE KIDNEY INJURY PYURIS, HEMATURIA, WBC

CASTS, EOSINOPHILIA OR URNIARY EOSINOPHILS KIDNEY BX =

INFLAMMATORY INTERSTITIAL INFLITRATE AND EDEMA WITH POSSIBLE

GRANULOMA FORMATION. FORMATION OF THE ATHEROMA: DIRECTILY

INVOLVED IN FIBROSE PORTION: =SMOOTH MUSCLE CELLS. PULMONARY

EDEMA: HISTOLOGY= ENGORGED CAPILLARIES AND ALVEOLI FILLED WITH

ACELLULAR MPINK MATERIAL

ACUTE TUBULAR NECROSIS IS DUE TO DECREASED RENAL PERFUSION DURING

CARIOGENIC SHOCK. AFFECTS THE RENAL MEDULLA, AND THE MOST

METABOLLICALLY ACTIVE SITES SUCH AS THE PROXIMAL TUBULE AND THICK

ASCENDING LIMB S/S= FLATTENING OF THE TUBULAR EPITHELIAL CELLS,

LOSS OF BRUSH BORDER, CELL NECROSIS, DENUDATION OF THE TUBULAR

BASEMENT MEMBRANE. MUDDY BROWN CASTS, PATHOGNOMONIC FOR ATN,

BUN/CREAT RATION LESS THAN 20 INDICATES INTRINSIC REANL AND

OLIGURIA. NEW DISEASE: SYSTEMIC MASTOCYTOSIS, LOOKS LIKE PCV, LOOKS

LIKE CARCINOID SYSTEMIC MASTOCYTOSIS =CLONAL MAST CELL

PROLIFERATION IN BONE MARROW, SKIN AND OTHER ORGANS, MUATIONS IN

KIT RECEPTOR TYROSINE KINASE. CELLS EXPRESE TRYPTASE: EXCESSIVE

HISTAMINE RELEASE MEDIATES, THE SYNCOPE, FLUSHING, H YPOTENSION,

UPRURITIUS AND URTICARIA, ALONG WITH INC GASTRIC ACID SECRETION.

RHEUMATOID ARTHRITIS: PAIN, SWELLING AND MORNING STIFFNESS IN

MULITPLE JOING, PIP, MICP MITP AND SPARES THE DIP SYSTEMIC FEVER, WT

LOSS, ANEMIA OF CHORNIC DIS. CERVIAL SPINE INVOLVEMENT: SUBLUXSTION

AND CORD COMPRESSION + RH FACTOR AND ANTI CCP ANTIBODIES, C

REACTIVE PROTIEN + ESR HIGH, X RAY SOFT TISSUE SWELLING, JOING SPACE

NARROWING

DIFFUSE ESOPHAGEAL SPASMS: NEW! IN DES SEVERAL SEGMENTS OF THE

ESOPHAGUS CONTRACT INAPPROPRIATELY AT THE SAME TIME, NON

PERSITALITC OCNTRACTION AND CORKSCREW ESOPHAGUS ON MARIUM

ESOPHAGORAM, TROUBLE WITH SWALLOWING, CHEST PAIN, HEARTBURN, :

PATHO= IMPARIED INBHIBITORY NERUOTRANSMISSION IN THE MYENTERIC

PLEXUS.

DIALYSIS: THINK AMYLOIDOSIS= TISSUE DEPOSITION OF BETA 2

MICROGLOBIULIN

PLASMA CELL AMYLOIDOSIS IMMUNOGLOBULIN LIGHT CHAINS CHRONIC DX =

AA AMYLOID ELDERLY = TRANSTHYRETIN, AKA PREALBUMIN ATTR

THROMBOSIS IN RT. OVARIAN VEIN CAN TRAVEL TO IVC. The patient undergoes a

total thyroidectomy and the day after their calcium drops below normal the medication that

they should receive is calcitriol which is the active form of vitamin D which is better than

giving calcidiol because calcidiol requires a parathyroid hormone to into the active form of

vitamin D.

DUChanes muscular dystrophy deletion of the dystrophin gene that encodes for the dystrophin

protein on the X chromosome P21 the most common mutation deletions that are not a multiple

of three change the reading frame and cause A-frame shift mutation which causes a

nonfunctional protein in contrast deletions that are multiples of three preserve the reading

frame but result in a truncated but functional protein and a milder clinical phenotype like

beckers. Dystrophin is a structural component of skeletal muscle fibers that provides

mechanical stability to the sarcolemma It links a component of the cytoskeleton actin to the

transmembrane proteins alpha and beta dystrophic glycans that are connected to the

extracellular matrix. Loss of the dystrophin results in cellular injury or myonecrosis

Menningioma

Phenylephrine: is an alpha one agonist: it works as a (G alpha q )on peripheral

vasoconstriction, urethral constriction and pupillary dilation. It increases IP3 It is given in

patient who are in shock, with low BP and compensatory tachycardia. Heres what happens. It

vasocontricts to raise BP, but will also raise HR, however, to keep the breaks on the baro

receptors kick in to lower heart rate and protect body from death. So beta one and muscarinic 2

kick in and reduce sympathetic stimulation of beta 1 and increased parasympathetic

stimulation of muscarinic 2 trigger a dec in cAMP leading to a dec in HR and contractility. The

temporal lobe injury can cause superior quadrantanopia due to Meyers loop being there. Ehlers

Danlos= coarctation of the aorta complications HITT type II =antiplatelet 4 heparin antibodies

Menstrual Cycle & Congenital Adrenal Hyperplasia – The Whole Nine! ■ Perfect choices!

These are MASSIVE USMLE topics and they actually connect beautifully. Let’s start with the

menstrual cycle foundation, then dive into CAH! The Menstrual Cycle – Master Framework

The Big Picture Players: Hypothalamus: GnRH (pulsatile release) Anterior pituitary: FSH and

LH Ovaries: Estrogen and progesterone Endometrium: Responds to hormones The Two Cycles

Running Simultaneously: Ovarian cycle: Follicular → Ovulation → Luteal Endometrial cycle:

Proliferative → Secretory → Menstrual Phase 1: Follicular Phase (Days 1-14) What’s

Happening in Ovaries: FSH rises (from low estrogen feedback) Multiple follicles start

developing One dominant follicle emerges Estrogen production increases progressively

Hormone Pattern: FSH: High initially, then drops as estrogen rises LH: Low baseline with

small rise Estrogen: Gradually increasing (from follicle) Progesterone: Low (no corpus luteum

yet) What’s Happening in Uterus: Proliferative phase (endometrial growth) Estrogen stimulates

endometrial thickening Glands become longer and straighter The LH Surge (Day 14) The

Trigger: High estrogen (>200 pg/mL for 48+ hours) Switches from negative to positive

feedback Massive LH surge (and smaller FSH surge) What the LH Surge Does: Triggers

ovulation (within 24-36 hours) Completes meiosis I in oocyte Luteinizes granulosa cells

Initiates corpus luteum formation Phase 2: Luteal Phase (Days 15-28) What’s Happening in

Ovaries: Corpus luteum produces progesterone + estrogen LH and FSH suppressed (negative

feedback) If no pregnancy: Corpus luteum degenerates Hormone Pattern: Progesterone: HIGH

(dominant hormone) Estrogen: Moderate (secondary peak) LH/FSH: Suppressed If no hCG:

All hormones crash → menstruation What’s Happening in Uterus: Secretory phase (preparing

for implantation) Progesterone makes glands coiled and secretory Endometrium becomes

receptive to embryo USMLE Clinical Scenarios – Menstrual Cycle Scenario 1: Ovulation

Timing A woman has 28-day cycles. On which day would you expect peak LH levels?

Answer: Day 14 (LH surge triggers ovulation mid-cycle) Scenario 2: Hormone Levels Day 21

labs in a woman with 28-day cycles show high progesterone. What does this indicate? Answer:

Ovulation occurred (corpus luteum producing progesterone) Scenario 3: Anovulation A

woman has irregular cycles with consistently low progesterone levels. What’s the most likely

problem? Answer: Anovulation (no corpus luteum formation)

Congenital Adrenal Hyperplasia (CAH) – The Enzyme Defects The Steroid Pathway

(Simplified for USMLE): Cholesterol ↓ (StAR protein) Pregnenolone ↓ (3β-hydroxysteroid

dehydrogenase) Progesterone ↓ (17α-hydroxylase) 17-hydroxyprogesterone ↓

(21-hydroxylase) ← MOST COMMON DEFECT 11-deoxycortisol ↓ (11β-hydroxylase)

Cortisol Side branch: 17-hydroxyprogesterone → Androgens (via 17,20-lyase) The Three

Main Types of CAH 1. 21-Hydroxylase Deficiency (90% of cases) What’s blocked:

17-hydroxyprogesterone → 11-deoxycortisol What accumulates: 17-hydroxyprogesterone

What’s deficient: Cortisol + Aldosterone Clinical presentation: Classic (severe): Ambiguous

genitalia in females, salt-wasting Non-classic (mild): Hirsutism, acne, irregular menses Lab

findings: ↑ 17-hydroxyprogesterone (diagnostic) ↑ ACTH (from low cortisol feedback) ↑

Androgens (shunted pathway) 2. 11β-Hydroxylase Deficiency (5% of cases) What’s blocked:

11-deoxycortisol → Cortisol What accumulates: 11-deoxycortisol + 11-deoxycorticosterone

What’s deficient: Cortisol Clinical presentation: Virilization (like 21-hydroxylase)

Hypertension (from 11-deoxycorticosterone) NO salt-wasting (mineralocorticoid activity

preserved) 3. 17α-Hydroxylase Deficiency (Rare) What’s blocked: Pregnenolone/Progesterone

→ 17-hydroxy compounds What accumulates: Mineralocorticoids What’s deficient: Cortisol +

Sex hormones Clinical presentation: Hypertension (excess mineralocorticoids) Sexual

infantilism (no sex hormone production) 46,XY: Female external genitalia 46,XX: Primary

amenorrhea USMLE Clinical Scenarios – CAH Scenario 1: Classic 21-Hydroxylase Deficiency

Newborn female with ambiguous genitalia, vomiting, and dehydration.

17-hydroxyprogesterone is markedly elevated. Question: What enzyme is deficient? Answer:

21-hydroxylase (salt-wasting CAH) Scenario 2: Hypertensive CAH Child with virilization

AND hypertension. 11-deoxycortisol levels are elevated. Question: What distinguishes this

from 21-hydroxylase deficiency? Answer: 11β-hydroxylase deficiency causes hypertension

(not salt-wasting) Scenario 3: Adult Woman 25-year-old woman with hirsutism and irregular

periods. Mild elevation of 17-hydroxyprogesterone. Question: What’s the most likely

diagnosis? Answer: Non-classic 21-hydroxylase deficiency CAH The Connection: CAH and

Reproductive Function How CAH Affects Reproduction: Excess androgens → Virilization,

hirsutism Disrupted HPG axis → Irregular cycles PCOS-like symptoms in non-classic CAH

Infertility from anovulation Key USMLE Concept: CAH should be in your differential for:

Hirsutism in women Irregular menstrual cycles Infertility with hyperandrogenism Want me to

dive deeper into any specific aspect? We could tackle: Detailed hormone feedback loops More

CAH enzyme defects Treatment approaches How to differentiate from PCOS

In aceties both the capillary oncotic pressure and portal capillary permeabiity are normal. High

lipophilic drugs are not eliminated in the kidney. Infants with hypothyroidism can have poor or

decreased absorption of levothyroid if they are taking Iron supplements. A patient with chrons

disease can have gallstones due to inflammation of the terminal ileum causing decreased bile

acid reabsorption, aka bile wasting. Ataxia telangiectasia; radiation indeced genetic mutation/

AR disorder/cerebellar atrophy, oculocutaneous /pts have severe immunodeiiency with

repeated sinopulmonary infections, the risk o caner is increased significantly beuase of

Inefficient DNA repair USMLE High-Yield Diseases by System ■ NEUROLOGICAL

SYSTEM Alzheimer Disease Progressive dementia with neurofibrillary tangles (tau) and

amyloid plaques (Aβ) Most common cause of dementia Acetylcholine deficiency →

cholinesterase inhibitors Amyotrophic Lateral Sclerosis (ALS) Motor neuron disease affecting

upper and lower motor neurons Progressive weakness, fasciculations, bulbar symptoms

Stephen Hawking disease Bell’s Palsy Idiopathic facial nerve (CN VII) paralysis Unilateral

facial droop, inability to close eye Most cases recover spontaneously Guillain-Barré Syndrome

Acute inflammatory demyelinating polyneuropathy Ascending paralysis after infection CSF:

high protein, normal cells Huntington Disease Autosomal dominant CAG repeat expansion

Chorea, dementia, psychiatric symptoms Caudate nucleus atrophy Meningitis (Bacterial) S.

pneumoniae (adults), N. meningitidis (young adults), H. influenzae (unvaccinated) Fever, neck

stiffness, altered mental status CSF: high WBC, low glucose, high protein Migraine Unilateral

throbbing headache with aura Triggers: stress, foods, hormones Treatment: triptans, preventive

medications Multiple Sclerosis Autoimmune demyelinating disease Plaques in white matter,

oligoclonal bands in CSF Relapsing-remitting pattern most common Myasthenia Gravis

Autoimmune acetylcholine receptor antibodies Weakness worsens with use, improves with

rest Positive edrophonium test Parkinson Disease Loss of dopaminergic neurons in substantia

nigra Resting tremor, rigidity, bradykinesia, postural instability Lewy bodies (α-synuclein)

Seizure Disorders Focal vs generalized seizures Status epilepticus: >5 minutes or recurrent

without recovery First-line: phenytoin, levetiracetam Stroke (Ischemic) Thrombotic vs embolic

tPA within 3-4.5 hours if eligible Risk factors: HTN, DM, smoking, Afib Stroke

(Hemorrhagic) Intracerebral or subarachnoid hemorrhage Sudden severe headache (“worst of

life”) CT shows blood immediately

❤■ CARDIOVASCULAR SYSTEM Acute Coronary Syndrome STEMI, NSTEMI, unstable

angina Troponin elevation in MI Treatment: dual antiplatelet, anticoagulation Aortic Stenosis

Most common valvular disease in elderly Syncope, angina, heart failure (SAD symptoms)

Systolic murmur radiating to carotids Atrial Fibrillation Most common arrhythmia Irregularly

irregular rhythm Anticoagulation based on CHA2DS2-VASc score Congestive Heart Failure

Systolic (HFrEF) vs diastolic (HFpEF) ACE inhibitors, beta-blockers, diuretics

BNP/NT-proBNP elevated Hypertension Primary (95%) vs secondary (5%) Target <130/80 in

most patients First-line: ACE inhibitors, ARBs, CCBs, thiazides Mitral Regurgitation Chronic:

mitral valve prolapse most common cause Acute: papillary muscle rupture post-MI

Holosystolic murmur radiating to axilla Myocardial Infarction STEMI: complete occlusion, ST

elevation NSTEMI: partial occlusion, troponin positive Primary PCI preferred over

fibrinolytics Pericarditis Sharp chest pain worse with lying flat Pericardial friction rub ST

elevation in all leads (vs MI in specific leads) Peripheral Artery Disease Claudication, rest

pain, tissue loss Ankle-brachial index <0.9 Risk factor modification, antiplatelet therapy

Pulmonary Embolism Wells score for pre-test probability D-dimer sensitive but not specific

CT pulmonary angiogram gold standard Ventricular Tachycardia Wide complex tachycardia

Hemodynamically unstable → immediate cardioversion Stable → amiodarone or lidocaine

■ PULMONARY SYSTEM Asthma Reversible airway obstruction Wheezing, cough,

dyspnea Beta-2 agonists, inhaled corticosteroids Chronic Obstructive Pulmonary Disease

(COPD) Emphysema + chronic bronchitis Smoking most common cause GOLD staging based

on FEV1 Lung Cancer Leading cause of cancer death Adenocarcinoma most common type

Smoking strongest risk factor Pneumonia (Community-Acquired) S. pneumoniae most

common Fever, productive cough, consolidation on CXR Empiric antibiotics based on severity

Pneumonia (Hospital-Acquired) Pseudomonas, Staph aureus, Klebsiella Ventilator-associated

pneumonia subset Broad-spectrum antibiotics initially Pneumothorax Primary: young, tall, thin

males Secondary: underlying lung disease Tension pneumothorax is emergency Pulmonary

Fibrosis Progressive scarring of lungs Restrictive pattern on PFTs Honeycombing on CT

Sarcoidosis Multisystem granulomatous disease Bilateral hilar lymphadenopathy Noncaseating

granulomas Sleep Apnea Obstructive vs central Obesity major risk factor CPAP first-line

treatment

■■ GASTROINTESTINAL SYSTEM Appendicitis Right lower quadrant pain, McBurney’s

point Rovsing sign, psoas sign Appendectomy treatment of choice Cholangitis Charcot’s triad:

fever, jaundice, RUQ pain E. coli most common organism ERCP for drainage Cholecystitis

Gallbladder inflammation Murphy’s sign positive Cholecystectomy definitive treatment

Cirrhosis End-stage liver disease Portal hypertension, ascites, varices Child-Pugh and MELD

scores Crohn Disease Transmural inflammation, skip lesions Terminal ileum most common

site Fistulas, strictures, perianal disease Diverticulitis Left-sided in Western countries Fever,

LLQ pain, leukocytosis CT scan for diagnosis Gastroesophageal Reflux Disease (GERD)

Heartburn, regurgitation Barrett’s esophagus complication PPIs first-line treatment Hepatitis B

DNA virus, chronic infection possible HBsAg positive in acute/chronic Vaccination available

Hepatitis C RNA virus, high chronicity rate Leading indication for liver transplant

Direct-acting antivirals curative Inflammatory Bowel Disease Crohn’s vs ulcerative colitis

Bloody diarrhea, weight loss Increased colorectal cancer risk Irritable Bowel Syndrome

Functional disorder Rome criteria for diagnosis No structural abnormalities Pancreatitis

(Acute) Alcohol and gallstones most common causes Severe epigastric pain radiating to back

Lipase more specific than amylase Peptic Ulcer Disease H. pylori and NSAIDs main causes

Duodenal vs gastric ulcers Triple therapy for H. pylori Ulcerative Colitis Continuous

inflammation from rectum Bloody diarrhea, urgency Crypt abscesses, no skip lesions

■■ MUSCULOSKELETAL SYSTEM Ankylosing Spondylitis HLA-B27 associated

Sacroiliitis, bamboo spine Young males predominantly Gout Uric acid crystal arthropathy

Podagra (first MTP joint) Negatively birefringent crystals Osteoarthritis Degenerative joint

disease Weight-bearing joints affected Heberden’s and Bouchard’s nodes Osteomyelitis S.

aureus most common Fever, bone pain, elevated ESR/CRP MRI most sensitive imaging

Osteoporosis T-score ≤ -2.5 on DEXA Hip and vertebral fractures Bisphosphonates first-line

Polymyalgia Rheumatica Shoulder and hip girdle pain/stiffness Age >50, elevated ESR

Associated with giant cell arteritis Pseudogout Calcium pyrophosphate dihydrate crystals

Chondrocalcinosis on X-ray Positively birefringent crystals Rheumatoid Arthritis Symmetric

polyarthritis Morning stiffness >1 hour Rheumatoid factor and anti-CCP positive Septic

Arthritis S. aureus most common Hot, swollen, painful joint Joint aspiration with >50,000

WBCs Systemic Lupus Erythematosus ANA positive, anti-dsDNA specific Malar rash,

photosensitivity Multisystem involvement

■ ENDOCRINE SYSTEM Addison Disease Primary adrenal insufficiency

Hyperpigmentation, hypotension High ACTH, low cortisol Cushing Syndrome Excess cortisol

Central obesity, purple striae, moon facies Dexamethasone suppression test Diabetes Mellitus

Type 1 Autoimmune beta cell destruction Ketosis-prone, insulin dependent Anti-GAD,

anti-islet cell antibodies Diabetes Mellitus Type 2 Insulin resistance + relative deficiency

Obesity, family history Metformin first-line Diabetic Ketoacidosis Glucose >250, ketones,

anion gap acidosis Type 1 diabetes complication Insulin, fluids, potassium replacement Graves

Disease Hyperthyroidism with diffuse goiter Exophthalmos, pretibial myxedema TSI

(thyroid-stimulating immunoglobulin) positive Hashimoto Thyroiditis Most common cause of

hypothyroidism Anti-TPO and anti-thyroglobulin antibodies Goitrous initially, then atrophic

Hyperparathyroidism “Stones, bones, groans, psychiatric moans” Hypercalcemia, high or

normal PTH Parathyroid adenoma most common Hyperthyroidism Weight loss, palpitations,

heat intolerance Suppressed TSH, elevated T3/T4 Graves disease most common cause

Hypothyroidism Weight gain, fatigue, cold intolerance Elevated TSH, low T4 Levothyroxine

replacement therapy Pheochromocytoma “Rule of 10s” – 10% malignant, bilateral,

extra-adrenal Episodic hypertension, headache, sweating 24-hour urine

catecholamines/metanephrines Syndrome of Inappropriate ADH (SIADH) Hyponatremia with

concentrated urine Lung cancer, CNS disorders Fluid restriction first-line

■ RENAL/GENITOURINARY SYSTEM Acute Kidney Injury Prerenal, intrinsic, postrenal

causes Creatinine rise ≥0.3 mg/dL or ≥50% FENa helpful in differentiating causes Acute

Tubular Necrosis Ischemic or nephrotoxic causes Muddy brown casts in urine Most common

cause of hospital-acquired AKI Benign Prostatic Hyperplasia Lower urinary tract symptoms

PSA may be elevated Alpha-blockers, 5-alpha reductase inhibitors Chronic Kidney Disease

GFR <60 for >3 months Diabetes and hypertension leading causes Complications: anemia,

bone disease, cardiovascular Glomerulonephritis (Acute) Post-infectious (post-streptococcal)

Hematuria, proteinuria, hypertension Low complement levels Nephrotic Syndrome Proteinuria

>3.5 g/day Hypoalbuminemia, edema, hyperlipidemia Minimal change disease in children

Polycystic Kidney Disease Autosomal dominant most common Bilateral enlarged kidneys with

cysts Associated with berry aneurysms Prostate Cancer Most common cancer in men Elevated

PSA, abnormal DRE Gleason score for grading Pyelonephritis Upper urinary tract infection

Fever, flank pain, costovertebral angle tenderness E. coli most common organism Renal Cell

Carcinoma Most common primary kidney tumor Hematuria, flank pain, palpable mass Clear

cell type most common Urinary Tract Infection Cystitis vs pyelonephritis E. coli most

common organism Nitrites and leukocyte esterase positive

■ REPRODUCTIVE SYSTEM Endometriosis Ectopic endometrial tissue Dysmenorrhea,

dyspareunia, infertility Chocolate cysts on ovaries Erectile Dysfunction Vascular, neurologic,

psychogenic causes PDE-5 inhibitors first-line Cardiovascular risk assessment important

Fibroids (Leiomyomas) Benign smooth muscle tumors Heavy menstrual bleeding, pelvic

pressure Most common pelvic tumor in women Ovarian Cancer Epithelial type most common

CA-125 tumor marker BRCA mutations increase risk Polycystic Ovary Syndrome (PCOS)

Hyperandrogenism, oligoovulation, polycystic ovaries Insulin resistance, metabolic syndrome

Metformin, OCPs for treatment Preeclampsia Hypertension and proteinuria after 20 weeks

Severe features: BP ≥160/110, symptoms Delivery is definitive treatment Prostatitis Acute vs

chronic, bacterial vs non-bacterial Pelvic pain, urinary symptoms Fluoroquinolones for

bacterial type Sexually Transmitted Infections Chlamydia, gonorrhea most common bacterial

HPV most common viral Screening and partner treatment important Testicular Cancer Most

common cancer in young men Painless testicular mass AFP, β-hCG tumor markers Urethritis

Gonococcal vs non-gonococcal Dysuria, urethral discharge Azithromycin + ceftriaxone for

gonorrhea

■ HEMATOLOGIC/ONCOLOGIC SYSTEM Acute Lymphoblastic Leukemia (ALL) Most

common childhood leukemia Lymphoblasts >20% in bone marrow B-cell vs T-cell types

Acute Myeloid Leukemia (AML) Myeloblasts >20% in bone marrow Auer rods

pathognomonic Cytogenetics important for prognosis Chronic Lymphocytic Leukemia (CLL)

Most common leukemia in adults Smudge cells on peripheral smear Watch and wait often

appropriate Chronic Myeloid Leukemia (CML) Philadelphia chromosome (BCR-ABL)

Chronic, accelerated, blast phases Imatinib (tyrosine kinase inhibitor) Hodgkin Lymphoma

Reed-Sternberg cells Bimodal age distribution Better prognosis than NHL Iron Deficiency

Anemia Microcytic, hypochromic Low ferritin, high TIBC GI bleeding workup in

men/postmenopausal women Multiple Myeloma Plasma cell malignancy CRAB criteria

(hypercalcemia, renal, anemia, bone) Monoclonal protein in serum/urine Non-Hodgkin

Lymphoma More common than Hodgkin B-cell vs T-cell types Extranodal involvement

common Sickle Cell Disease Hemoglobin S (HbS) Vaso-occlusive crises Hydroxyurea reduces

crises Thrombocytopenia ITP, TTP, HUS major causes Platelet count <150,000 Bleeding risk

increases <50,000

■ INFECTIOUS DISEASES Cellulitis S. pyogenes, S. aureus most common Erythema,

warmth, swelling Antibiotics based on severity Endocarditis Acute (S. aureus) vs subacute

(Viridans strep) Duke criteria for diagnosis Blood cultures before antibiotics HIV/AIDS CD4

count determines opportunistic infections Highly active antiretroviral therapy (HAART) PCP

prophylaxis when CD4 <200 Influenza Seasonal epidemics, pandemic potential Oseltamivir

within 48 hours Annual vaccination recommended Meningitis Bacterial vs viral vs fungal

Lumbar puncture for diagnosis Empiric antibiotics before culture results Pneumonia

Community vs hospital-acquired Atypical organisms (Mycoplasma, Chlamydia) Chest X-ray

for diagnosis Sepsis SIRS + infection qSOFA score for bedside assessment Early antibiotics

and fluid resuscitation Tuberculosis Mycobacterium tuberculosis Latent vs active infection

DOTS (directly observed therapy) Urinary Tract Infection Cystitis vs pyelonephritis

Uncomplicated vs complicated Nitrofurantoin for uncomplicated cystitis

■ PSYCHIATRY Anxiety Disorders Generalized anxiety, panic, phobias SSRIs first-line

treatment CBT effective therapy Bipolar Disorder Manic and depressive episodes Lithium,

valproate, antipsychotics Type I vs Type II Depression Major depressive disorder SSRIs,

SNRIs first-line Psychotherapy adjunct Schizophrenia Positive and negative symptoms

Antipsychotics mainstay of treatment Chronic, debilitating course Substance Use Disorders

Alcohol, opioids, stimulants Withdrawal syndromes Medication-assisted treatment

____________-

USMLE High-Yield Medications by System ■ NEUROLOGICAL MEDICATIONS

Acetazolamide Receptor/Target: Carbonic anhydrase inhibitor Location: Choroid plexus,

kidneys MOA: Reduces CSF production, decreases intracranial pressure Use: Idiopathic

intracranial hypertension, altitude sickness Carbamazepine Receptor/Target: Voltage-gated

sodium channels (use-dependent blockade) Location: Neuronal membranes MOA: Stabilizes

inactivated sodium channels, reduces repetitive firing Use: Focal seizures, trigeminal

neuralgia, bipolar disorder Donepezil Receptor/Target: Acetylcholinesterase inhibitor

Location: Synaptic cleft (CNS) MOA: Increases acetylcholine levels by preventing breakdown

Use: Alzheimer’s disease Ethosuximide Receptor/Target: T-type calcium channels (Cav3.1)

Location: Thalamic neurons MOA: Blocks T-type calcium channels, prevents 3-Hz

spike-wave Use: Absence seizures (first-line) Gabapentin Receptor/Target: α2δ subunit of

voltage-gated calcium channels Location: Presynaptic nerve terminals MOA: Reduces calcium

influx, decreases neurotransmitter release Use: Neuropathic pain, partial seizures

Levetiracetam Receptor/Target: SV2A protein (synaptic vesicle protein) Location: Presynaptic

terminals MOA: Inhibits vesicle exocytosis, reduces neurotransmitter release Use:

Broad-spectrum anticonvulsant Levodopa/Carbidopa Receptor/Target: Dopamine precursor +

AADC inhibitor Location: CNS (levodopa crosses BBB, carbidopa doesn’t) MOA: Increases

dopamine in brain, carbidopa prevents peripheral conversion Use: Parkinson’s disease

Phenytoin Receptor/Target: Voltage-gated sodium channels (use-dependent) Location:

Neuronal membranes MOA: Stabilizes inactivated sodium channels, blocks high-frequency

firing Use: Tonic-clonic seizures, status epilepticus Sumatriptan Receptor/Target: 5-HT1B/1D

receptors Location: Cerebral blood vessels, trigeminal nerve MOA: Vasoconstriction, inhibits

trigeminal nerve activation Use: Acute migraine treatment Valproic Acid Receptor/Target:

Multiple targets (sodium channels, GABA transaminase, T-type calcium channels) Location:

Neuronal membranes, GABA synapses MOA: Broad spectrum – sodium channel blockade,

increased GABA, calcium channel blockade Use: Broad-spectrum anticonvulsant, bipolar

disorder, migraine prophylaxis

❤■ CARDIOVASCULAR MEDICATIONS Amlodipine Receptor/Target: L-type calcium

channels (Cav1.2) Location: Vascular smooth muscle, cardiac muscle MOA: Blocks calcium

influx, causes vasodilation and negative inotropy Use: Hypertension, angina Atenolol

Receptor/Target: β1-adrenergic receptors (selective) Location: Heart (SA node, myocardium)

MOA: Blocks β1 receptors, decreases heart rate and contractility Use: Hypertension, angina,

post-MI Atorvastatin Receptor/Target: HMG-CoA reductase Location: Liver (hepatocytes)

MOA: Inhibits cholesterol synthesis, upregulates LDL receptors Use: Hyperlipidemia,

cardiovascular risk reduction Digoxin Receptor/Target: Na+/K+-ATPase pump Location:

Cardiac myocytes MOA: Inhibits pump → increased intracellular Na+ → increased Ca2+ →

positive inotropy Use: Heart failure, atrial fibrillation (rate control) Enalapril Receptor/Target:

Angiotensin-converting enzyme (ACE) Location: Lungs, kidneys, blood vessels MOA: Blocks

conversion of angiotensin I to II, decreases aldosterone Use: Hypertension, heart failure,

post-MI Furosemide Receptor/Target: Na+/K+/2Cl− cotransporter (NKCC2) Location: Thick

ascending limb of loop of Henle MOA: Blocks sodium reabsorption, promotes diuresis Use:

Heart failure, edema, hypertension Heparin Receptor/Target: Antithrombin III (cofactor)

Location: Bloodstream MOA: Enhances antithrombin III activity, inactivates thrombin and

factor Xa Use: Anticoagulation (DVT, PE, ACS) Lidocaine Receptor/Target: Voltage-gated

sodium channels Location: Cardiac myocytes (Purkinje fibers) MOA: Use-dependent sodium

channel blockade, Class IB antiarrhythmic Use: Ventricular arrhythmias Metoprolol

Receptor/Target: β1-adrenergic receptors (selective) Location: Heart MOA: Blocks β1

receptors, decreases heart rate and contractility Use: Hypertension, heart failure, post-MI

Nitroglycerin Receptor/Target: Guanylyl cyclase (via NO release) Location: Vascular smooth

muscle MOA: Releases NO → increased cGMP → venodilation (preload reduction) Use:

Angina, acute coronary syndrome Propranolol Receptor/Target: β1 and β2-adrenergic

receptors (non-selective) Location: Heart, blood vessels, lungs MOA: Blocks all β receptors,

decreases heart rate and contractility Use: Hypertension, migraine prophylaxis, performance

anxiety Warfarin Receptor/Target: Vitamin K epoxide reductase Location: Liver MOA:

Inhibits vitamin K recycling, decreases synthesis of factors II, VII, IX, X Use: Long-term

anticoagulation (atrial fibrillation, mechanical valves)

■ PULMONARY MEDICATIONS Albuterol Receptor/Target: β2-adrenergic receptors

Location: Bronchial smooth muscle MOA: Gs → increased cAMP → smooth muscle

relaxation → bronchodilation Use: Acute asthma/COPD exacerbations Beclomethasone

Receptor/Target: Glucocorticoid receptors Location: Airway epithelium, inflammatory cells

MOA: Anti-inflammatory, reduces airway hyperresponsiveness Use: Asthma controller

therapy Ipratropium Receptor/Target: M3 muscarinic receptors (antagonist) Location:

Bronchial smooth muscle MOA: Blocks acetylcholine → prevents bronchoconstriction Use:

COPD, asthma (adjunct) Montelukast Receptor/Target: Leukotriene D4 (LTD4) receptors

Location: Bronchial smooth muscle, inflammatory cells MOA: Blocks leukotriene-induced

bronchoconstriction and inflammation Use: Asthma, allergic rhinitis Prednisone

Receptor/Target: Glucocorticoid receptors Location: Multiple tissues (lungs, immune cells)

MOA: Anti-inflammatory, immunosuppressive Use: Asthma/COPD exacerbations,

inflammatory conditions Salmeterol Receptor/Target: β2-adrenergic receptors (long-acting)

Location: Bronchial smooth muscle MOA: Long-acting bronchodilation via cAMP Use:

Asthma/COPD maintenance therapy Theophylline Receptor/Target: Phosphodiesterase

inhibitor, adenosine receptor antagonist Location: Bronchial smooth muscle MOA: Increases

cAMP levels, bronchodilation Use: Asthma/COPD (third-line, narrow therapeutic window)

■■ GASTROINTESTINAL MEDICATIONS Bismuth Subsalicylate Receptor/Target:

Multiple mechanisms Location: GI tract MOA: Anti-inflammatory, antimicrobial, protective

coating Use: Peptic ulcer disease (H. pylori), traveler’s diarrhea Esomeprazole

Receptor/Target: H+/K+-ATPase (proton pump) Location: Gastric parietal cells MOA:

Irreversibly inhibits proton pump, reduces acid production Use: GERD, peptic ulcer disease,

H. pylori eradication Loperamide Receptor/Target: µ-opioid receptors (peripheral) Location:

GI tract (doesn’t cross BBB) MOA: Decreases GI motility, increases transit time Use: Diarrhea

(symptomatic relief) Metoclopramide Receptor/Target: D2 dopamine receptors (antagonist)

Location: GI tract, chemoreceptor trigger zone MOA: Promotes gastric emptying, antiemetic

Use: Gastroparesis, nausea/vomiting Omeprazole Receptor/Target: H+/K+-ATPase (proton

pump) Location: Gastric parietal cells MOA: Irreversibly inhibits proton pump Use: GERD,

peptic ulcer disease Ondansetron Receptor/Target: 5-HT3 receptors (antagonist) Location:

Chemoreceptor trigger zone, GI tract MOA: Blocks serotonin-induced nausea/vomiting Use:

Chemotherapy-induced nausea, postoperative nausea Ranitidine (Note: Withdrawn due to

NDMA contamination) Receptor/Target: H2 histamine receptors Location: Gastric parietal

cells MOA: Blocks histamine-stimulated acid production Use: GERD, peptic ulcer disease

Sucralfate Receptor/Target: Physical barrier formation Location: GI mucosa (ulcer sites)

MOA: Forms protective barrier over ulcers Use: Peptic ulcer disease

■ ENDOCRINE MEDICATIONS Desmopressin (DDAVP) Receptor/Target: V2 vasopressin

receptors Location: Collecting duct principal cells MOA: Increases cAMP → inserts

aquaporin-2 channels → water reabsorption Use: Central diabetes insipidus, nocturnal enuresis

Glipizide Receptor/Target: ATP-sensitive K+ channels (SUR1 subunit) Location: Pancreatic

β-cells MOA: Closes K+ channels → depolarization → Ca2+ influx → insulin release Use:

Type 2 diabetes mellitus Insulin Receptor/Target: Insulin receptors (tyrosine kinase) Location:

Muscle, liver, adipose tissue MOA: Promotes glucose uptake, glycogen synthesis, lipogenesis

Use: Type 1 DM, Type 2 DM, diabetic ketoacidosis Levothyroxine Receptor/Target: Thyroid

hormone receptors (nuclear) Location: Multiple tissues MOA: Thyroid hormone replacement,

increases metabolic rate Use: Hypothyroidism Metformin Receptor/Target: AMP-activated

protein kinase (AMPK) Location: Liver, muscle, intestine MOA: Decreases hepatic glucose

production, increases peripheral glucose uptake Use: Type 2 diabetes mellitus (first-line)

Pioglitazone Receptor/Target: PPARγ (peroxisome proliferator-activated receptor γ) Location:

Adipose tissue, muscle, liver MOA: Increases insulin sensitivity, glucose uptake Use: Type 2

diabetes mellitus Prednisone Receptor/Target: Glucocorticoid receptors Location: Multiple

tissues MOA: Anti-inflammatory, immunosuppressive, metabolic effects Use: Inflammatory

conditions, adrenal insufficiency

■ RENAL/GENITOURINARY MEDICATIONS Acetazolamide Receptor/Target: Carbonic

anhydrase Location: Proximal convoluted tubule MOA: Inhibits carbonic anhydrase →

decreased H+ secretion and Na+ reabsorption Use: Glaucoma, altitude sickness, metabolic

alkalosis Amiloride Receptor/Target: Epithelial sodium channels (ENaC) Location: Collecting

duct principal cells MOA: Blocks sodium reabsorption, potassium-sparing Use: Hypertension,

heart failure (with other diuretics) Furosemide Receptor/Target: Na+/K+/2Cl− cotransporter

(NKCC2) Location: Thick ascending limb of loop of Henle MOA: Blocks sodium reabsorption

→ powerful diuresis Use: Heart failure, edema, hypertension Hydrochlorothiazide (HCTZ)

Receptor/Target: Na+/Cl− cotransporter (NCCT) Location: Distal convoluted tubule MOA:

Blocks sodium reabsorption, promotes calcium reabsorption Use: Hypertension, heart failure

Spironolactone Receptor/Target: Mineralocorticoid receptors (antagonist) Location: Collecting

duct principal cells MOA: Blocks aldosterone action, potassium-sparing diuretic Use: Heart

failure, hypertension, hyperaldosteronism Triamterene Receptor/Target: Epithelial sodium

channels (ENaC) Location: Collecting duct MOA: Blocks sodium channels, potassium-sparing

Use: Hypertension (combination with HCTZ)

■ REPRODUCTIVE MEDICATIONS Clomiphene Receptor/Target: Estrogen receptors

(selective modulator) Location: Hypothalamus, pituitary MOA: Blocks estrogen negative

feedback → increased FSH/LH → ovulation Use: Infertility (anovulation) Ethinyl Estradiol

Receptor/Target: Estrogen receptors Location: Multiple tissues MOA: Estrogen

replacement/supplementation Use: Oral contraceptives, hormone replacement therapy

Finasteride Receptor/Target: 5α-reductase type II Location: Prostate, hair follicles MOA:

Blocks conversion of testosterone to DHT Use: Benign prostatic hyperplasia, male pattern

baldness Leuprolide Receptor/Target: GnRH receptors (agonist → downregulation) Location:

Pituitary gonadotropes MOA: Initial stimulation then receptor downregulation → decreased

LH/FSH Use: Prostate cancer, endometriosis, precocious puberty Mifepristone

Receptor/Target: Progesterone receptors (antagonist) Location: Uterus MOA: Blocks

progesterone action, promotes uterine contractions Use: Medical abortion (with misoprostol)

Norethindrone Receptor/Target: Progesterone receptors Location: Uterus, other reproductive

tissues MOA: Synthetic progestin activity Use: Oral contraceptives, hormone replacement

therapy Oxytocin Receptor/Target: Oxytocin receptors Location: Uterine smooth muscle,

mammary glands MOA: Increases intracellular calcium → uterine contractions Use: Labor

induction, postpartum hemorrhage Sildenafil Receptor/Target: Phosphodiesterase type 5

(PDE5) Location: Penile blood vessels MOA: Inhibits PDE5 → increased cGMP →

vasodilation Use: Erectile dysfunction, pulmonary arterial hypertension Tamoxifen

Receptor/Target: Estrogen receptors (selective modulator) Location: Breast tissue, bone, uterus

MOA: Estrogen antagonist in breast, agonist in bone/uterus Use: Breast cancer treatment and

prevention

■ HEMATOLOGIC/ONCOLOGIC MEDICATIONS Aspirin Receptor/Target:

Cyclooxygenase-1 and 2 (COX-1/2) Location: Platelets, blood vessels MOA: Irreversibly

inhibits COX → decreased thromboxane A2 → antiplatelet effect Use: Cardiovascular

protection, stroke prevention Clopidogrel Receptor/Target: P2Y12 ADP receptors (irreversible

antagonist) Location: Platelets MOA: Blocks ADP-induced platelet aggregation Use: Acute

coronary syndrome, stroke prevention Doxorubicin Receptor/Target: DNA topoisomerase II,

DNA intercalation Location: Rapidly dividing cells MOA: Inhibits DNA replication and

transcription Use: Various cancers (cardiotoxic side effect) Filgrastim (G-CSF)

Receptor/Target: G-CSF receptors Location: Bone marrow neutrophil precursors MOA:

Stimulates neutrophil production and maturation Use: Neutropenia (chemotherapy-induced)

Imatinib Receptor/Target: BCR-ABL tyrosine kinase Location: CML cells with Philadelphia

chromosome MOA: Selective tyrosine kinase inhibitor Use: Chronic myeloid leukemia

Methotrexate Receptor/Target: Dihydrofolate reductase Location: Rapidly dividing cells

MOA: Inhibits folate synthesis → impairs DNA synthesis Use: Cancer, rheumatoid arthritis,

psoriasis Rituximab Receptor/Target: CD20 antigen Location: B lymphocytes MOA:

Monoclonal antibody causing B-cell depletion Use: B-cell lymphomas, rheumatoid arthritis

Warfarin Receptor/Target: Vitamin K epoxide reductase Location: Liver MOA: Inhibits

vitamin K recycling → decreased clotting factor synthesis Use: Long-term anticoagulation

■ ANTI-INFECTIVE MEDICATIONS Acyclovir Receptor/Target: Viral DNA polymerase

Location: HSV/VZV infected cells MOA: Nucleoside analog, chain termination during DNA

synthesis Use: Herpes simplex, varicella-zoster virus Amoxicillin Receptor/Target: Bacterial

cell wall synthesis (transpeptidase) Location: Bacterial cell wall MOA: β-lactam antibiotic,

inhibits peptidoglycan synthesis Use: Respiratory tract infections, UTIs, H. pylori

Azithromycin Receptor/Target: 50S ribosomal subunit Location: Bacterial ribosomes MOA:

Inhibits protein synthesis (bacteriostatic) Use: Respiratory infections, atypical pneumonia,

STIs Ciprofloxacin Receptor/Target: DNA gyrase (topoisomerase II) Location: Bacterial DNA

replication machinery MOA: Inhibits DNA supercoiling and replication Use: UTIs, GI

infections, anthrax exposure Fluconazole Receptor/Target: 14α-demethylase (CYP51)

Location: Fungal cell membrane MOA: Inhibits ergosterol synthesis, disrupts membrane Use:

Candidiasis, cryptococcal meningitis Isoniazid Receptor/Target: Mycolic acid synthesis

Location: Mycobacterial cell wall MOA: Inhibits mycolic acid synthesis (TB-specific) Use:

Tuberculosis (first-line) Oseltamivir Receptor/Target: Neuraminidase Location: Influenza

virus surface MOA: Prevents viral release from infected cells Use: Influenza treatment and

prophylaxis Vancomycin Receptor/Target: D-Ala-D-Ala peptidoglycan precursors Location:

Bacterial cell wall MOA: Inhibits cell wall synthesis, different from β-lactams Use: MRSA

infections, C. difficile colitis (oral)

■ PSYCHIATRIC MEDICATIONS Bupropion Receptor/Target: Dopamine and

norepinephrine reuptake transporters Location: CNS synapses MOA: Inhibits DA and NE

reuptake (atypical antidepressant) Use: Depression, smoking cessation Fluoxetine

Receptor/Target: Serotonin reuptake transporter (SERT) Location: CNS synapses MOA:

Selective serotonin reuptake inhibitor (SSRI) Use: Depression, anxiety disorders, OCD

Haloperidol Receptor/Target: D2 dopamine receptors (antagonist) Location: CNS

(mesolimbic, nigrostriatal pathways) MOA: Blocks dopamine receptors (typical antipsychotic)

Use: Schizophrenia, acute psychosis, delirium Lithium Receptor/Target: Multiple mechanisms

(inositol depletion, protein kinase C) Location: CNS neurons MOA: Mood stabilization

through multiple pathways Use: Bipolar disorder (mood stabilizer) Lorazepam

Receptor/Target: GABA-A receptors (positive allosteric modulator) Location: CNS GABA

synapses MOA: Enhances GABA-mediated chloride influx Use: Anxiety, seizures, alcohol

withdrawal Quetiapine Receptor/Target: Multiple (D2, 5-HT2A, H1, α1-adrenergic) Location:

CNS MOA: Atypical antipsychotic with multiple receptor actions Use: Schizophrenia, bipolar

disorder Sertraline Receptor/Target: Serotonin reuptake transporter (SERT) Location: CNS

synapses MOA: Selective serotonin reuptake inhibitor (SSRI) Use: Depression, anxiety

disorders, PTSD Venlafaxine Receptor/Target: Serotonin and norepinephrine reuptake

transporters Location: CNS synapses MOA: SNRI (serotonin-norepinephrine reuptake

inhibitor) Use: Depression, generalized anxiety disorder ______________- ■ LEUKEMIAS

Acute Lymphoblastic Leukemia (ALL) B-Cell ALL Markers: CD19+, CD20+, CD10+

(CALLA), TdT+ Cytogenetics: t(12;21) – TEL-AML1 (good prognosis) t(9;22) – Philadelphia

chromosome BCR-ABL (poor prognosis) t(4;11) – MLL-AF4 (poor prognosis, infants) T-Cell

ALL Markers: CD3+, CD7+, CD5+, TdT+ Location: Often mediastinal mass (thymic

involvement) Medications for ALL: Chemotherapy Regimens: Vincristine Target:

Microtubules (tubulin) Cell Cycle: M phase (metaphase arrest) MOA: Prevents spindle

formation, blocks mitosis Prednisone Target: Glucocorticoid receptors Location:

Lymphoblasts (especially B-cells) MOA: Induces apoptosis in lymphoid cells L-Asparaginase

Target: Asparagine (amino acid) Location: Extracellular MOA: Depletes asparagine; leukemic

cells can’t synthesize it Methotrexate Target: Dihydrofolate reductase Cell Cycle: S phase

(DNA synthesis) MOA: Blocks folate metabolism, impairs DNA synthesis Targeted Therapy

(Philadelphia+ ALL): Imatinib Target: BCR-ABL tyrosine kinase Location: Cytoplasm of

leukemic cells MOA: Blocks ATP binding site of BCR-ABL kinase

Acute Myeloid Leukemia (AML) Subtypes & Markers: M0: Minimally differentiated –

CD13+, CD33+ M1: Myeloblastic without maturation – CD13+, CD33+ M2: Myeloblastic

with maturation – CD13+, CD33+ M3: Promyelocytic (APL) – CD33+, t(15;17) PML-RARA

M4: Myelomonocytic – CD13+, CD33+, CD14+ M5: Monocytic – CD14+, CD68+ M6:

Erythroid – Glycophorin A+ M7: Megakaryocytic – CD41+, CD61+ Key Cytogenetics:

t(15;17) – PML-RARA (APL, good prognosis) t(8;21) – RUNX1-RUNX1T1 (good prognosis)

inv(16) – CBFB-MYH11 (good prognosis) FLT3 mutations – Poor prognosis Medications for

AML: Standard Chemotherapy: Cytarabine (Ara-C) Target: DNA polymerase Cell Cycle: S

phase MOA: Nucleoside analog, chain termination Daunorubicin Target: Topoisomerase II,

DNA intercalation Cell Cycle: Multiple phases MOA: Creates DNA breaks, prevents

replication Targeted Therapy (APL): All-Trans Retinoic Acid (ATRA) Target: PML-RARA

fusion protein Location: Nuclear retinoic acid receptors MOA: Promotes differentiation of

promyelocytes Arsenic Trioxide Target: PML-RARA fusion protein Location: Nuclear MOA:

Causes fusion protein degradation, induces apoptosis Targeted Therapy (FLT3+ AML):

Midostaurin Target: FLT3 tyrosine kinase Location: Cell membrane/cytoplasm MOA: Inhibits

FLT3 kinase activity

Chronic Lymphocytic Leukemia (CLL) Markers: CD19+, CD20+ (dim), CD5+, CD23+ Light

chain restriction (κ or λ) Characteristic: Smudge cells on peripheral smear Cytogenetics:

del(13q) – Good prognosis del(11q) – Intermediate prognosis del(17p) – Poor prognosis (p53

deletion) Medications for CLL: Rituximab Target: CD20 antigen Location: B-cell surface

MOA: Monoclonal antibody causes complement-mediated lysis Ibrutinib Target: Bruton’s

tyrosine kinase (BTK) Location: B-cell signaling pathway MOA: Irreversibly inhibits BTK,

blocks B-cell proliferation Venetoclax Target: BCL-2 protein Location: Mitochondria MOA:

Promotes apoptosis by blocking anti-apoptotic BCL-2

Chronic Myeloid Leukemia (CML) Markers: Philadelphia chromosome: t(9;22) BCR-ABL

Phases: Chronic → Accelerated → Blast crisis LAP score: Low (vs. high in leukemoid

reaction) Medications for CML: Imatinib (Gleevec) Target: BCR-ABL tyrosine kinase

Location: Cytoplasm MOA: Blocks ATP binding site, prevents kinase activity Dasatinib

Target: BCR-ABL, SRC family kinases Location: Cytoplasm MOA: More potent BCR-ABL

inhibitor, active against T315I mutation Nilotinib Target: BCR-ABL Location: Cytoplasm

MOA: Second-generation BCR-ABL inhibitor

■ LYMPHOMAS Hodgkin Lymphoma Subtypes & Markers: Classical HL: Reed-Sternberg

cells CD15+, CD30+, CD20- Nodular Lymphocyte Predominant: LP cells CD20+, CD15-,

CD30- Medications for Hodgkin Lymphoma: ABVD Regimen: Adriamycin (Doxorubicin)

Target: Topoisomerase II, DNA intercalation Cell Cycle: Multiple phases MOA: Creates DNA

strand breaks Bleomycin Target: DNA (causes strand breaks) Cell Cycle: G2 phase primarily

MOA: Free radical formation, DNA fragmentation Vinblastine Target: Microtubules Cell

Cycle: M phase MOA: Prevents spindle formation Dacarbazine (DTIC) Target: DNA

(alkylating agent) Cell Cycle: Multiple phases MOA: DNA cross-linking, prevents replication

Targeted Therapy: Brentuximab Vedotin Target: CD30 antigen Location: Reed-Sternberg cell

surface MOA: Antibody-drug conjugate, delivers cytotoxic payload

Non-Hodgkin Lymphomas B-Cell Lymphomas: Burkitt Lymphoma Markers: CD10+, CD19+,

CD20+, BCL-6+ Cytogenetics: t(8;14) – MYC-IGH translocation Variants: Endemic (EBV+),

Sporadic, Immunodeficiency-associated Diffuse Large B-Cell Lymphoma (DLBCL) Markers:

CD19+, CD20+, CD79a+ Subtypes: GCB vs ABC (based on gene expression) Follicular

Lymphoma Markers: CD10+, CD19+, CD20+, BCL-2+ Cytogenetics: t(14;18) – BCL-2-IGH

translocation Mantle Cell Lymphoma Markers: CD5+, CD19+, CD20+, Cyclin D1+

Cytogenetics: t(11;14) – CCND1-IGH translocation Marginal Zone Lymphoma (MALT)

Location: Extranodal sites (stomach, salivary glands) Association: H. pylori infection (gastric

MALT) T-Cell Lymphomas: Peripheral T-Cell Lymphoma Markers: CD3+, CD5+, variable

others Subtypes: PTCL-NOS, AITL, ALCL Anaplastic Large Cell Lymphoma (ALCL)

Markers: CD30+, ALK+ (in some cases) Cytogenetics: t(2;5) – NPM-ALK translocation

Medications for NHL: B-Cell Lymphomas: Rituximab Target: CD20 antigen Location: B-cell

surface MOA: Complement-mediated cytotoxicity, ADCC Obinutuzumab Target: CD20

antigen (different epitope) Location: B-cell surface MOA: Enhanced antibody-dependent

cellular cytotoxicity Burkitt Lymphoma Specific: High-dose Methotrexate Target:

Dihydrofolate reductase Cell Cycle: S phase MOA: Crosses blood-brain barrier, prevents CNS

relapse Follicular Lymphoma: Bendamustine Target: DNA (alkylating agent) Cell Cycle:

Multiple phases MOA: DNA cross-linking, less cross-resistance Mantle Cell Lymphoma:

Ibrutinib Target: BTK (Bruton’s tyrosine kinase) Location: B-cell receptor signaling MOA:

Blocks B-cell proliferation signals T-Cell Lymphomas: Romidepsin Target: Histone

deacetylases (HDACs) Location: Nuclear MOA: Epigenetic modulation, promotes apoptosis

■ MULTIPLE MYELOMA Markers: CD138+ (syndecan-1), CD38+, CD56+ Plasma cell

morphology with clock-face chromatin Monoclonal protein (M-protein) in serum/urine

Cytogenetics: t(11;14) – CCND1 overexpression t(4;14) – FGFR3/MMSET (poor prognosis)

t(14;16) – MAF (poor prognosis) del(17p) – p53 deletion (poor prognosis) Medications for

Multiple Myeloma: Proteasome Inhibitors: Bortezomib Target: 26S proteasome Location:

Cytoplasm MOA: Blocks protein degradation, induces apoptosis Carfilzomib Target: 20S

proteasome (irreversible) Location: Cytoplasm MOA: More selective proteasome inhibition

Immunomodulatory Drugs (IMiDs): Lenalidomide Target: Cereblon (E3 ubiquitin ligase)

Location: Cytoplasm MOA: Promotes degradation of IKZF1/IKZF3, enhances immunity

Pomalidomide Target: Cereblon Location: Cytoplasm MOA: Similar to lenalidomide, active in

resistant disease Monoclonal Antibodies: Daratumumab Target: CD38 antigen Location:

Myeloma cell surface MOA: Direct cytotoxicity, complement activation, ADCC HDAC

Inhibitors: Panobinostat Target: Histone deacetylases Location: Nuclear MOA: Epigenetic

modulation, synergistic with proteasome inhibitors

■ SOLID TUMORS (Selected Examples) Breast Cancer Subtypes: ER+/PR+, HER2-

(Luminal A/B) HER2+ (HER2-enriched) Triple-negative (ER-, PR-, HER2-) Medications:

Hormone Receptor Positive: Tamoxifen Target: Estrogen receptors Location: Nuclear MOA:

SERM – antagonist in breast, agonist in bone/uterus Anastrozole Target: Aromatase

(CYP19A1) Location: Peripheral tissues MOA: Blocks estrogen synthesis from androgens

HER2-Positive: Trastuzumab (Herceptin) Target: HER2/neu receptor Location: Cell surface

MOA: Blocks HER2 signaling, promotes ADCC Pertuzumab Target: HER2 (different epitope)

Location: Cell surface MOA: Prevents HER2 dimerization CDK4/6 Inhibitors: Palbociclib

Target: Cyclin-dependent kinases 4 and 6 Cell Cycle: G1/S checkpoint MOA: Blocks cell

cycle progression

Lung Cancer Non-Small Cell Lung Cancer (NSCLC): EGFR-Mutated: Erlotinib Target: EGFR

tyrosine kinase Location: Cell membrane/cytoplasm MOA: Blocks EGFR autophosphorylation

ALK-Rearranged: Crizotinib Target: ALK tyrosine kinase Location: Cytoplasm MOA:

Inhibits ALK kinase activity PD-L1 Expressing: Pembrolizumab Target: PD-1 receptor

Location: T-cell surface MOA: Checkpoint inhibitor, enhances T-cell activity

Colorectal Cancer KRAS Wild-Type: Cetuximab Target: EGFR Location: Cell surface MOA:

Blocks EGFR signaling (only effective if KRAS wild-type) Angiogenesis Inhibition:

Bevacizumab Target: VEGF-A Location: Extracellular (circulating VEGF) MOA: Decoy

receptor – binds and neutralizes VEGF

■ CELL CYCLE SPECIFIC DRUGS G1/S Checkpoint: Methotrexate, 5-FU, Hydroxyurea

Target: DNA synthesis machinery MOA: Block nucleotide synthesis/incorporation S Phase:

Cytarabine, Gemcitabine, Topoisomerase inhibitors Target: DNA replication/repair MOA:

Chain termination, DNA damage G2/M Checkpoint: Bleomycin, Etoposide Target: DNA

integrity checkpoints MOA: DNA damage triggers G2 arrest M Phase: Vincristine,

Vinblastine, Paclitaxel Target: Microtubules/spindle apparatus MOA: Prevent chromosome

separation Cell Cycle Non-Specific: Alkylating agents, Anthracyclines Target: DNA

throughout cycle MOA: DNA cross-linking, strand breaks

■ MECHANISM CATEGORIES Monoclonal Antibodies (Decoy Receptors): Rituximab

(CD20), Trastuzumab (HER2), Bevacizumab (VEGF) MOA: Bind target proteins, prevent

normal signaling Tyrosine Kinase Inhibitors: Imatinib (BCR-ABL), Erlotinib (EGFR),

Ibrutinib (BTK) MOA: Block ATP binding sites, prevent phosphorylation Proteasome

Inhibitors: Bortezomib, Carfilzomib MOA: Prevent protein degradation, accumulate

pro-apoptotic proteins Epigenetic Modulators: HDAC inhibitors, DNMT inhibitors MOA:

Alter gene expression without changing DNA sequence Cell Cycle Checkpoint Inhibitors:

CDK4/6 inhibitors, Checkpoint inhibitors (PD-1/PD-L1) MOA: Remove brakes on cell

division or immune response

USMLE Essential Statistical Equations & Examples ■ BASIC EPIDEMIOLOGICAL RATES

Incidence Rate Incidence Rate = New Cases / (Population at Risk × Time) Example: 500 new

diabetes cases in 10,000 healthy people over 5 years Incidence = 500 ÷ (10,000 × 5) = 500 ÷

50,000 = 0.01 per person-year = 10 per 1,000 person-years Prevalence Prevalence = Total

Cases / Total Population Example: 1,200 people with hypertension in a town of 20,000

Prevalence = 1,200 ÷ 20,000 = 0.06 = 6% Attack Rate Attack Rate = Cases After Exposure /

Total Exposed × 100 Example: 30 people got food poisoning out of 150 who ate the potato

salad Attack Rate = 30 ÷ 150 × 100 = 20% Case Fatality Rate Case Fatality Rate = Deaths

from Disease / Total Cases of Disease × 100 Example: 25 deaths among 500 people with

pneumonia CFR = 25 ÷ 500 × 100 = 5% Mortality Rate Mortality Rate = Deaths / Total

Population × 1,000 (or 100,000) Example: 800 deaths in a city of 200,000 people in one year

Mortality Rate = 800 ÷ 200,000 × 1,000 = 4 per 1,000

■ DIAGNOSTIC TEST PERFORMANCE Sensitivity Sensitivity = True Positives / (True

Positives + False Negatives) Sensitivity = TP / (TP + FN) Example: HIV test: 90 HIV+

patients test positive, 10 test negative Sensitivity = 90 ÷ (90 + 10) = 90 ÷ 100 = 90% “Of all

people WITH disease, 90% test positive” Specificity Specificity = True Negatives / (True

Negatives + False Positives) Specificity = TN / (TN + FP) Example: HIV test: 950 HIV-

patients test negative, 50 test positive Specificity = 950 ÷ (950 + 50) = 950 ÷ 1,000 = 95% “Of

all people WITHOUT disease, 95% test negative” Positive Predictive Value (PPV) PPV =

True Positives / (True Positives + False Positives) PPV = TP / (TP + FP) Example: Using same

HIV test: 90 true positives, 50 false positives PPV = 90 ÷ (90 + 50) = 90 ÷ 140 = 64.3% “If test

is positive, 64.3% chance you actually have HIV” Negative Predictive Value (NPV) NPV =

True Negatives / (True Negatives + False Negatives) NPV = TN / (TN + FN) Example: Using

same HIV test: 950 true negatives, 10 false negatives NPV = 950 ÷ (950 + 10) = 950 ÷ 960 =

99.0% “If test is negative, 99% chance you don’t have HIV”

■ MEASURES OF ASSOCIATION Relative Risk (Risk Ratio) Relative Risk = Risk in

Exposed / Risk in Unexposed RR = [a/(a+b)] / [c/(c+d)] 2×2 Table Setup: Example: Smoking

study: 80 lung cancers in 1,000 smokers, 10 in 1,000 non-smokers Risk in smokers = 80/1,000

= 0.08 Risk in non-smokers = 10/1,000 = 0.01 RR = 0.08 ÷ 0.01 = 8.0 “Smokers are 8 times

more likely to get lung cancer” Odds Ratio Odds Ratio = (a × d) / (b × c) OR = Odds of

Disease in Exposed / Odds of Disease in Unexposed Example: Case-control study: 60 MI

patients smoked, 40 didn’t; 30 controls smoked, 70 didn’t OR = (60 × 70) ÷ (40 × 30) = 4,200 ÷

1,200 = 3.5 “Odds of smoking are 3.5 times higher in MI patients” Attributable Risk (Risk

Difference) Attributable Risk = Risk in Exposed – Risk in Unexposed AR = [a/(a+b)] –

[c/(c+d)] Example: Using smoking example: 0.08 – 0.01 = 0.07 or 7% “7% of lung cancer in

smokers is attributable to smoking” Attributable Risk Percent AR% = [(RR – 1) / RR] × 100

Example: Using RR = 8.0: [(8.0 – 1) ÷ 8.0] × 100 = 87.5% “87.5% of lung cancer in smokers is

due to smoking”

■ STUDY DESIGN CALCULATIONS Number Needed to Treat (NNT) NNT = 1 / Absolute

Risk Reduction NNT = 1 / (Control Event Rate – Treatment Event Rate) Example: Drug

prevents 3% of heart attacks, placebo prevents 1% ARR = 3% – 1% = 2% = 0.02 NNT = 1 ÷

0.02 = 50 “Need to treat 50 patients to prevent 1 heart attack” Number Needed to Harm (NNH)

NNH = 1 / Absolute Risk Increase NNH = 1 / (Treatment Event Rate – Control Event Rate)

Example: Drug causes 4% nausea, placebo causes 1% ARI = 4% – 1% = 3% = 0.03 NNH = 1 ÷

0.03 = 33.3 ≈ 34 “For every 34 patients treated, 1 will get nausea from the drug” Sample Size

Calculation (Simplified) n = 16 × (p■ + p■) × (1 – (p■ + p■)/2) / (p■ – p■)² Where p■ and

p■ are expected proportions in two groups Key Factors Affecting Sample Size: Larger effect

size → Smaller sample needed Higher power → Larger sample needed Lower α (significance

level) → Larger sample needed

■ CONFIDENCE INTERVALS & HYPOTHESIS TESTING 95% Confidence Interval for

Proportions CI = p ± 1.96 × √[p(1-p)/n] Example: 60 successes in 100 trials: p = 0.6 SE =

√[0.6 × 0.4 ÷ 100] = √0.0024 = 0.049 95% CI = 0.6 ± (1.96 × 0.049) = 0.6 ± 0.096 = 50.4% to

69.6% Standard Error (SE) SE = Standard Deviation / √n Example: Mean height = 170 cm, SD

= 10 cm, n = 100 SE = 10 ÷ √100 = 10 ÷ 10 = 1 cm t-Test (Two Sample) t = (Mean■ –

Mean■) / SE_difference Example: Group 1: Mean = 120, Group 2: Mean = 110, SE_diff = 5 t

= (120 – 110) ÷ 5 = 2.0

■ PROBABILITY & BAYES’ THEOREM Basic Probability P(A and B) = P(A) × P(B|A) [if

dependent] P(A or B) = P(A) + P(B) – P(A and B) Bayes’ Theorem P(Disease|Test+) =

[P(Test+|Disease) × P(Disease)] / P(Test+) Example: Disease prevalence = 1% Test sensitivity

= 95%, specificity = 90% P(Test+) = (0.95 × 0.01) + (0.10 × 0.99) = 0.0095 + 0.099 = 0.1085

P(Disease|Test+) = (0.95 × 0.01) ÷ 0.1085 = 8.8% “Even with positive test, only 8.8% chance

of having disease”

■ CORRELATION & REGRESSION Correlation Coefficient (Pearson’s r) r = Σ[(xi – x■)(yi –

■)] / √[Σ(xi – x■)² × Σ(yi – ■)²] Interpretation: r = +1: Perfect positive correlation r = 0: No

correlation r = -1: Perfect negative correlation Linear Regression y = a + bx where: b = slope, a

= y-intercept Coefficient of Determination (R²) R² = (Correlation coefficient)² Example: If r =

0.8, then R² = 0.64 “64% of variance in y is explained by x”

■ SURVIVAL ANALYSIS Kaplan-Meier Survival S(t) = Π[1 – (di/ni)] Where di = deaths at

time i, ni = number at risk at time i Hazard Ratio HR = Hazard in Treatment Group / Hazard in

Control Group Interpretation: HR = 1: No difference HR < 1: Treatment reduces risk HR > 1:

Treatment increases risk

■ PHARMACOKINETICS Clearance Clearance = (Dose × Bioavailability) / AUC Cl = Rate

of Elimination / Plasma Concentration Half-Life t■/■ = 0.693 × Vd / Cl Steady State Time to

Steady State = 5 × Half-lives Steady State Concentration = (Dose Rate) / Clearance Loading

Dose Loading Dose = (Target Concentration × Vd) / Bioavailability Example: Want digoxin

level of 2 ng/mL, Vd = 7 L/kg, weight = 70 kg Loading dose = 2 × (7 × 70) ÷ 0.7 = 1,400 µg

■ QUICK REFERENCE FORMULAS The Big 4 Test Characteristics: Sensitivity =

TP/(TP+FN) – “Positive in Disease” Specificity = TN/(TN+FP) – “Negative in Health” PPV =

TP/(TP+FP) – “Disease if Positive” NPV = TN/(TN+FN) – “Health if Negative” The Big 3

Association Measures: Relative Risk = Risk_exposed/Risk_unexposed – Cohort studies Odds

Ratio = (a×d)/(b×c) – Case-control studies Attributable Risk = Risk_exposed – Risk_unexposed

• Excess risk Clinical Utility: NNT = 1/ARR – How many to treat for benefit NNH = 1/ARI –

How many to harm Pre-test odds × LR = Post-test odds – Diagnostic reasoning

■ MEMORY TRICKS 2×2 Table Memory: Disease Test + | – + | a | b | PPV = a/(a+b) – | c | d |

NPV = d/(c+d)

Sensitivity = a/(a+c) Specificity = d/(b+d) RR vs OR: Cohort studies → Can calculate Relative

Risk Case-control studies → Can only calculate Odds Ratio When disease is rare → OR ≈ RR

Confidence Intervals: Includes 1.0 → Not significant (for RR, OR, HR) Doesn’t include 1.0 →

Significant For differences (like mean difference) → look for includes 0